The Role of Immunological Receptors CD74 and CD44 in Association with the Macrophage Migration Inhibitory Factor (MIF) on Human Breast Cancer Derived Cells by Al ssadh, Hussain
The Role of Immunological Receptors CD74 and 
CD44 in Association with the Macrophage 
Migration Inhibitory Factor (MIF) on Human 
Breast Cancer Derived Cells 
 
Hussain M M Al Ssadh 
A thesis submitted for the degree of Doctorate of Philosophy in 
Biological Sciences 
 
 
School of Biological Sciences 
University of Essex 
February 2016 
Abstract 
 
 
I 
Abstract 
Synergistic interaction between pairs of membrane-bound receptors has been linked to 
signalling, cell communication and tumour progression. This study has shown that cluster 
of differentiation (CD) 74 and CD44 act in synergy and are susceptible to the effect of the 
macrophage migration inhibitory factor (MIF). MIF is a 12.5 kDa chemokine-like 
inflammatory mediator, whose ligand is the transmembrane receptor CD74.  Recent data 
suggests that CD74 is involved in proinflammatory responses and tumorigenesis but 
detailed mechanisms are not fully understood.  In normal cells CD74 functions as a 
chaperone of human leukocyte antigen (HLA)-DR biosynthesis and is expressed in 
antigen presenting cells in the absence of tumours. Notably, CD44 is also a 
transmembrane receptor and member of a family of cell adhesion molecules responsible 
for adhesion between adjacent cells (e.g. antigen presenting cells) and cells in the 
extracellular matrix. Western blotting and flow cytometry were employed to determine 
the quantitative expression of CD74, MIF and CD44 in three distinct breast tumour cell 
lines: CAMA-1, MDA-MB-231 and MDA-MB-435. All three cell lines showed a high 
expression of CD74, MIF and CD44. Modulation studies showed that IFN-γ and LPS can 
play a significant role in regulating the expression of CD74, proliferation and cell 
migration in CAMA-1 and MDA-MB-231 cells; suggesting that CD74 might be involved 
in controlling immunogenicity and immunoediting of breast cancer cells. To investigate 
the interaction of CD74 with CD44 and MIF, confocal microscopy and co-
immunoprecipitation techniques were used. The three molecules form a multimeric 
complex in cytoplasmic compartments as measured by confocal microscopy, suggesting a 
mechanistic mode of action; in addition CD74, MIF and CD44 showed significant 
quantitative variations on all breast cancer derived cells. Knockdown of CD74 by CD74 
siRNA significantly reduced CAMA-1 and MDA-MB-231 cell proliferation but increased 
the level of apoptotic cells. These data suggests that CD74, MIF and CD44, might 
facilitate signalling and hence could affect tumour progression. Measuring the co-
expression levels of CD74, MIF and CD44 could potentially be used as a ‘biomarker 
signature’ for monitoring breast cancer tumours at different stages of the disease. 
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1.1 Tumour immunology 
The association between tumours and the immune system was first identified in the 19th 
century when Rudolf Virchow observed the presence of leukocytes within tumours (Igney 
and Krammer, 2002; Grivennikov et al., 2010). However, because the lack of knowledge 
and technology the molecular and cellular basis of immunity and the mechanistic action 
of cancer, the validity of this idea proved is difficult to establish. It is only during the last 
10 years that true evidence has been obtained showing that inflammation plays a 
significant role in tumorgenesis and some of the molecular mechanisms were elucidated 
(Hakim et al., 2004; Bucala and Donnelly, 2007; Grivennikov et al., 2010). 
The concept of tumour immunology is based on the assumption that the immune system 
plays a fundamental role in immune responses against a wide range of diseases including 
cancer (Melvold and Sticca, 2007). Due to the ability of the immune system to distinguish 
between normal and cancerous cells, it can eliminate abnormal cells and hence, protect 
the host in absence of external therapeutic agents. It is also believed that the immune 
system has a dual curial role in tumour progression. Therefore, the immune system is not 
only capable of suppressing growth by destroying cancer cells or inhibiting their 
outgrowth but it also has the features to promote tumour progression either by selecting 
for tumour cells that are more fit to survive in an immunocompetent host or by 
establishing conditions within the tumour microenvironment to facilitate tumour 
outgrowth. The process of protecting the host from the development of cancer and 
altering tumour progression by driving the outgrowth of tumour cells - with decreased 
sensitivity to immune attack - is known as cancer immunoediting (Dunn et al., 2004; 
Grivennikov et al., 2010; Schreiber et al., 2011). 
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Immuno-oncology research over the last 30 years has provided increasing evidence that 
tumours might be recognised and controlled by the immune system. Therefore, scientists 
have become more concerned with the study of interactions between the immune system 
and tumours as well as tumour progression (Finn, 2012).  Recently, Butrym et al. (2013) 
have showed a correlation between high expression of CD74 and zeta-chain-associated 
protein kinase 70 (ZAB70) expression in B-cell chronic lymphocytic leukemia patients. 
In breast cancer, Jiang et al. (2013) have shown that wingless-type integration site family, 
member 5A (WNT5A) inhibits metastasis and alters splicing of CD44 in breast cancer 
cells. Moreover, Richard et al. (2014) confirmed the role of macrophage migration 
inhibitory factor (MIF) and CD74 in human breast cancer. In this context, breast cancer is 
one of the most common cancers with more than 1.3 million cases and 450,000 deaths 
every year worldwide (Ferlay et al., 2013). In order to understand the biology of breast 
cancer and its subtypes, the anatomy of breast will be reviewed. 
1.2 Anatomy of the human breast 
The breast (or mammary gland) is the organ that functions to produce the milk protein 
and fat to feed the offspring (Capuco and Ellis, 2013; Hassiotou and Geddes, 2013). The 
normal mature breast consisted of three main components known as the lobules (or 
gland), milk ducts and stroma (connective tissue) (Figure 1-1) (Ali and Coombes, 2002). 
The lobules are joined together by alveoli, which consist of the gland and cells that are 
responsible for milk production. However, the function of ducts is to carry the milk from 
the lobule to the nipple within the breast. The lobules and ducts are made up of epithelial 
cells and are embedded in a fat pad composed of adipocyte (Watson and Khaled, 2008; 
Lemaine and Simmons, 2013). The stroma is comprised of fibroblast (connective tissue), 
fat various immune cells, lymphatic vessels and blood (Macéa and Fregnani, 2006). A 
lymphatic vessel and blood vessel network is made up with endothelial cells. The 
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epithelial cells of the mammary gland are composed of two main types of epithelium; 
luminal and basal (Watson and Khaled, 2008). In response to various stages of breast 
development, the breast undergoes different stages in function, shape and size during 
growth (Turashvili et al., 2005; Geddes, 2007). Theses stages are known as embryonic, 
pubertal and adult (Russo and Russo, 2004). The embryonic stage of breast development 
is similar in males and females and it begins when the buds are formed in the ectoderm 
(Hynes and Watson, 2010). The formation of buds depends on the activation of 
parathyroid hormone-related protein (PTHrP) (Watson and Khaled, 2008). Association of 
parathyroid hormone-related protein (PTHrP) and bone morphogenetic protein-4 (BMP4) 
enhances the outgrowth and elongation of the buds. The interaction of (PTHrP) and 
(BMP4) is also responsible for signaling pathways in mammary mesenchyme to induce 
the proliferation and differentiation of the epithelium (Hens et al., 2007). This process is 
regulated by a number of hormones and growth factors (Hens and Wysolmerski, 2005; 
Hens et al., 2007). Before puberty, the growth of the mammary tree is algometric. 
Terminal end buds (TEBs) are formed by the tips of ducts that are responsible for 
invading mammary stroma and causing elongation of the milk ducts (Hinck and 
Silberstein, 2005). TEBs consist of two different cells type; an outer layer of cap cells and 
a bulk of cells at the duct tips. When estrogen levels increase in the serum during puberty, 
proliferation within TEBs causes ductal elongation. However, the surrounding fat and 
extra-cellular matrix (ECM) is involved in aiding tabular formation either physically or 
by secreting growth factors (Couldrey et al., 2002). In addition to elongation, cleft TEBs 
enhance splitting the ducts and forming the branches. It is suggested at this stage that 
apoptosis could be detected in TEB cells forming ductal lumens (Humphreys et al., 1996). 
Several factors regulate and control branching morphogenesis including hormones, 
growth factors, extra-cellular matrix (ECM), matrix metalloproteinase (MMPs) and 
immune cells (Kouros-Mehr et al., 2006; Sternlicht et al., 2006). 
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Figure 1-1:Anatomy of normal breast. 
From the nipple long ducts terminate in alveoli networks called lobes. The ducts and alveoli penetrate the 
stroma and adipose tissue. The rib, as well as the muscle underlying the breast followed by loose connective 
tissue is also shown. Suspensory ligaments and the skin are indicated. Breast cancers most often arise in 
luminal epithelial cells lining the normal breast ducts and are called ductal carcinomas. (Ali and Coombes, 
2002). 
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The mammary gland undergoes for further development unlike most other organs of the 
body during pregnancy and preparation for lactation (Figure 1-2) (Hassiotou and Geddes, 
2013). At this stage, specialized cells are created for milk production and secretion 
(Hennighausen and Robinson, 2005; Topper, 2013). Progesterone stimulates the 
formation of alveolar and extensive branching, and in combination with prolactin 
promotes the differentiation of alveoli for future milk secretion (Watson and Khaled, 
2008; Topper, 2013; Hassiotou and Geddes, 2013). Once the mother stops feeding the 
infant, the mammary gland returns to its original non-milk secreting state through the 
process of involution. The process of breast-feeding cessation induces apoptosis and the 
shedding of detached cells from the lumens (Sloane, 2012). As a result, matrix 
metalloproteinases (MMP) are activated, which break down the ECM around each 
alveolus resulting in alveolar collapse. Re-differentiation of adipocytes via plasmid and 
MMP3 activation complete the remodeling (Fata et al., 2003; Watson, 2006). During 
lifetime, normal mammary gland development undergoes many phases and processes 
including cell proliferation, migration and break down of the ECM (Lanigan et al., 2007). 
These processes are regulated by several soluble factors such as hormones and growth 
factors as well as ECM and stromal interactions (Wiseman and Werb, 2002). As a result, 
it is expected that dysregulation of any of these processes could lead to a 
pathophysiological outcome (Lanigan et al., 2007; Schedin and Keely, 2011). 
Specifically, the similarities between developmental processes and the characteristics of 
breast cancer have been studied, and it is currently the most commonly diagnosed female 
disease throughout the world (DeSantis et al., 2011; Eccles et al., 2013). Statistical 
surveys have estimated that around 550,000-570,000 females are diagnosed with breast 
cancer in the United Kingdom (Maddams et al., 2009). Thus, it is believed that 
understanding the molecular processes and molecular biology of breast cancer initiation 
and progression would be greatly beneficial and add to current research.  
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Figure 1-2: Mouse mammary gland development during puberty, mature virgin 
pregnancy and lactation.  
Schematic (Aa–d) and wholemount (Ba–d) presentations of the different stages and the principal hormones 
that control development. A basic ductal design within the mammary fat pad is visible at birth, which grows 
at the same rate as the animal until the onset of puberty. (Aa, Ba). The cyclical production of ovarian 
oestrogen and progesterone during puberty promotes and accelerates ductal outgrowth. The highest level of 
cell division occurs in the stage of puberty where the structure of end buds (TEBs) are formed. (Ab, Bb) in 
the mature virgin stage, the entire fat pad is filled with primary and secondary ducts so the branches begin 
to form and disappear in each oestrous cycle. (Ac, Bc) During pregnancy, the secretion of prolactin, 
placental lactogens and progesterone increase cell proliferation and the formation of alveolar buds. (Ad, Bd) 
Alveoli are fully matured and the luminal cells synthesize and secrete milk components into the lumina in 
preparation for lactation. (Hennighausen and Robinson, 2005). 
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1.3 Biology of breast cancer  
Breast cancer is the most frequently diagnosed cancer in women over the world and the 
fifth most common cause of malignancy associated death (Götte and Yip, 2006; 
Hutchinson, 2010; Richard et al., 2014). Breast cancer is found in breast sites and it is 
more common in females than males (Richard et al., 2014). 50,000 cases in females are 
recorded yearly in the UK alone. Every year, 458,000 people die from breast cancer over 
the world making it the most common cause of female cancer death in both the developed 
and developing world (Eccles et al., 2013). In the UK, the age-standardised incidence of 
breast cancer in women has increased by 6% over the last decade, between 1999 to 2001 
and 2008 to 2010 (Ferlay et al., 2010). Based on current projection it is expected that the 
number of women who are diagnosed with breast cancer will increase three-fold by 2040 
(Maddams et al., 2012). Recently, breast cancer research indicated that the annual cost of 
breast cancer healthcare has increased by over a third compared to the last 10 years 
(Eccles et al., 2013).   
Breast cancer is a condition in which normal cellular regulation ceases to function and 
cells in the breast are allowed to proliferate unchecked, abnormally and then escape the 
DNA repair mechanisms (Helzlsouer et al., 1996; Hanahan and Weinberg, 2000; Culver 
et al., 2003; Hanahan and Weinberg, 2011). Breast cancer is considered as a 
heterogeneous group of diseases caused by both non-genetic and genetic factors that vary 
in morphology, biology and behaviour rather than a single disease (Vargo-Gogola and 
Rosen, 2007; Rakha and Ellis, 2009; Polyak, 2011). Most breast cancers are considered 
adenocarcinomas and arise from epithelial cells and other types constitute less than 5% of 
the total (Elenbaas et al., 2001; Dimri et al., 2005; Kumar et al., 2005). Moreover, most 
breast cancers arise form terminal ductal–lobular units (TDLUs) (Dimri et al., 2005). 
Figure 1-3 describes briefly the biology of breast cancer. 
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Figure 1-3: The biology of breast cancer. 
(A) Breast cancer is a heterogeneous disease. The terminal ductal lobular unit (TDLU) of normal breast 
contains lobules and ducts, which consist of a bi-layered epithelium of luminal and myoepithelial cells. 
Atypical ductal hyperplasia (ADH) is a premalignant growth characterized by abnormal cell layers within 
the duct or lobule. ADH is classified as precursor of ductal carcinoma in situ (DCIS), which is a non-
invasive lesion that contains abnormal cells. The risk of developing malignant or invasive breast cancer 
(IBC) increases with each stage. Ductal carcinoma in situ (DCIS) may develop into IBC (indicated by a 
blue star adjacent to a DCIS lesion), but it is unclear how to predict which lesions will progress. The 
primary site for breast cancer metastasis (MET; indicated by a blue star) is the lymph nodes. (B) A 
schematic of breast cancer progression is shown. The transformation of breast epithelial cells to breast 
cancer is controlled by an amalgamation of epigenetic and genetic changes and aberrant interactions within 
the microenvironment. The process of transformation itself is controlled by proliferation, survival, 
differentiation and migration advancing into deregulated, and aberrant tumour–stromal cell interactions. 
When the cells invade the basement membrane, they enter the vasculature (intravasate), survive in the 
absence of adhesion, exit the vasculature (extravasate) and establish a new tumour in a foreign 
microenvironment. Thus they become metastatic. (C) There are several links between normal breast stem or 
progenitor cells and cancer cells, such as dormancy, self-renewal and differentiation capabilities, that have 
lead researchers to propose that cancer cells with stem cell-like characteristics (called 'cancer stem cells' or 
'tumour-initiating cells', which is a more appropriate designation), drive breast cancer initiation, progression 
and recurrence. This hypothesis is depicted as epigenetic and genetic alterations that occur in different stem 
or progenitor cells, including the long term (LT), short term (ST) and luminal or basal (myoepithelial) 
progenitors, and give rise to different subtypes of tumours that consist of different cell types (mixed, 
luminal or basal lineage), which display characteristic gene-expression profiles and exhibit distinct 
prognoses. (Vargo-Gogola and Rosen, 2007). 
A 
B 
C 
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Several genetic mutations have been identified in human breast cancer, yet the exact 
mechanisms and events that are responsible for the transformation of normal cells and 
tumour formation remain unclear (Elenbaas et al., 2001; Dimri et al., 2005). However, it 
is well known that breast tumour formation is linked to intrinsic factors such as genetics, 
mutations and genomic instability in a number of genes that promote breast cancer 
progression (Elenbaas et al., 2001; Vollebergh et al., 2012). The most significant genes 
that are involved in breast cancer are the breast cancer susceptibility genes (BRCA1 and 
BRCA2) in high-risk families. It has been noticed that only 10 % of all breast cancer 
cases are caused by the lack of a tumour suppressor gene, as opposed to the gain of an 
oncogene (Laakso et al., 2005; Ligresti et al., 2008). BRCA1 and BRCA2 are responsible 
for 80-90% of breast cancer cases. These genes are rarely mutated in irregular forms, 
suggesting they play a pathogenetic role in the promotion of carcinogenesis (Welcsh and 
King, 2001; Ligresti et al., 2008).  
Moreover, loss of function of p53 and phosphatase and tensin homolog (PTEN) genes are 
associated with aggressive breast cancer phenotypes (Elenbaas et al., 2001; Cheah and 
Looi, 2001; Lane, 2004). PTEN and p53 are both tumour suppresser genes (Ligresti et al., 
2008). p53 is a transcriptional factor involved in cell cycle regulation and DNA repair. 
Dysregulation of p53 production in the cell cycle will allow cells to proliferate unchecked 
and as a result, inhibit apoptosis (Monti et al., 2007). PTEN is a tumour suppressor gene 
that is located at human chromosome 10q23. PTEN has a crucial role in cell proliferation, 
the cell cycle and the apoptosis of cancer cells (Li et al., 2007). 
Additional genes that are commonly thought to play a role in tumour information include 
HER-2/neu and PI3K (Ligresti et al., 2008). Human epidermal growth factor receptor 2 
(HER-2/neu) is a member of the oncogene family and it is related to the epidermal growth 
factor receptor (EGFR) although it has a unique form (Zhang and Liu, 2008). It has been 
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confirmed that this oncogene has a role in human breast cancer cell line progression, and 
many studies indicate a close correlation between its expression and prognosis in breast 
cancer (Zhang and Liu, 2008; Revillion et al., 2008). The phosphoinositide-3-kinase 
(PI3K) gene consists of an 85-kDa regulatory subunit that contains two domains; SH2 and 
SH3 and a 110-kDa catalytic subunit. PI3K has a critical role in oncogenic transformation 
and control of cellular proliferation (Chang et al., 2003a; Chang et al., 2003b; Lai et al., 
2008). 
There are two main hypotheses that have been proposed to explain the cellular nature of 
breast cancer formation (Molyneux et al., 2007). The first hypothesis suggests that all 
cells within a tumour have equal potential to be tumourigenic.  So, it is believed that in 
response to outside signals or treatment, spontaneous mutations occur within normal 
breast cell populations leading to the formation of tumour cells. However, it has been 
suggested recently that the formation of a tumour has been linked to tumour initiating 
cells or cancer stem cells. It is proposed that breast cells are heterogeneous to begin with 
and therefore have a high potential for tumourigenesis (Reya et al., 2001; Molyneux et al., 
2007). Since during pregnancy the normal mammary gland undergoes different stages of 
proliferation, differentiation and involution, it is believed that their growth is sustained 
with the aid of mammary epithelial stem cells. Interestingly, it is has been reported that 
females who are pregnant at a young age are less likely to develop breast cancer cells 
(Gabriel and Domchek, 2010). Under the given conditions, cancer stem cells enhance the 
differentiation and tumour growth of non-tumourgenic cells, in turn affecting normal 
tissue development (Molyneux et al., 2007). Consequently, it has been proposed that the 
eradication of cancer stem cells fails using conventional breast cancer therapies. 
Based on the mentioned above theory regarding the origin of breast cancer, it has been 
suggested that breast cancer stem cells are formed by epithelial-mesenchymal transition 
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(EMT). This is because cells that underwent EMT have been shown to have similar 
features, characteristics and behaviours to normal and neoplastic cells (Thiery and 
Sleeman, 2006; Mani et al., 2008). It has been also reported that the induction of EMT in 
normal epithelial cells of the mammary gland can produce cell populations with similar 
characteristics to stem cells (Morel et al., 2008).  The alternative theory suggested that 
cancer stem cells are formed by deregulation, self-renewal and differentiation of normal 
stem cells. The evidence of this theory is based on the similarity between normal and 
cancer stem cells in the level of features and biochemical characteristics (Dontu et al., 
2003). In addition, since normal stem cells have long lifespans, this might increase their 
potential to gain mutations and oncogenic transformation (Ponti et al., 2005; Velasco-
Velázquez et al., 2012). A study by Al-Hajj et al. (2003) suggested that breast cancer stem 
cells originate from basal mammary stem/progenitor cells based on the surface protein 
expression profiles of the two cell types (Al-Hajj et al., 2003). The theories about the 
origin of cancer stem cells are not considered exclusive. Recently, it has been suggested 
that normal and malignant breast cancer stem cells exist in inter-convertible states of 
EMT and mesenchymal-epithelial transition MET under the regulation of micro-RNAs 
(Liu et al., 2012). In this context, different states of breast cancer stem cells and their 
various differentiation states give rise to breast cancer heterogeneity and different tumour 
subtypes.  
1.4 Breast cancer classification  
Since breast cancer is considered both a genetically and clinically heterogeneous disorder, 
a classification system for breast cancer types has been established (Wen et al., 2015). It 
is believed that these classification schemes would assist the biologist in diagnosis, 
treatment and prognosis (Stingl and Caldas 2007; Malhotra et al., 2010; Viale, 2012). 
Breast cancer is classified based on histological level, molecular level, staging of cancer 
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and the function of cancer (Bauer et al., 2007; Eroles et al., 2012). However, histological 
and molecular classifications are the most common classification and they have been used 
widely in clinical settings (Malhotra et al., 2010).  
1.4.1 Histological classifications of breast cancer subtypes 
Breast cancer can be classified histologically into two main types; non-invasive or ductal 
carcinoma in situ (DCIS) and invasive ductal carcinoma (IDCs) (Viale, 2012; Wen et al., 
2015). Ductal carcinoma in situ (DCIS) is an early form of breast cancer and it is 
developed within the milk ducts (Malhotra et al., 2010; Viale, 2012). This type of cancer 
does not invade the basement membrane and is thus confined within the terminal in in-
situ cancers. Ductal carcinoma in situ (DCIS) is classified into lobular carcinoma in-situ 
and ductal carcinoma in-situ (Fabbri et al., 2008). In contrast, invasive breast cancer often 
has the potential to invade the basement membrane (Andersson, 2005). In addition to this, 
there are two main types of invasive breast cancer; invasive lobular and ductal carcinoma 
(Pestalozzi et al., 2008). The main difference between in-situ and invasive cancers is the 
ability of the invasive forms to spread through the lymphatic and vascular vessels located 
under the basement membrane leading to regional lymphatic and distant organ metastases 
(Bauer et al., 2007; Eroles et al., 2012; Viale, 2012). DCIS has traditionally been further 
subclassified based on the architectural features of the tumour, which has given rise to 
five well recognized subtypes; Comedo, Cribiform, Micropapillary, Papillary and Solid 
(Figure 1-4) (Malhotra et al., 2010). 
1.4.2 Molecular classifications of breast cancer subtypes 
Breast cancer can be also classified into five subtypes distinguished by different gene and 
protein expressions at the molecular level (Polyak, 2011) (Figure 1-5). Two hormone-
receptor positive subtypes are luminal A and luminal B, and three hormone-receptor 
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negative subtypes include human epidermal growth factor receptor-2 (HER-2–), basal-like 
and normal breast-like (Weigelt et al., 2010; Elias, 2010; Reddy, 2011; Shastry and 
Yardley, 2013). However, each of these subtypes has its own risk factors for breast cancer 
incidence, preferential organ sites of metastases, risk of disease progression and response 
to treatment. For example, luminal tumours are positive for oestrogen receptors (ER+) and 
progesterone receptors (PR+) therefore the majority respond to hormonal interventions. 
However, HER-2+ tumours have amplification and overexpression of the ErbB2; the 
member of oncogene family and it is related to the epidermal growth factor receptor 
(EGFR) and has been effectively controlled by anti-HER-2 therapies (Wen et al., 2015). 
General basal-like tumours lack hormone receptors and HER-2 so the majority of these 
tumours are also called triple-negative breast cancer (TNBC) (Greenwood et al., 2011; 
Wen et al., 2015). The molecular subtypes of breast cancer have been associated with 
tumour progression and thus have been widely used in clinical settings to predict cancer 
prognoses and guide treatment options (Weigelt et al., 2010; Elias, 2010). 
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Figure 1-4: Histological classification of breast cancer subtypes.  
This scheme, currently used by clinicians, categorizes the heterogeneity found in breast cancer based on 
architectural features and growth patterns. HPF: high power field. (Malhotra et al., 2010). 
 
 
Figure 1-5:Molecular classification of breast cancer. 
This classification is based on the intrinsic molecular subtypes of breast cancer identified by microarray 
analysis of patient tumour specimens. (Malhotra et al., 2010). 
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1.5 Models of human breast cancer  
Breast cancer cell lines have been used widely in research as a model to investigate their 
morphology, structure, features and characteristics including proliferation, apoptosis and 
migration during the breast cancer progression (Carlsson et al., 2007; Vargo-Gogola and 
Rosen, 2007; Holliday and Speirs, 2011). The use of these cell lines has allowed much 
information to be obtained regarding the genetic and molecular mechanisms of various 
signalling pathways (Vargo-Gogola and Rosen, 2007). Breast cancer cell lines share 
many of the genetic and genomic features of human breast cancers, including representing 
several breast cancer subtypes. There is also evidence that gene-expression profiles of 
primary tumours and their metastatic counterparts are not markedly different (Lacroix and 
Leclercq, 2004). However, most breast cancer cell lines are obtained from advanced 
tumours so may represent the most malignant variants that could be adapted to culture 
(Charafe-Jauffret et al., 2006).  
1.5.1 CAMA-1 
The CAMA-1 cell line is classified as luminal-type human breast cancer cells that have a 
rounded morphology in adherent tissue culture. CAMA-1 cells were isolated from 
mammary gland/breast, and derived from metastatic pleural effusion. They are weakly 
invasive. These cells are considered negative for human epidermal growth factor receptor  
(HER-2–) but positive for estrogen receptors (ER+) and progesterone receptors (PR+) 
(ER+/PR+/ HER-2–). They are responsive to estrogen and sensitive to growth inhibition by 
tamoxifen. CAMA-1 cells have an in-frame mutation in the E-cadherin gene, resulting in 
a truncated, non-functional protein. In addition, they have oncogenic mutations in PTEN 
and p53 as well as amplification of the cyclin D1; the protein coding gene (Wang et al., 
2007; Kenny et al., 2007). 
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1.5.2 MDA-MB-231 
The MDA-MB-231 cell line is classified as a triple negative breast cancer cell line since it 
is negative for estrogen receptors (ER–), progesterone receptors (PR–), and human 
epidermal growth factor receptor  (HER-2–) (ER–, PR–, HER-2–)(Liu et al., 2003). These 
cells are derived from a metastatic adenocarcinoma of the mammary gland of a 51-year-
old Caucasian woman, according to the data sheet of the American Type Culture 
Collection (ATCC). This adherent epithelial cell line likely contains more than one cell 
population and is a highly aggressive, invasive and poorly differentiated human breast 
cancer cell line. Similar to other invasive cancer cell lines, the MDA-MB-231 cells 
display invasiveness by mediating the proteolytic degradation of the extracellular matrix 
(ECM), including the basement membrane and several mechanical barriers to the ECM, 
through the increased expression of matrix metalloproteinases (MMPs), including 
gelatinases, en route to their destinations (Yin, 2011). 
1.5.3 MDA-MB-435 
In the past, as shown by a paper authored by Rae JM has been argued that MDA-MB-435 
cells are derived from M14 melanoma cells, results showed that MDA-MB-435 and M14 
melanoma cell lines were identical in respect of gene expression patterns, cytogenic 
characteristics and other minor differences which they explained to be caused by 
phenotypic and clonal drifts (Creighton et al., 2007). However, another study released 
two years later revealed a contradictory view, in which despite the subsequent expression 
arrays studies and gene expression profile studies, MDA-MB-435 cells are indeed from 
metastatic breast cancer origin, the alternate conclusion was drawn from the explanation 
that many cell lines can display “lineage infidelity” and that it would be unreliable to 
conclude that MDA-MB-435 cells are derived from M14 cell lines, based on expression 
patterns (Chambers, 2009). Therefore it can be safely assume that MDA-MB-435 cells 
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used in this experiment are derived from metastatic breast cancer origin and several 
researches still used as model for human breast cancer (Prasad and Gopalan, 2015). 
The MDA-MB-435 cell line was derived in the late 1970s from the pleural effusion of a 
female patient with breast cancer, and has been shown to be highly metastatic in nude 
mice (Cailleau et al., 1978; Chambers, 2009). This cell line has been used for a large 
number of studies on the biology and molecular biology of breast cancer. These cells are 
considered positive for human epidermal growth factor receptor  (HER-2+) but negative 
for estrogen receptors (ER–) and progesterone receptors (PR–) (ER–/PR–/ HER-2+) 
(Holliday and Speirs, 2011). 
Breast cancer and breast cancer cell lines are considered highly tumourigenic since the 
investigation has shown that patients who suffer from the breast cancer have pre-existent 
immune responses, both humoral and cellular, against a variety of proteins expressed in 
their tumours (Disis, 2002). In addition, it has been shown that tumour cells are uniquely 
able to utilize the immune cells and the tumour microenvironment leading to initial 
propagation of carcinogenesis (Zamarron and Chen, 2011). In this respect, understanding 
the immune system and its role against tumour initiation would provide a better 
understanding of tumour cell survival. 
1.6 Immune system 
The immune system is divided into two main parts known as innate and adaptive 
(acquired) response systems. They are determined by speed, memory and specificity of 
the reaction, even though in practice there is much association between them (Crotzer and 
Blum, 2010). The physical, chemical and microbiological barriers are usually referred to 
as innate immunity. However, specifically innate immunity consists of the basic elements 
of the immune system (neutrophils, monocytes, macrophages, complements, cytokines 
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and acute phase proteins), which present instant host defence and protection against 
pathogens. Innate response is termed as the nature of the response since it can be seen 
even in the simplest animals thus it corroborates its crucial role in survival. In contrast, 
adaptive immunity is considered as the hallmark of the immune system of higher animals 
including human beings. The adaptive response consists of T-lymphocytes and B-
lymphocytes, which are produced via antigen specific reactions. The innate immunity is 
quick to respond however; it can cause damage to normal cells and tissues due to the lack 
of specificity. On the other hand, adaptive immunity takes several days or even weeks to 
show a response but it is highly specific and precise. Moreover, the adaptive immunity is 
highly distinct because it has memory cells and as a result, subsequent exposure leads to 
more various and rapid responses even though it is not immediate (Parkin and Cohen, 
2001; Abbas and Lichthman, 2005; Whiteside, 2006). 
1.6.1 Immune system and breast cancer  
The interaction between tumour cells and the immune system is complex and its 
mechanism for the protection of the human body is not yet clear (Goldsby et al., 2003; 
Thibodeau et al., 2012). The complexity of the tumour increases immunodeficiency and 
therefore increases the level of tumourigenicity in tumour cells (Poschke et al., 2011). In 
addition, it has been reported that many tumours downregulate the expression of major 
histocompatibility complex (MHC) molecules suggesting a significant role of the immune 
system in controlling and evaluating the progression of tumours cells (Poschke et al., 
2011; Thibodeau et al., 2012). Consequently, solid tumours, stromal cells and 
neighboring tissues are often infiltrated by a vast array of immune cells (Bindea et al., 
2011). 
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T cells are the key cells of adaptive immune responses for tumour immunosurveillance. 
The recognition of antigens on tumour cells by T cell receptors (TCR) activates CD8+ T 
cells to cytotoxic cells (CTL) that can kill the tumour cell target (Igney and Krammer, 
2002; Grivennikov et al., 2010; Thibodeau et al., 2012). The activation of CD8+ T cells is 
achieved by one subset of CD4+ T cells, which is known as T helper cells type 1 (Th1) 
(Swann and Smyth, 2007; Gajewski et al., 2013). Th2 cells (the second subset of CD4+ T 
cells) are involved in the stimulation of hormonal responses and suppression of the 
development of Th1 responses. Interestingly, in the same manner to CD8+, CD4+ cells can 
also show cytotoxic activity once it is required (Standish et al., 2008). The recognition of 
antigens as peptides by CD8+ and CD4+ tumour cells is presented via major MCH class I 
class II molecules respectively (Igney and Krammer, 2002). 
T cells can recognize a number of tumour antigens that have been identified in several 
solid tumours (Igney and Krammer, 2002; Grivennikov et al., 2010; Coulie et al., 2014). 
The antigens that are expressed exclusively by tumours are known as tumour specific 
antigens (Thibodeau et al., 2012). These antigens arise from mutations or translocation of 
normal cellular genes such as cyclin-dependent kinase-4 (CDK-4), and these mutations 
may involve directly in carcinogenesis. In contrast, the antigens that are expressed by 
tumour cells are known as tumour-associated antigens. Additionally, overexpression of 
mutated proteins such p53 and HER-2/neu may serve as tumour antigens for T cells 
(Igney and Krammer, 2002). Tumour-infiltrating lymphocytes that are reactive against 
differentiation antigens present on normal melanocytes as well as melanomas have also 
been identified (e.g., MART-1/Melan-A, tyrosinase, gp100) (Lee and Margolin, 2012; 
Lee et al., 2012). Moreover, antigens from tumourigenic viruses can be expressed on 
tumour cells. The expression of tumour antigens may be heterogeneous within the tumour 
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so the patient can develop an immune response to multiple antigens (Wortzel et al., 1983; 
Lee et al., 1999; Igney and Krammer, 2002).  
Natural Killer (NK) cells are the main component of the innate immune system, and also 
play a significant role in the immunosurveillance of tumours (Igney and Krammer, 2002; 
Gajewski et al., 2013). The main role of NK cells is to kill MHC class I-deficient cells, a 
phenomen leading to the “missing self” hypothesis. The activity of NK cells is controlled 
by a number of events and different signalling pathways (Igney and Krammer, 2002; 
Vesely et al., 2011). MHC class molecules block signalling activity through engagement 
with specific inhibitory receptors. There are two families of inhibitory receptors that have 
been identified in humans known as the immunoglobulin-like killer cell inhibitory 
receptors and the lectin-like CD94-NKG2 receptors. Stimulatory receptors including 
CD16, CD94-NKG2 and natural cytotoxicity receptors bind to fundamentally expressed 
ligands and NKG2d receptors, which bind to induced molecules by cellular stress (Boyton 
and Altmann, 2007; Moretta et al., 2009). In humans, the MHC class I chain related 
(MIC) glycoproteins MICA and MICB are the ligands for NKG2d receptors. 
Macrophages and neutrophils are additional cells of the innate immune system that are 
involved in immune responses against tumours (Nowarski et al., 2013). These cells are 
responsible for killing tumour cells directly through the destruction of tumour cells and 
vessels and by inhibition of angiogenesis (Igney and Krammer, 2002; Nowarski et al., 
2013). They also present tumour antigens and enhance other immune cells such as CTL, 
NK cells and APCs (Maruyama et al., 2011). In contrast, the role of inflammatory cells is 
to increase progression by production of tumour growth factors and stimulation of 
angiogenesis. Macrophages and neutrophils are recruited to the tumour site by expression 
of adhesion molecules on endothelial cells and by chemotactic proteins (Igney and 
Krammer, 2002; Vesely et al., 2011). 
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Two different mechanisms have been proposed to protect the human body against 
tumours by the immune system. These mechanisms are known as the concept of 
immunosurveillance (cancer immunoediting) and the danger model (Möller and Möller, 
1976; Igney and Krammer, 2002). In 1994, Polly Matzinger presented a new theory called 
the danger model suggesting that specific immune response develops as a result of danger 
detection rather than discrimination between self and non-self antigens (Matzinger, 1994; 
Kowalczyk, 2002). Although this model refers mainly to immune tolerance its 
assumptions are valid for such distant subjects as tumors or apparently unrelated with 
immunology gene therapy. The danger model mechanism proposes that tumour cells do 
not seem to be dangerous to the immune system so the presence and response of T cells to 
tumours is not initiated. Because danger model suggests that the immune system may be 
concerned with the detection of damaged cells rather than recognition of non-self 
(Matzinger, 2001, 2002), cancer immunoediting theory will be discussed in more detail. 
1.6.2 Cancer immunoediting 
In 1957, Burnet and Thomas hypothesised that the immune system is capable of 
recognising and destroying or eliminating nascent transformed cells in cancer 
immunosurveillance (Burnet, 1957; Dunn et al., 2002, 2004; Urosevic and Dummer, 
2008). The concept of immunosurveillance was based on evidence that the adaptive 
response was responsible for protecting the immunocompetent host through preventing 
cancer development. However, the hypothesis of immunosurveillance was poorly 
supported by Stutman’s studies (Dunn et al., 2004; Schreiber et al., 2011).  By the 1990s, 
some studies rekindled the concept of immunosurveillance by discovering the importance 
of interferon-gamma (IFN-γ) in promoting immunologically induced rejection of 
transplanted tumour cells and also by demonstrating that mice lack either IFN-γ or 
adaptive immunity, T cells, B cells and NK cells. These studies were carried out in order 
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to reassess the role of immunity in cancer control (Schreiber et al., 2011). However, a 
major revision was made in the immunosurveillance hypothesis in 2001 when it was 
discovered that the immune system is not only responsible for controlling the tumour 
quantity but also tumour quality (immunogenicity). This study demonstrated that tumours 
formed in mice that lacked an intact immune system were highly immunogenic and 
classified as “unedited” compared to tumours that were derived from immunocompetent 
mice and were termed “edited”. Therefore, the hypothesis of immunosurveillance was 
replaced with cancer immunoediting, which stresses the protective, and tumour promoting 
actions of immunity for the host, in developing tumours (Dunn et al., 2004; Schreiber et 
al., 2011). The process of cancer immunoediting consists of three main phases: 
elimination (also known as immunosurveillance), equilibrium and escape. Specifically, 
the elimination phase is divided into four phases (phases 1-4) with each phase having a 
critical role. Therefore, it is believed that a full understanding of cancer immunoediting 
and immunosurveillance will hopefully stimulate the development of effective 
immunotherapeutic approaches to eliminate or at least control human cancer (Dunn et al., 
2002, 2004; Schreiber et al., 2011). The three phases of cancer immunoediting process are 
illustrated in (Figure 1-6). 
The cells and molecules of innate and adaptive immune responses to tumour cells have 
the potential to eradicate the developing tumour and protect the host from tumour 
formation, through the process of elimination. However, the tumour cells may also go 
through the equilibrium phase if the elimination phase is not completely successful. In the 
equilibrium phase, tumour cells may be either maintained chronically or 
immunologically, sculpted by the immune editor to produce a new population of tumour 
variants. These variants may eventually evade the immune system through a variety of 
mechanisms and become clinically detectable in the escape phase. Several cells are 
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involved in cancer immunoediting, such as NK cells, NK T cells, macrophages, together 
with molecules like IFN-γ and TNF-α. Therefore, it is believed that studying the 
mechanism of action of one of the aforementioned molecules might enable scientists to 
design an appropriate drug for treating cancer at least in the level of in vitro (Dunn et al., 
2002, 2004; Schreiber et al., 2011; DuPage et al., 2012; Matsushita et al., 2012). 
A number of molecules are involved in cancer immunoediting; CD74, a cell-surface 
molecule, is believed to enable tumours to escape immune system (Chao et al., 2012). It 
has also been suggested that high levels of CD74 expression is associated with class II 
MHC expression and might prevent tumour antigen presentation by blocking the peptide-
binding cleft, thus leading to a lack of recognition of tumour cells by immune cells 
(Beswick and Reyes, 2009; Borghese and Clanchy, 2011; Zheng et al., 2012). Several 
studies have shown that upregulation of CD74 expression in human cancers also appears 
to influence tumour growth and dissemination suggesting that CD74 may have a role in 
escaping the equilibrium phase of cancer immunoediting (Chao et al., 2012). 
Current biomarkers cannot accurately target all breast cancer subtypes, so further research 
is required to discover new tumour antigens. This study will be emphasising the 
importance of CD74, MIF and CD44 potential as biomarkers. CD74 and CD44 along with 
MIF have been previously shown to be co-expressed in metastatic prostate cancer cell 
lines LNcap and DU-145. CD74 serves as a cell-surface receptor for MIF in association 
with CD44, which when bound to the encoded protein initiates cell survival signalling 
pathways through extracellular signal-regulated kinase (ERK1 and ERK2) activation. 
Furthermore, both LNcap and DU-145 had increased gene MIF overexpression in 
comparison to normal and benign prostate human cells (Meyer-Siegler et al., 2006). 
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Figure 1-6:The phases of cancer immunoediting process.  
Cancer immunoediting is an extrinsic tumour suppressor mechanism that engages only after cellular 
transformation has occurred and an intrinsic tumour suppressor has failed.  Cancer immunoediting consists 
of three phases: elimination, equilibrium and escape. Innate and adaptive immunity are included in the 
elimination phase in order to destroy developing tumours before they appear clinically. However, the 
tumour cells may also go through the equilibrium phase if the elimination phase is not completely 
successful. In the equilibrium phase, tumour cells may be either maintained chronically or 
immunologically, sculpted by the immune editor to produce a new population of tumour variants. These 
variants may eventually evade the immune system by a variety of mechanisms and become clinically 
detectable in the escape phase (Dunn et al., 2004). 
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1.7 Cluster of differentiation 74 (CD74)  
In humans, the gene that encodes the CD74 or invariant chain (Ii) molecule is found on 
chromosome 5 whereas in mice, the gene is located on chromosome 18 (Yamamoto, 
1985). Jones and his colleagues were the first to recognize the Ii protein in 1979, 
specifically when the MHC class α chain and Ii was separated in 2D-gels. In spite of this, 
in 1989 it was found that Ii has a crucial role in antigen presentation through influencing 
the expression and peptide loading of MHC class II molecules (Badve et al., 2002). In 
1995, the name CD74 was given to Ii by ‘Leukocyte Typing Workshop’ (Landsverk et al., 
2009). Cluster of differentiation (CD) 74, also known as invariant chain, Ii or MIF 
receptor, is classified as a type II transmembrane glycoprotein that is expressed on 
antigen presenting cells and has diverse immunological functions (Burton et al., 2004; 
Stein et al., 2007; Beswick and Reyes, 2009). CD74 is post-translationally glycosylated 
and exists in various isoforms. There are four isoforms of CD74 in human beings, P33, 
P35, P41 and P43. Through alternative splicing of the Ii transcript where the P41 isoform 
has an extra exon, (exon 6b) these isoforms can be distinguished. However, the most 
common isoform (P33) has a molecular weight of 33 kDa (Landsverk et al., 2009; 
Beswick and Reyes, 2009). The structure of CD74 (shown in Figure 1-7) consists of 30 
NH2- terminal, intracytoplasmic residues, a 26 amino acid hydrophobic transmembrane 
region and 244 amino acid extracytoplasmic domains containing two N-linked 
carbohydrate chains (Stein et al., 2007; Landsverk et al., 2009; Shachar and Haran 2011; 
Gil-Yarom et al., 2014). CD74 is synthesized on the rough endoplasmic reticulum in 
same manner as MHC class II molecules despite the genes of these molecules being 
located on different chromosomes (Badve et al., 2002).  
The most well known function of CD74 is its ability to associate with MHC class II α and 
β chains, directing the transport of the αβIi complex to the endosome and lysosome (Pyrz 
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et al., 2010). Specifically, the role of CD74 in antigen presentation has been divided into 
three main functions. Firstly, CD74 acts as a chaperone that is responsible for stabilizing 
nascent human leukocyte antigen (HLA)-DR αβ-heterodimers by formation of a trimetric 
structure. Secondly, by means of various sorting and internalization signals in its N-
terminal cytoplasmic tail, CD74 directs HLA-DR molecules to subcellular compartments. 
Thirdly, CD74 prevents loading of antigenic peptides into the groove of HLA-DR 
molecules outside endosomes/lysosomes through a stretch called CLIP (class II-
associated invariant chain) (Moldenhauer et al., 1999). CD74 has begun to emerge as a 
more versatile molecule beyond its well-known function of regulating class II MHC 
trafficking. Several studies have revealed that cell-surface expression of CD74 is not 
always dependent on class II MHC (Wilson et al., 1993; Beswick and Reyes, 2009). In 
this context, CD74 has been suggested to function as a cytokine and bacterial receptor. 
CD74 has also been shown to be involved in signalling along with MIF and CD44 
pathways as a survival receptor (Stein et al., 2007; Beswick and Reyes, 2009). CD74 was 
also demonstrated to be involved the maturation of B cells through a pathway involving 
NF-κB (Stein et al., 2007). 
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Figure 1-7: Schematic diagram of gene and protein structure of CD74. 
The corresponding gene of CD74 consists of nine exons. The 33 kDa and 35 kDa forms of Ii, are both 
encoded by eight exons but they differ in 16 N-terminal residues as a result of alternative translation 
initiation. The 41 kDa isoform is encoded by nine exons generated by the alternative splicing of a common 
pre-mRNA. Theoretically, an additional 43-kDa form could be expected but is not yet unequivocally 
detected in immunoprecipitates from human cells. The additional exon 6b in Ii41 and Ii43 encodes a 
cysteine-rich stretch of 64 amino acids near the C-terminus that displays a striking homology to a repetitive 
sequence of thyroglobulin. (Strubin et al., 1986 and Gregers et al., 2003). 
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1.7.1 CD74 and the antigen presentation process 
The MHC class II molecule is restrictedly expressed by a limited set of cells called 
professional antigen presenting cells (APCs), which include cells of the monocyte-
macrophage lineage, dendritic cells (DCs) and B-lymphocytes, unlike MHC class I 
molecules which are ubiquitously expressed on all nucleated cells. The function of MHC 
class II is to present antigenic peptides from exogenous origin to a specialized T cell, 
CD4+ in the presence of invariant chain (CD74). Hence, when CD74 is synthesized, it 
begins to associate with MHC class II (HLA-DR-α) and MHC class II (HLA-DR-β) 
within the endoplasmic reticulum (Burton et al., 2004; Stein et al., 2007; Landsverk et al., 
2009; Neefjes et al., 2011). The association between these molecules is believed to take 
place in the rough endoplasmic reticulum through the sequential addition of DR α and β 
heterodimers to a trimeric core of CD74 molecules in order to from a nine-subunit 
complex with an equimolar amount of CD74–MHC class II.  The resulting complex of 
CD74 and MHC class II is then gradually transported through Golgi apertures to the late 
endosomal compartment that is termed the MHC class II compartment (MIIC) either 
directly or within the plasma membrane. Here, CD74 is digested and cleaved into peptide 
fragments by endosomal/lysosomal proteases, leaving residual class II-associated Ii 
peptides (CLIP; amino acids 91-99) in the peptide-binding groove of the MHC class II 
heterodimer. In order to facilitate the exchange of CLIP fragments for specific peptides 
derived from a protein degraded in the endosomal pathway, MHC class II molecules 
require HLA-DM. By reaching this stage, MHC class II molecules are ready for 
transporting via the plasma membrane to present their peptides to CD4+ cells (Burton et 
al., 2004; Stein et al., 2007; Landsverk et al., 2009; Beswick and Reyes, 2009; Neefjes et 
al., 2011). 
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1.7.2 The role of CD74 in breast cancer 
The expression of CD74 has been found in several normal tissues, such as HLA class II- 
positive cells, including B cells, monocytes, macrophages, langerhans cells, dendritic 
cells, a subset of T activated cells and thymic epithelium. However, several studies have 
confirmed that CD74 is highly expressed in inflammatory disorders and several types of 
tumours (Stein et al., 2007; Beswick and Reyes, 2009). For example, 90% of B-cell 
cancers and the majority of cell lines derived from these cancers express CD74 in high 
levels compared to normal tissues (Stein et al., 2007). In particular, CD74 is expressed on 
different cancer cells, such as myeloma; prostate cancer cells, cancers of the 
gastrointestinal tract as well as breast cancer (Beswick and Reyes, 2009; Verjans et al., 
2009). CD74 expression has also been shown to be correlated positively with gastric 
cancer stages (Zheng et al., 2012). Recently, CD74 has been classified as a new 
prognostic factor for patients with malignant pleural mesothelioma (Otterstrom et al., 
2014). Moreover, Cheng et al. (2015) have also revealed that CD74 has a high potential in 
treating thyroid carcinoma. 
Verjans et al (2009) have shown that breast cancer tissues and breast cancer cell lines 
overexpressed CD74. Interestingly, Leth-Larsen et al. (2009) observed that CD74 was 
present in tumour cells of 61% of ER–/PR– breast cancer biopsies but in only 33% of the 
ER+/PR+ biopsies. Greenwood et al. (2011) also revealed that triple negative breast cancer 
highly expressed signal transducer and activator of transcription (STAT-1) and CD74. 
Similarly, Tian et al. (2012) have shown that CD74 was negatively expressed in non-
triple negative breast cancer while it is highly expressed on triple negative breast cancer 
and metastatic lymph nodes. Richard et al. (2014) showed that stromal CD74 expression 
significantly correlated with triple-negative receptor status and the absence of estrogen 
receptors. Recently, according to Yaprak et al. (2015) patients who suffer from breast 
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cancer with no CD74 expression had significantly better surgical outcomes than CD74-
positive.To emphasize the role of CD74 in tumourigenicity and immunogenicity, the 
expression of CD74 has been assessed under proinflammatory and inflammatory 
conditions using interferon-gamma and lipopolysaccharide (Greenwood et al., 2011; 
Zheng et al., 2012). Since then CD74 has been identified as a potential novel target for 
breast cancer therapies as well as other types of cancer such as prostate, gastric cancer 
and thyroid carcinoma (Meyer-Siegler et al., 2006; Leth-Larsen et al., 2009; Verjans et 
al., 2009; Tian et al., 2012; Zheng et al., 2012; Richard et al., 2014; Cheng et al., 2015). 
1.7.3 CD74 and interferon-gamma (IFN-γ) 
In terms of proinflammatory cytokines, Möller and Moldenhauer (1999) have shown that 
the expression of CD74 can be induced using several types of cytokines such as IFN-γ, 
TNF-α and IL-4. Maubach et al. (2007) revealed that CD74 expression was upregulated 
when hepatic stellate cells (HSCs) were treated with IFN-γ for 30 hr. Martín-Ventura et 
al. (2009) demonstrated that the expression of CD74 increased after IFN-γ treatment in 
human aortic VSMCs and THP-1 cells. Moldenhauer et al. (1999) also showed that the 
expression of CD74, HLA-DR and HLA-A, B, C increased when colon carcinoma cell 
lines (HT-29 cells) were incubated with recombinant-IFN-γ (rIFN-γ). Similarly, Burton et 
al. (2010) revealed that cell-surface and cytoplasmic expression of CD74 was upregulated 
in acute myeloid leukaemia (AML) lines after IFN-γ exposure in AML patient specimens 
and cell lines. In the same manner, Greenwood et al. (2011) recently demonstrated that 
the expression of CD74 is upregulated in breast cancer cell lines. Their findings suggested 
that overexpression of CD74 using IFN-γ treatment increased adhesion of tumour cells 
(Greenwood et al., 2011). Interferon-gamma (IFN-γ) is a potent proinflammatory 
cytokine that has many critical roles including; promoting immune responses, 
immunopathological processes, cell maturation, differentiation, activation, and apoptosis 
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(Pestka et al., 1987; Platt and Hunt, 1998; Dranoff, 2004). INF- γ is a member of a family 
of proteins originally identified by their capacity to non-specifically protect cells from 
viral infections. IFN-γ is divided into two main classes on the basis of structural and 
functional criteria as well as the stimuli that induce their expression (Farrar and Schreiber, 
1993; Ikeda et al., 2002; Schroder et al., 2004).  It is know that IFN-γ plays a critical role 
in cancer and cancer progression by controlling apoptosis, cell proliferation, angiogenesis 
and the expression of MHC class I and II (Sikora and Smedley, 1983; Gooch et al., 2000; 
Brandacher et al., 2006; Zaidi and Merlino, 2011;). However, IFN-γ has another face that 
functions against the immune system, and increases the tumourigenicity of tumour cells 
(Zaidi and Merlino, 2011). There is now emerging evidence that IFN-γ may also be 
involved at the equilibrium and/or evasion stages, roles that may be more pro-
tumourigenic. IFN-γ has been shown to upregulate the suppression of CTL- and NK cell-
mediated immune responses, and is central to tumour immune escape (Brody et al., 2009). 
IFN-γ has also been suggested to enable tumours to escape innate immune system 
surveillance and influence tumour growth and dissemination by induction of CD74 
(Greenwood et al., 2011; Chao et al., 2012). 
IFN-γ is a pleiotropic cytokine involved in aspects of immune regulation including 
transcription. Upon engagement of IFN-γ with its receptors; interferon gamma receptor 
(IFNGR1 and IFNGR2), janus tyrosine kinases (JAK) are activated and subsequently 
phosphorylate the signal transducer and activator of transcription-1 (STAT-1) protein, 
which dimerises and translocates to the nucleus to induce target gene transcription by 
binding to gamma activated sequences (GAS) in the promoter of IFN-γ- responsive genes 
(Ma et al., 2005). 
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1.7.4 CD74 and lipopolysaccharide (LPS) 
During bacterial infection, it has been reported that the expression of CD74 is increased 
under inflammatory conditions.In, Helicobacter pylori (H.pylori) infection the bacterium 
can also use CD74 as a point of attachment to gastric cancer cell lines (Beswick et al., 
2006; Beswick and Reyes, 2009; Zheng et al., 2012). H.pylori is classified as a gram-
negative spiral bacterium that colonizes the human gastroduodenal mucosa. In this 
context, Zheng et al. (2012) reported that CD74 expression is upregulated after exposure 
to lipopolysaccharide (LPS) in gastric cancer cell line MKN-45. 
Lipopolysaccharide (LPS) is unique for gram-negative bacteria, present in the outer 
membrane, and is made of both hydrophobic and hydrophilic domains. It is important for 
bacteria to survive and protects them from hydrolytic degradation by other organisms. 
LPS consists of three components: (i) Lipid A, (ii) core Oligosaccharide (iii) O-specific 
side chain or O-antigen (Qiao et al., 2014). A lipid, which connects with epitopes of 
CD14, contains two acylated GIcNAc-P residues (GIcN). The core part consists of KDO 
(3-deoxy-D-manno-octulosonic acid), heptoses (Hep), and neutral sugars such as 
galactose. The outer O-antigen is made of repeating units of two to eight sugars 
(Hardaway, 2000; Hashimoto, 2003; Qiao et al., 2014). 
1.7.5 The role of CD74 in cancer immunoediting 
Research has shown that CD74 plays a significant role in tumour immunosurveillance and 
cancer immunoediting. Chao et al. (2012) hypothesised that over expressed CD74 might 
enable tumours to escape the immunosurveillance recognition via evasion of 
phagocytosis. It is believed that CD74 inhibits phagocytosis via the ligation of expressed 
signal regulatory protein-α (SIRP-α) by phagocytes leading to tyrosine activation and 
inhibition of myosin accumulation at the submembrane assembly site of the phagocytic 
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synapse (Tsai and Discher, 2008). So, CD74 functions as a ‘don’t eat me signal’ and a 
marker of self, as loss of CD74 may lead to homeostasis of phagocytosis of damaged and 
aged cells (Oldenborg et al., 2000; Blazar et al., 2001; Chao et al., 2012). This process 
occurs when CD74 on tumour cells binds to SIRP-α on phagocytes leading to promotion 
of phagocyte inhibition and tumour survival (Chao et al., 2012). In support of this 
hypothesis, it has been shown that forced expression of CD74 enhances dissemination and 
fulminantes death in xenografted mice in a CD74-deficient myeloid leukaemia cell lines 
(Jaiswal et al., 2009).  
CD74 expression by tumour cells has been linked to the process of tumour recognition by 
T cells and antigen presentation (Beswick and Reyes, 2009). CD74 is thought to be a link 
molecule between the endogenous and the exogenous antigen presentation pathway as 
shown recently by Basha and his group (Basha et al., 2012). It has been also shown that 
CD74 exhibits physical association with HLA-DR promoting re-cycling of HLA-DR into 
the endosomes. It was proposed that the high level expression of CD74 might prevent the 
antigen presentation process by blocking the peptide binding cleft rendering tumours less 
immunogenic. Moreover, it has been demonstrated that upregulation of CD74 in human 
cancer cells directly influences tumours growth and dissemination suggesting that CD74 
may have a role in escaping the equilibrium phase of cancer immuneediting (Chao et al., 
2012).  
In addition, it has been confirmed recently that blocking CD74 expression on tumour cells 
by anti-CD74 antibodies may facilitate the elimination of tumour cells by the immune 
system (Zheng et al., 2012; Otterstrom et al., 2014). It has been suggested that the anti-
CD74 antibody eradicates tumour cells through the Fc-dependent mechanism including 
complement dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity 
(ADCC) (Chao et al., 2012). Interestingly, it was found that the anti-CD74 antibody 
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induces cytotoxicity of NK cells against head and neck cancer (Kim et al., 2008). Another 
suggestion proposed is that blocking CD74 may induce the level of tumour cells apoptosis 
in vivo and in vitro (Kikuchi et al., 2005; Uno et al., 2007). Anti-CD47 antibody-mediated 
apoptosis occurred independent of the caspase cell death pathway and may also involve 
ligation and activation of thrombospondin, an additional ligand of CD47 (Mateo et al., 
2002; Manna and Frazier, 2004). In support of this finding, CD74 has been suggested to 
be involved in signalling pathways via MIF and CD44 increasing tumour cell survival and 
inhibition of apoptosis (Tillmann et al., 2013; Yaddanapudi et al., 2013; Richard et al., 
2014). Further, Verjans et al. (2009) found that MIF/CD74 interactions play a crucial role 
in breast tumourigenesis. 
1.7.6 The interaction of CD74 along with MIF and CD44 
Several studies have shown that MIF can bind to the extracellular domain of CD74 to 
promote signalling pathways including inflammatory processes, activation of ERK1 and 
ERK2 members of the family of mitogen-activated protein kinases (MAPKs), cell 
proliferation, prostaglandin E2 (PGE2) production, chemokine-mediated signalling and 
apoptosis (Leng et al., 2003; Shi et al., 2006; Starlets et al., 2006; Bach et al., 2009; Fan 
et al., 2011; Tillmann et al., 2013). However, the short cytoplasmic tail of CD74 lacks a 
signal-transducing intracellular domain, although phosphorylation of the serine residues 
takes place on the P35 variant of CD74 and requires CD44 (Zernecke et al., 2008; 
Borghese and Clanchy, 2011). CD44 binding is necessary for MIF mediated signalling 
cascades to start along with Src-tyrosine kinase (Shi et al., 2006). So, CD74 that has been 
modified by the addition of chondroitin sulfate interacts with CD44, a polymorphic 
transmembrane protein with kinase activating properties, forming a receptor complex 
(Naujokas et al., 1993; Borghese and Clanchy, 2011). This leads to phosphorylation of 
ERK1 and ERK2, which further triggers various effector proteins involved in 
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inflammatory processes and cell proliferation. ERK1 and ERK2 remain phosphorylated 
for many hours and hence this cascade continues for a longer time (Mitchell et al., 1999; 
Lue et al., 2006). Along with this, the Akt pathway is also activated by MIF (Lue et al., 
2007). This leads to phosphorylation of pro-apoptotic proteins, namely BAD and BAX and 
the cells acquire signals to withstand apoptosis (Lue et al., 2007). In B-lymphocytes, MIF 
induces a signalling cascade that leads to nuclear factor-κB (NF-κB) activation, 
proliferation and survival (Matza et al., 2001; Starlets et al., 2006). These findings 
suggest that CD74 stimulation initiates a pro-survival signal. 
1.8 Macrophage migration inhibitory factor (MIF) 
Rich and Lewis originally reported MIF as immunological mediators in 1932 when they 
noticed an apparent active inhibition of inflammatory cell migration in vitro (Rich and 
Lewis, 1932; Flaster et al., 2007). In the 1950s, the name macrophage migration 
inhibitory factor was given to substances that were believed to be responsible for arresting 
the movement of monocytes in vitro by cellular inflammatory reactions. MIF is 
considered one of the first cytokines that have been described and its role in both innate 
and adaptive immunity was shown approximately 50 years ago in 1966 (Bach et al., 
2008). MIF was classified as a T-cell-derived factor, which is believed to be responsible 
in macrophage migration inhibition in research carried out to characterize delayed-type 
hypersensitivity (Calandra and Roger, 2003; Bucala and Donnelly 2007; Conroy et al., 
2010). In addition, MIF and interferon have been identified as the first two cytokines that 
have a central role in immune responses. However, the precise role of MIF in biological 
activities remained unclear until the cloning of human MIF complementary DNA in 1989 
(Weiser et al., 1989).  In 1991, research showed that MIF showed activity similar to 
hormones after the exposure of the anterior pituitary gland to the endotoxin LPS. 
Therefore, these observations suggest that MIF might be a mediator that links the immune 
Chapter 1 Introduction 
 
 
56 
system to endocrine via its activity (Calandra and Roger, 2003; Bucala and Donnelly, 
2007).  
The expression of MIF has previously been linked to be the main cellular source of T 
cells in the immune system (Leng and Bucala, 2006). However, it was later confirmed 
that the expression of MIF could be found in several types of immune cells, such as 
monocytes, macrophages, blood dendritic cells, B cells, neutrophils, mast cells and 
basophils (de Dios Rosado and Rodriguez-Sosa, 2011). Since MIF is constitutively 
expressed and stored in intracellular pools, its secretion does not require de novo protein 
synthesis. In addition to its expression by immune cells, MIF was found to be expressed 
by cells and tissue in direct contact with the host’s natural environment, such as 
gastrointestinal and genitourinary tracts, the lung and the epithelial lining of the skin. 
Another feature that makes MIF unique is that it can be highly expressed by some tissues 
of the endocrine system specifically by the hypothalamus, pituitary and adrenal glands 
(Flaster et al., 2007; Calandra and Roger, 2003). 
The human MIF gene was first reported in 1994 by Paralkar and Wistow (Paralkar and 
Wistow, 1994; Donn and Ray, 2004). The MIF gene of the human genome is located on 
chromosome 22 (22q11.1). The human gene of MIF is composed of three different short 
exons of 107, 172 and 66 base pairs; and two introns of 188 and 94 base pairs as shown in 
Figure 1-8. The 5’ end region has several consensus DNA-binding sequences for 
transcription factors, such as activator protein 1 (AP1), NF-κB, EST, erythroid 
transcription factor (GATA), SP1 and cAMP response element binding protein (CREB). 
However, knowledge concerning these putative DNA-binding sites in the regulation of 
expression of the human MIF gene is still limited (Brunner and Bernhagen, 2000; 
Calandra and Roger, 2003).  
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Three laboratories first determined the three-dimensional structure of the MIF protein in 
1996. These observations have shown that human and rat MIF is a homotrimer.  It has 
been also demonstrated that determination of MIF showed that there is a marked three-
dimensional structural homology between MIF and three microbial enzymes; 
oxalocrotonate tautomerase, 5-carboxymethyl-2-hydroxymuconate isomerase and 
chorismate mutase (Calandra and Roger, 2003; Leng and Bucala, 2006; Conroy et al., 
2010). Furthermore, unlike any other cytokine or pituitary hormones, the primary 
structure of MIF consists of 115 amino acids with a molecular weight of 12.5 kD. It has 
also been shown that the secondary structure of MIF consists of 6 β-plated sheets and 2 
antiparallel α-helices with a high similarity to major histocompatibility complex (MHC) 
molecules (Bach et al., 2009; Cornry et al., 2010). Three-dimensional structural homology 
of top and side view of MIF is shown in Figure 1-9. 
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Figure 1-8: The structure of human MIF gene.  
The green regions show short exons, pink regions illustrate the introns. It is known that exons are codes of 
proteins, while introns are not involved with the coding for proteins (Calandra and Roger, 2003). 
 
 
Figure 1-9: Three-dimensional structural homology of top and side view of MIF.  
Three identical monomers are shown; each monomer consists of 2 anti-parallel α-helices that pack against 6 
β-plated sheets (Calandra and Roger, 2003). 
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MIF is also known as a pleiotropic cytokine and plays a pivotal role in both innate and 
adaptive immunity. MIF is one of the most important cytokines since it is considered a 
multi-functional molecule that has several roles in immune responses (Verjans et al., 
2009). It has been found that MIF is capable of stimulating other cytokines to the site of 
infections. With regards to MIF structure, Rosengren et al. (1996) suggested that MIF 
might play an enzymatic role; however knowledge regarding its activity as enzyme is still 
limited (Bach et al., 2009). MIF has been found to be a modulator in the immune system. 
Since MIF is highly expressed by most cells of immune system, such as monocytes, 
macrophages, dendritic cells and B cells, it is believed that MIF has a central role in both 
innate and adaptive immunity (Rice et al., 2003). Monocytes/macrophages are the first 
defensive line of immune cells that are activated against foreign invaders. MIF is released 
from macrophages for cytokine production, such as IFN-γ, IL-2, TNF-α and IL1-β. 
However, mRNA production and protein synthesis are required in order to secrete TNF-α 
and IL1-β. In general, the main function of MIF in the presence of these cytokines is to 
attract the other immune cells to the sites of infections and to elevate inflammatory 
interactions against intracellular pathogens (Calandra et al., 1994, 2000; Benigni, 2000). 
MIF has a critical role in tumourigenesis due to its overexpression by cancer cells. It has 
been found that MIF is overexpressed in various tumours, such as breast cancer, prostate 
cancer and colon carcinoma. For instance, the expression of MIF was higher in tumour 
tissue compared to normal tissue in a mouse model for intestinal cancer (Bach et al., 
2008; Conroy et al., 2010).  It has been confirmed that MIF may play a significant role in 
inducing angiogenesis, promoting cell cycle progression, inhibiting apoptosis, inhibiting 
the lysing of tumour cells by NK cells, inhibiting p53-dependent gene expression, 
activating ERK1 and ERK2 signalling and upregulating TLR4 expression. The expression 
of MIF is chiefly controlled by cell stress and growth factors. Chesney and Takahashi 
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have demonstrated that using anti-MIF treatment can alter the proliferative state of 
tumour cells (Takahashi et al., 1998; Chesney et al., 1999; Calandra and Roger, 2003). 
MIF is capable of inhibiting acute inflammation and killing cells; a function that is 
thought to be the first step in tumourigenesis. It is believed that MIF inhibits the action of 
glucocorticoids by preventing the activation of NF-κB, a primary target of steroids. 
Steroids play a central role in the induction of mitogen-activated protein kinase 
phosphatases. This mechanism is regulated by MIF, which is essential in down-regulation 
of MKA kinase activation (Bach et al., 2008; Tillmann et al., 2013).  
Within the breast, Bando et al. (2002) documented the overexpression of MIF in 93 
primary breast cancer tissues with MIF localization to tumour, as well as stromal cells. 
Xu et al. (2008) found that MIF was overexpressed in breast cancer tissues compared with 
normal tissues. In the same manner, Verjans et al. (2009) have also shown that MIF is 
overexpressed in non-invasive breast cancer cells lines such as MDA-MB-468 and ZR- 
75-1 as well as breast cancer tissue. High expression of MIF in breast tumour tissue has 
also been correlated with tumour size and hormone receptor status and is associated with 
favourable survival (Verjans et al., 2009). Surprisingly, MIF overexpression in breast 
cancer cells was most abundantly observed in non-invasive breast cancer cells, but not in 
invasive cells, which in turn expressed higher levels of the MIF receptor CD74 (El 
Bounkari and Bernhagen, 2012). Richard et al. (2014) also observed an inverse corre-
lation between stromal MIF expression and tumour size, as well as an elevated MIF 
presence in fibroblasts surrounding the tumour tissue. Their findings suggested that there 
is a positive correlation between the expressions of MIF and CD74 in breast cancer 
(Richard et al., 2014). In support of this hypothesis, McClelland et al. (2009) 
demonstrated that co-expression of MIF and CD74 was associated with greater 
vascularity and higher levels of pro-angiogenic chemokine receptors (CXC). 
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Despite knowledge about the role of MIF in tumourigenesis, identification of potential 
receptor of MIF and obtaining information concerning the intracellular signalling cascade 
took some time. It was believed that MIF might interact with a constituent of albumin 
known as sarcolectin although no studies have been carried out to support these 
observations. Kleemann et al. (2000) showed that MIF is taken up by cells and binds to c-
Jun activation domain-binding protein-1, inhibiting the activation of the transcription 
factor AP-1. Leng et al. (2003) were the first to demonstrate that there is a relationship 
between MIF and CD74 as a potential MIF receptor in signalling pathways. It has also 
been shown that fluorescence-coupled MIF binds with high affinity to the CD74 receptor. 
CD74 has been known to play a role in the transport of export enzymes from the Golgi 
apparatus to the endoplasmic reticulum. However, CD74 is expressed on the cell-surface, 
so it appears very likely that it also serves as receptor for MIF in the presence of CD44. 
CD44 is classified as a transmembrane co-receptor that is required for MIF-induced 
ERK1 and ERK2 kinase phosphorylation. The binding of MIF is also associated with 
serine phosphorylation of both CD74 and CD44 receptors. However, protection from 
apoptosis is required in order to activate both CD74 and CD44 receptors. MIF has been 
known as a non-cognate ligand for chemokine receptors (CXCR4 and CXCR2) in 
addition to its capability to interact with CD74 and CD44. CXCR4 and CXCR2 have been 
described previously as functional receptors (Bernhagen et al., 2007; Tillmann et al., 
2013).  
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1.9 Cluster of differentiation 44 (CD44) 
Cluster of differentiation 44 (CD44) is a transmembrane glycoprotein that acts as the 
major receptor for hyaluronan and it is considered a member of a large family of cell 
adhesion molecules (CAMs). The human gene of CD44 is located on the short arm (p13) 
of chromosome 11. The CD44 gene consists of 20 exons spanning approximately 60 Kb 
of human DNA and they are classified to two main groups (Sneath and Mangham, 1998; 
Cichy and Puré, 2003). The first five exons 1-5 as well as exons 16-20 are spliced 
together to form a transcript and encode the ubiquitously expressed isoforms that are 
abbreviated to CD44s or CD44H. The 10 variable exons 6-15 (also known as v1-10) can 
be alternatively spliced and included within the standard exons at the insertion site 
between exons 5 and 16. CD44 expressed from the variable exons is abbreviated, to 
CD44v. Theoretically, more than 1000 isoforms of CD44 would be allowed for 
expression based on alternative splicing. Since CD44 is a transmembrane glycoprotein, 
the extracellular domain of protein is encoded by exons 1-17, the short transmembrane 
domain is encoded by exon 18 and the cytoplasmic domain is encoded by part of exon 18 
and by exons 19 and 20 (Sneath and Mangham, 1998; Lesley and Hyman, 1998; 
Goodison et al., 1999; Cichy and Puré, 2003).  
The molecular weights of CD44 proteins range from 80-230 kDa for three reasons. 
Firstly, the variety of mRNAs generated by alternative splicing of ten variant exons 
during its pre-mRNA. Secondly, the posttranslational modifications including N- and O-
linked glycosylation and the attachment of glycosaminoglycans generate additional 
structure of diversity of CD44. Thirdly, the proteins often get shortened in vivo owing to 
partial cleavage by matrix metalloproteases; this affects most CD44 in human cancer 
types (Naor et al., 1997; Iczkowski, 2011). Gene and protein structures of CD44 are 
shown in Figure 1-10. 
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Figure 1-10: Schematic diagram of gene and protein structure of CD44. 
(A) CD44 pre mRNA consists of 20 exons, some of which are constant region exons that are used in every 
CD44 mRNA and protein (orange bars) and others are variant exons (coloured bars) that are used in the 
CD44 variant proteins and are selected by alternative splicing. (B) The protein structure of CD44s is 
compared with the largest variant isoform CD44v1–10. The CD44 protein is composed of an extracellular 
link domain, a stalk-like region in the extracellular domain close to the transmembrane region, where the 
variant exon products (green) are inserted, the transmembrane region (TM) and the cytoplasmic tail (CP). 
(C) The amino-terminal domain of CD44 proteins contains the hyaluronan-binding motifs, which are in the 
link domain and a basic motif that is outside the link domain. The stability of the link module is contributed 
to by four highly conserved cysteine residues that form interchain disulphide links 141. (D) The stem 
structure of CD44s consists of 46 amino acids, but can be enlarged by up to 381 variant-exon-encoded 
amino acids in human or 423 in mouse, as shown for CD44v1–10. The unique heparan sulphate addition 
site that is encoded by exon v3 is important for the binding of heparan-sulphate-dependent growth factors. 
(E) The carboxy-terminal cytoplasmic domain supports the binding of proteins with crucial functions in 
cytoskeletal organization and signalling. Ezrin, radixin, moesin (ERM) proteins bind to amino acids 292–
300 and ankyrin to amino acids 304–318. Amino acids 331 and 332 are necessary for basolateral 
distribution of CD44 in polarized epithelia145 (Zöller, 2011). 
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The smallest isoform of human CD44 proteins (CD44s), which lacks the variant exons 
contains 363 amino acids and its theoretical molecule mass is 37 kDa. The CD44 protein 
consists of three different regions; C-terminal cytoplasmic domain 72 (aa), 
transmembrane domain 21 (aa) and extracellular domain 270 (aa). The predominant form 
of CD44 has an approximate molecular weight of 80 to 95 kDa, and has been denoted as 
CD44 standard form (CD44s). In addition, a large number of higher molecular weight 
variant isoforms (CD44v) exist (Sneath and Mangham, 1998; Lesley and Hyman, 1998; 
Goodison et al., 1999; Cichy and Puré, 2003).  
The function of CD44 is diverse due to its varied structure and distribution in tissues and 
cells. CD44 is involved in cellular adhesion (aggregation and migration), hyaluronate 
degradation, lymphocyte activation, lymph node homing, angiogenesis and release of 
cytokines (Sneath and Mangham, 1998; Marhaba and Zöller, 2004). Interestingly, CD44 
also has several roles in neoplasia such as tumourigenesis and metastasis formation 
(Klingbeil et al., 2010; Orian-Rousseau, 2015). It has been found that CD44 expression is 
associated with a high rate of cell division. The proliferation status of tumour cells 
increases when CD44 is overexpressed (Sneath and Mangham, 1998). Several studies 
have also shown that CD44 isoforms are associated with metastatic behaviour (Goodison 
et al., 1999; Cichy and Puré, 2003). Additionally, CD44 plays a significant role in PI3K 
signalling which increases cell proliferation and survival (Torre et al., 2010). The ERK1 
and ERK2 pathway can be stimulated by CD44/CD74/MIF complex activation, which in 
turn leads to Scr association with the cytoplasmic tail of CD44 and subsequent ERK1 and 
ERK2 phosphorylation (Shi et al., 2006).  
Generally, the expression of CD44 has been found in wide range of cells and tissues 
including hematopoietic, central nervous system, lung, liver, pancreatic, endothelial and 
fetal tissues (Naor et al., 1997). In particular, CD44v expression has lower distribution 
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than CD44s because the process of alternative splicing is normally tightly regulated 
(Lesley and Hyman, 1998). As a result, it is expressed on a variety of endothelial cells 
and epithelial linage in a tissue specific pattern. The expression of CD44 on endothelial 
cells can vary between layers and also between cells. For example, it has been reported 
that the expression of CD44v6 was restricted to the serum basal and the stratum spinosum 
of normal uterine cervical squamous epithelium. It was later shown that normal 
melanocytes and naevi do not express CD44 although the keratinocytes express CD44vs-
10 (Lesley and Hyman, 1998; Goodison et al., 1999; Cichy and Puré, 2003).  
The expression of CD44 has been linked to several tumour types such as prostate tumour, 
head and neck squamous tumour, nervous system tumours, respiratory tract tumours, 
melanomas and breast cancer (Jaggupilli and Elkord, 2005; Fillmore and Kuperwasser, 
2007). It has been reported that most CD44v forms were present in pancreatic cancer 
cases. Interestingly, CD44v, v2/v6 expression was associated with not only a poorer 
prognosis but also favourable prognosis. On the other hand, several reports indicated that 
loss of CD44 expression could be considered a predictor of a poor prognosis in some 
types of tumours, including tongue cancer laryngeal cancer and colorectal cancer. 
However, another study reported conflicting findings, where it was demonstrated that 
positive CD44 expression can be the most important indicator of poor prognosis in 
patients with colorectal cancer (Sneath and Mangham, 1998; Assimakopoulos et al., 
2002; Eberth et al., 2010; Iczkowski, 2011; Olsson et al., 2011). 
CD44 has been the subject of extensive research for more than three decades due to its 
role in breast cancer. Importantly, it has been shown that the role of CD44 can be 
involved in both tumour suppression and progression (Götte and Yip, 2006). CD44 
expression has also been reported to promote pro-tumourigenic signalling and advance 
the metastatic cascade (Louderbough and Schroeder, 2011a). Conversely, CD44 has been 
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shown to suppress growth and metastasis (Louderbough and Schroeder, 2011a). In the 
same manner, Louderbough et al. (2011b) reported conflicting results regarding the role 
of CD44 as a tumour suppressor or promoter, which highlights the importance of studying 
the cell type–specific function of proteins important to cancer progression. Histological 
researches of CD44 expression in human breast cancer have been correlated to both 
favourable and unfavourable clinical outcomes (Anand and Kumar, 2014). Recently, 
significant attention has been paid to CD44 expression in stem cells as a potential 
therapeutic target (Götte and Yip, 2006; DeLisser, 2009; Louderbough and Schroeder, 
2011a). CD44 has been shown to mark cancer-initiating cells (CIC), thus indicating its 
significant role in maintaining cancer cells including progression, proliferation and 
metastasis (Sieuwerts et al., 2009; Trapé and Gonzalez-Angulo, 2012; Anand and Kumar, 
2014). Huang et al. (2007) reported that over expressed serine/arginine gene (SRp40) in 
breast cancer correlates with the alternative splicing of CD44, forming variants such as 
CD44v2, v3, v5 and v6.  
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1.10 Project description 
1.10.1 Overview  
In recent years there has been a rapid growth of interest in breast cancer immunotherapy.   
Of particular current interest is the question of which of the many immunogenic proteins 
present in a breast tumour should be harnessed for therapeutic purposes, an outgrowth of 
research on whether breast cancer is immunogenic (Disis, 2002; Wolchok and Chan, 
2014). The present study sought to determine the expression and function of CD74, MIF 
and CD44 in the breast tumour cell lines CAMA-1, MDA-MB-231 and MDA-MB-435. 
To date, co-expression of CD74, along with MIF and CD44, has not been studied in 
breast cancer. However, it has been described in prostate and non-small cell lung cancer. 
In prostate cancer, MIF staining was intense, but CD74 staining was weak and patchy 
(Meyer-Siegler et al., 2006). In lung cancer, CD74 was mainly detected in the stromal 
compartment or in stromal and epithelial cells (McClelland et al., 2009). Recently, 
Richard et al. (2014) studied the involvement of MIF and its receptor CD74 in human 
breast cancer. However, they did not consider the relationship between CD74 and MIF 
and the expression of CD44.  It is proposed herein that co-expression of CD74/MIF and 
CD44 might play a significant role in breast tumour progression and survival, in addition 
to the role that each molecule individually has in breast tumour.  
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1.10.2 Aims  
The overall aim of this project was to study the expression and the role of CD74, MIF and 
CD44 in human breast cancer derived cell lines. The aims of this study were: 
•  To analyse and profile the expression of CD74, MIF and CD44 in human breast 
cancer cell lines (CAMA-1, MDA-MB-231 and MDA-MB-435).  To validate the 
study by investigating the expression of CD74, MIF and CD44 in immortalized 
normal breast luminal cells (226LDM), normal breast tissue lysate (Abcam, USA) 
and normal breast tissue slides. 
•  Modulation studies: study of the effect of interferon-gamma (IFN-γ) and 
lipopolysaccharide (LPS) on the migration, proliferation and expression of CD74 
in CAMA-1 and MDA-MB-231cells. 
•  To study of CD74 and its potential interaction with MIF and CD44 in the breast 
cancer-derived cell lines (CAMA-1, MDA-MB-231 and MDA-MB-435); the 
interactive partners of CD74, along with MIF and CD44, were analyzed using 
target imaging and co-immunoprecipitation.  
•  To study the effects of apoptosis and cell proliferation in CD74 siRNA transfected 
cells (CAMA- 1 and MDA-MB-231). 
•  Proteomics study of IFN-γ in the CAMA-1 and MDA-MB-231 cell lines. 
 
 
 
 
  
 
69 
 
 
 
 
 
 
 
 
 
 
 
 Materials and MethodsChapter 2
Chapter 2 Materials and Methods  
 
 
 
70 
2.1 Materials 
2.1.1 General laboratory chemicals 
The majority of chemicals used in this study were from Sigma (Poole, England, UK) 
specifically; Accutase, Dimethyl Sulphoxide (DMSO), Cellytic M Cell Lysis Reagent, 
Protease Inhibitor Cocktail, Ponceau S solution, Paraformaldehyde (PFA), Tween-20, 
Saponin and Triton-x 100. Other chemicals such as Sodium chloride, acetone, methanol 
and Virkon were from Fisons (Leicester, England, UK); Fetal Calf Serum (FCS) was 
from Imperial Laboratories, England. Recombinant Human Interferon Gamma (IFN-γ) 
was from Immuno Tools, Germany. Lipopolysaccaride (LPS) from E. coli serotype 
EH100 was purchased from Sigma Aldrich, UK. Dulbecco's Modified Eagle's Medium 
(DMEM), Dulbecco’s Modified Eagle’s Medium (DMEM)/F-12 and RPMI-1640 were 
from Fisher Scientific, UK. 
2.1.2 Commercial kits 
The commercial kits used in this study were: 
• Protease Inhibitor Cocktail Set III (Calbiochem, UK) 
• Breast (Human) Tissue Lysate - Normal tissue (Abcam, UK) 
• Breast Tissue Slide (Normal) (ProSci, USA) 
• DNAse treatment kit (Life technologies, UK) 
These kits were used according to the manufacturer’s recommendations. 
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2.1.3 Cell lines  
For the purpose of the present study, we employed two kinds of cell lines. First, we used 
breast cancer cell line CAMA-1 and MDA-MB-231 as the main cell lines. Also, we 
included other cell lines as positive control, including; 226LDM, THP-1, Raji, Jurkat and 
HeLa. The CAMA-1 breast cancer cell line was isolated from mammary gland/breast; 
derived from metastatic site: pleural effusion (Ji et al., 1994). This cell line was 
maintained in RPMI-1640 supplemented with 10% (v/v) Foetal Calf Serum (FCS) from 
Imperial Laboratories. MDA-MB-231 breast cancer cell line was obtained from a patient 
in 1973. This cell line was maintained in D-MEM (high glucose) supplemented with 10 % 
FCS. 226LDM are immortalized normal breast luminal cells, kindly provided by Elena 
Klenova (School of Biological Sciences, University of Essex). This cell line was 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)/F-12 and was 
supplemented with 10% (FCS), 50 mg/ml gentamicine, 5 µg/m Insulin, l ng/ml 
Hydrocortine, 20 ng/ml EGF and 20 ng/ml cholera toxin. 
Secondary cell lines were used in the present study as a positive control since they 
express a considerable level of CD74, MIF and CD44. The secondary cell lines that were 
used in this study are as follows: THP-1, Raji, HeLa and Jurkat. All the types of 
secondary cell lines were kindly provided by Prof. Nelson Fernandez, (School of 
Biological Sciences, University of Essex, UK). The cell lines were cultured in RPMI-
1640 medium and maintained at 37 °C and 5% CO2. The cell lines used in this study were 
obtained from different sources as shown in Table 2-1 below:  
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Table 2-1: Details of cell lines used in this study. 
  Cell line Origin Cell culture 
MDA-MB-435 Cell lines was originally derived 
from pleural effusion of a female 
breast cancer 
RPMI-1640 supplemented with % 
FCS 
CAMA-1 Epithelial cells was derived from 
a human breast carcinoma 
RPMI-1640 supplemented with % 
FCS 
MDA-MB-231 Epithelial cells was derived from 
pleural effusion of breast cancer 
D-MEM (high glucose) 
supplemented with 10 % FCS 
226LDM Immortalized normal breast 
luminal cells 
DMEM/F-12 supplemented with 
10% (FCS), 50 mg/ml 
gentamicine, 5 µg/m Insulin, l 
ng/ml Hydrocortine, 20 ng/ml 
EGF and 20 ng/ml cholera toxin. 
THP-1 Human monocyte was derived 
from patients with Acute 
Lymphocytic Leukaemia (ALL) 
RPMI-1640 supplemented with % 
FCS 
Raji Human lymphoblastoid cells 
derived from a Burkitt 
lymphoma. 
RPMI-1640 supplemented with % 
FCS 
Jurkat Established from the peripheral 
blood of a 14-year-old boy with 
Acute Lymphoblastic Leukemia 
(ALL) 
RPMI-1640 supplemented with % 
FCS 
HeLa Epithelial cells was derived from 
human cervical carcinoma 
D-MEM (high glucose) 
supplemented with 10 % FCS 
The details and features of each cell lines are available in American Type Culture 
Collection (ATCC) website; (http://www.lgcstandards-atcc.org/). 
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2.1.4 Antibodies  
The primary and secondary used in this study were obtained from different sources as 
shown in Table 2-2 below:  
Table 2-2: List of the antibodies used for all the applications in the project. 
Specificity Type Clone Cat. no. Company 
Mouse anti-human HLA-A, B, C Primary W6/32 311415 Cambridge Biosciences 
Mouse anti-human HLA-A, B, C Primary W6/32 Supernatant Cambridge 
Mouse anti-human HLA-DR Primary LN3 327001 Biolegand 
Mouse anti-human CD74 Primary By2 sc-20062 Santa Cruz 
Mouse anti-human CD74 Primary BU45 Supernatant Cambridge 
Mouse anti-human MIF Primary D-2 sc-271631 Santa Cruz 
Mouse anti-human MIF Primary Polyclonal ab55445 Abcam 
Mouse anti-human CD44 Primary 156-3c11 3570 Cell signalling 
Mouse anti-human α Tubulin Primary TU-02 sc-8035 Santa Cruz 
Mouse IgG2b antibody Isotype MPC-11 400301 Biolegand 
Rabbit anti-human β-actin Primary poly6221 622102 Biolegand 
Goat anti-mouse Alexa 488 Secondary Polyclonal A-10667 Invitrogen 
Goat anti-mouse Alexa 555 Secondary Polyclonal A-21422 Invitrogen 
Donkey anti-mouse IRDye® 
800CW 
Secondary Polyclonal 925-32212 Li-Cor Bioescieces 
Goat anti-Rabbit IRDye® 
680LT 
Secondary Polyclonal 925-68022 Li-Cor Bioescieces 
Mouse IgG2b antibody Isotype MPC-11 400301 Biolegand 
Goat anti-mouse antibody Secondary Poly4053 405305 Biolegand 
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2.2 Methods  
2.2.1 Cell cultures  
2.2.1.1 Thawing of cells  
Cryogenic vials with 1 × 106 cells/ml in a 9:1(v/v) solution of FCS: dimethyl sulphoxide 
(DMSO) were removed from liquid nitrogen. Special precautions were taken which 
included using a protective mask and heavy padded gloves. Cells were thawed rapidly at 
37oC and then transferred using a sterile glass pipette to a 10 ml centrifuge tube 
containing 5 ml of fresh complete medium to dilute out the DMSO. After centrifugation 
for 5 minutes at 1000 rpm, the medium was removed, the cell pellet was re-suspended in 
5ml of fresh medium, and the number of the cells was counted using a haemocytometer. 
A final concentration of 1 × 105 cells/ml was transferred to either a flask or petri dish. 
Cells were cultured at 37oC in a humidified tissue culture incubator with 5% (v/v) CO2. 
2.2.1.2 Cell cultures of cell lines 
MDA-MB-435 cell line was of immense importance for all the experiments in this study 
as it was the control or model with which the new cell lines (CAMA-1 and MDA-MB-
231) were compared. MDA-MB-435 cells were passaged at 70-80% confluence at every 3 
to 4 days. The cells were washed with 1X Phosphate buffer saline (PBS) and lifted from 
the flask with 1 ml of accutase (Sigma-Aldrich; Dorset, UK) by incubating at 37°C for 
about 5-10 minutes. The cells were then counted with a hemocytometer and plated out at 
a density of 1 × 103 in new culture flask. CAMA-1, MDA-MB-231, 226LDM and HeLa 
cell lines were expanded in a similar way. The steps followed were exactly as for the 
MDA-MB-435 cell line. THP-1, Jurkat, and Raji are suspension cell lines. The cells were 
centrifuged at 1000 rpm for 5 minutes, supernatant was aspirated and fresh medium was 
added to the cell pellet. Then, cells were seeded at density of 1 × 105 in new culture 
flasks. 
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2.2.1.3 Cryopreservation of cells 
Cells were cryopreserved at 70% confluence. Cells were briefly detached using accutase, 
counted and checked for viability as mentioned above and then centrifuged. Cells were 
then re-suspended so that they were about 1.25 × 106 cells/ ml of freezing mixture (90% 
FCS and 10% Dimethyl sulphide [DMSO]). 1 ml of the cell suspension was then 
dispensed into each cryo tube (Fisher Scientific, UK) and placed in -80 oC freezer for 1-2 
days before transferring them to liquid nitrogen at -196oC for long-term storage. 
2.2.1.4 Growth curve 
As both CAMA-1 and MDA-MB-231 cell lines are grown in culture; there are three 
distinct phases that can be detected. The first is the Lag Phase, which is usually no further 
than 1-2 days in length, during which there is slight increase in cell number. It is assumed 
that during this period of time, the cells are adjusting to the new media. This is followed 
by the Log Phase. During this phase, the cell number increases exponentially. The final 
phase is the confluent phase. During this phase, the number of cells remains constant. 
Eventually, the cells will die unless they are sub cultured or fresh media is added. 
Approximately 3 × 104 cells/ml was plated onto 35 mm dishes and cell number was 
determined at approximately 24 hr intervals for 192 hr. Three dishes were read every day 
using a haemocytometer and the mean number of the cells in the squares was calculated. 
This value multiplied by the amount of media in the dish gave the total number of cells.  
2.2.1.5 Cell viability test 
The following cell viability test, based on the trypan blue exclusion, was used to check 
whether the cells used here produce a result of dead or living cells. First the cells were 
washed with PBS (phosphate buffered saline). Then accutase treatment was used to split 
them and the cell suspension was placed in a conical centrifuge tube. Then a cell 
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suspension of 1:2 dilution in trypan blue (Sigma, UK) was prepared. Approximately 10 µl 
of diluted cell suspension was loaded into both the haemocytometer chambers, and cells 
were viewed under the light microscope. The cells were observed as total cells and non-
viable (blue) cells. Live cells would have the cell membranes intact and would exclude 
the trypan blue dye, where dead cells did not. 
2.2.2 Cell stimulations 
2.2.2.1 Recombinant human interferon-gamma (IFN-γ) 
Synthetic IFN-γ is a single, non-glycosylated, polypeptide chain containing 144 amino 
acids and was purchased from ImmunoTools, Germany, in white lyophilized (freeze-
dried) powder. IFN-γ was dissolved in 1 ml of sterile H2O (stock 1), 50 µl from stock 1 
was added to 450 µl of sterile H2O (stock 2) and was stored at -18° C in accordance to the 
manufacturer’s instructions. CAMA-1 and MDA-MB-231 cells were grown in RPMI-
1640 and D-MEM respectively containing 10% FCS overnight before stimulation. Cells 
were then stimulated with IFN-γ at a concentration of 100, 500 and 1000 IU/ml for 72 hr. 
Cells were counted using a haemocytometer, checked for viability and harvested for 
sample preparation. 
2.2.2.2 Lipopolysaccharide (LPS) 
LPS is unique for gram-negative bacteria, present in the outer membrane, and is made of 
both hydrophobic and hydrophilic domains. It was purchased from (Sigma Aldrich, UK) 
in freeze-dried powder form. LPS was dissolved in 1ml of sterile 1X PBS to a vial (1 mg) 
and gently swirled until the powder dissolved. Solutions would be further diluted to the 
desired working concentration with additional sterile balanced cell culture media and 
were stored at - 20°C in accordance with the manufacturer’s instructions. CAMA-1 and 
MDA-MB-231 cells were grown in RPMI-1640 and D-MEM respectively containing 
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10% FCS, overnight before stimulation. Cells were then stimulated with LPS at a 
concentration of 100, 500 and 1000 ng/ml for 24 hr. Cells were counted using a 
haemocytometer, checked for viability and harvested for sample preparation. 
2.2.3 MTT Cell proliferation assay 
2.2.3.1 Principle 
This is a colorimetric method for determining cell viability. Cell proliferation was 
determined using MTT reagent (Sigma-Aldrich, UK). This solution contains (3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a tetrazole). Assays were 
performed by adding a small amount of the solution directly to culture wells and then 
incubated for 4 hr. The absorbance was measured at 595 nm with a reference wavelength 
of 620 nm. 
2.2.3.2 Experimental protocol 
Breast cancer cells CAMA-1 and MDA-MB-231 (1 × 104 cells/well) cells were cultured 
in 96 well flat bottom plates at 37 °C. After 24 hr incubation to allow cells to adhere, cells 
were exposed to varying concentrations of (IFN-γ or LPS) or no treatment (10 % FCS 
medium only). Cells were incubated for 24 or 72 hr after treatments. The MTT assay was 
then used to assess cell proliferation. Briefly, 20 µl of MTT solution (5 mg/ml in PBS) 
and 100 µl was added per well and cells were incubated at 37oC with 5% CO2 in a 
humidified chamber for 4 hr for colour development. The resultant Formazan crystals 
were dissolved in dimethyl sulfoxide (100 µl) and the absorbance intensity measured at 
595 nm using a micro plate reader (Versamax). The percentage of cell proliferation was 
calculated relative to the rate of proliferation in untreated cells. 
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2.2.4 Cell migration assay 
2.2.4.1 Principle 
The transwell migration assay is a commonly used test to study the migratory response of 
endothelial cells to angiogenic inducers or inhibitors. This assay is also known as the 
Boyden or modified Boyden chamber assay. During this assay, endothelial cells were 
placed on the upper layer of a cell permeable membrane and a solution containing the test 
agent was placed below the cell permeable membrane. Following an incubation period 
(3–18 hr), the cells that had migrated through the membrane were stained and counted. 
The membrane was coated with an extracellular matrix component (e.g. collagen), which 
facilitated both adherence and migration. 
The main advantage of this assay is its detection sensitivity since very low levels of 
angiogenic inducers can cause migration through the permeable filter. Prolonged studies 
are difficult, due to the fact that the test-agent concentration will quickly equalize 
between the compartment below the membrane and the compartment above the 
membrane. Another disadvantage is the relative difficulty in setting up the transwells. 
Commercially available transwells have alleviated this burden, but they are expensive.    
2.2.4.2 Experimental protocol 
Both CAMA-1 and MDA-MB-231 cells were detached, counted and seeded in serum free 
medium in the upper chamber of a 6-well cell culture plate placed with 24 mm polyester 
membrane transwell insert (pore size: 4.0 µm) from Corning Incorporated Life Sciences, 
UK. The cells were then allowed to attach with medium alone that was added to the upper 
chamber of the plate. Either medium containing 10% FCS was added or serum free 
medium was added to the lower chamber and the cells were allowed to migrate and 
invade for 24 hr.  Migrated cells were washed twice in PBS and fixed with 4% 
paraformaldehyde (PFA) for 20 minutes at room temperature. The cells were then 
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permeabilized using 100% methanol for 20 minutes at room temperature followed by 
washing in PBS. The cells were then stained using Giemsa stain for 15 minutes and then 
washed three times in PBS. Non-migrated cells were then carefully scraped off with 
cotton swabs. Migrated cells were mounted and the slides were visualized under low 
magnification on a BX41 microscope. 
2.2.5 Polymerase chain reaction (PCR) 
2.2.5.1 Principle 
The polymerase chain reaction (PCR) one of the most widely used techniques in 
molecular biology to amplify a single piece of DNA across several orders of magnitude, 
by multiplying a particular DNA sequence. PCR involves three steps; denaturation, 
annealing and extension. This method is useful in the investigation of a large number of 
diseases using DNA as a target, rather than RNA, due to the higher stability of the DNA 
molecule as well as the ease with which DNA can be isolated. Qualitative PCR can be 
used for detecting human, viral and bacterial genes.  
2.2.5.2 Primer design 
The primers of CD74 and β-actin were designed using primer plus 3 tools. All 
considerations were taken into account such as annealing temperature (Tm), GC content, 
the length of primers and the size of the PCR product. The primers were ordered from 
Fisher Scientific (Invitrogen). 
2.2.5.3 RNA extraction 
Total RNA from 1 × 106 CAMA-1, MDA-MB231 and THP-1 cells grown in a 75 cm2 
flask was extracted using 1 ml of TRIsure reagent (Bioline) according to the 
manufacturer’s recommendations (Chomczynski and Mackey, 1995). The reagent was 
mixed well with a pipette and divided into an equal number of Eppendorf tubes. 200 µl of 
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chloroform was added to each tube and mixed thoroughly. The tubes were incubated at 
room temperature for 5 minutes, then centrifuged at 13,000 rpm for 20 minutes at 4°C. 
The supernatant from these was collected and put into new tubes. 500 µl of isopropanol 
(VWR chemicals, UK) was added to each tube and then mixed by inverting. After being 
incubated at room temperature for 10 minutes, the tubes were again centrifuged at 13,000 
rpm for 20 minutes at 4°C. The supernatant was discarded, and the white pellet retained. 
The pellet was washed with ice cold 75% ethanol. The following supernatant was 
discarded and the tubes were spun briefly to remove any traces of ethanol, and air dried 
for 15-20 minutes. 
2.2.5.4 DNase treatment 
DNase treatment was carried out for total RNA using a DNase treatment kit. 300 µl of the 
master mix (3 µl buffer, 1 µl DNase enzyme and 26 µl sterile double distilled H2O) was 
added to each tube and the pellet was dissolved into it. The tubes were then placed into a 
water bath at 37°C for 30 minutes. 5 µl of the inactivation reagent (Fermentas, UK) was 
then added, and the samples mixed thoroughly. After being incubated at room 
temperature for few minutes the tubes were then centrifuged at 13,000 rpm for 5 minutes 
at 4°C. The supernatant collected consisted of the RNA extracted. 270 µl of sterile double 
distilled H2O, 750 µl of ice cold 100% ethanol and 3M Sodium Acetate (Fermentas, UK) 
were added to the collected supernatant. After an overnight incubation at -20 degrees, the 
tubes were spun at 13,000 rpm for 20 minutes at 4°C. The supernatant was discarded and 
pellet washed with 1 ml of ice cold 75% ethanol. The centrifugation step was repeated 
again at 13,000 rpm for 5 minutes at 4°C. The supernatant was then discarded and the 
tubes were spun briefly to remove any traces of ethanol. The pellet retained in the tubes 
was dissolved in 26 µl of sterile double distilled H2O. The concentration of the RNA was 
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then determined using a NanoDrop. The quality of the RNA was also checked by 
electrophoresis in a 1% agarose denaturing gel. 
2.2.5.5 Complementary DNA conversion 
Tubes containing the RNA were vortexed, then prepared from 2 µg of total RNA using 1 
µl of random hexamers and 1 µl of sterile double distilled H2O (Fermentas, UK). The 
tubes were then placed into a water bath at 65°C for 10 minutes, and then chilled on ice 
for about 5 minutes. 8 µl of the master mix (4 µl of 5x buffer (enzyme buffer), 1 µl of 
sterile double distilled H2O, 2 µl of dNTPs, and 1µl of Reverse Transcriptase) (Fermentas, 
UK) was added and mixed thoroughly by pipetting. The samples were then ready for use 
in PCR experiments. 
2.2.5.6 Reverse transcriptase (RT-PCR) 
The CD74 primers was PCR amplified using CD74-specific primers, CD74-F (5’ 
TGACCAGCG CGACCTTATCT 3’) and CD74-R (3’ GAGCAGGTGCATCACATGGT 
5’) (Burton et al. 2004). PCR conditions were 95°C for 5 minutes; 35 cycles of 95°C for 
30 seconds, 55°C for 30 seconds, and 72°C for 25 seconds; 5 minutes at 72°C. Control 
PCR amplification of β-actin using specific primers β-actin-F (5’ 
ATCTGGCACCACACCTTCTACAATGAGCTGCC 3’) and β-actin-R (3’ 
CGTCATACTCCTGCTTGCTGATCCACATCTCC 5’) was carried out so as to evaluate 
the RNA in all the samples. PCR conditions were 95°C for 5 minutes; 35 cycles of 95°C 
for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute; 6 minutes at 72°C. PCR 
products were then analysed by electrophoresis in a 1% agarose gel stained with ethidium 
bromide or safe view (NBS Biologicals, UK). The results of the gel were then analysed 
using an ultraviolet camera. To estimate the size of DNA bands we used the DNA ladder 
from (Fermentas, UK #SM0383) size from 80- 1031 bp. 
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2.2.6 Flow cytometry 
2.2.6.1  Principle 
Flow cytometry is a technique used to analyse and measure various properties of cells. 
The cells are usually labelled with a fluorescent probe, normally a fluorphore conjugated 
to an antibody. The cells are suspended in fluid, and the cells carrying fluid pass through 
a beam of light. This technique uses the principles of light scattering, light excitation, and 
the emission of fluorochrome molecules to generate specific multi- parameter data from 
cells. There are three parameters that are measured by photomultiplier tubes. These 
parameters are forward scatter (FSC), side scatter (SSC) and fluorescence (FL). One 
advantage of the flow cytometer is its ability to evaluate a large population of cells 
accurately and quickly with semi quantitative results. This makes the flow cytometry 
technique an ideal tool for quantitative analysis of certain cellular properties, especially 
when the cells of interest are a small fraction of other cell types in a cell population. The 
results are displayed in many ways, including histogram, dot plot, and contour. As 
standard practice, an irrelevant or nonspecific isotype antibody was used as a negative 
control to evaluate the degree of positivity for other surface proteins in terms of the 
fluorescence intensity. 
2.2.6.2  Cell-surface and intracellular staining 
For cell-surface staining of specific cell antigens, cell cultures of cell lines were washed 
twice with 1X PBS and incubated with accutase for 5-10 minutes at 37 ºC. Cell 
suspensions (1 × 106 cells/ sample) per sample were centrifuged at 300 rpm for 10 
minutes. The cells were fixed with a fixation buffer to ensure free access of the antibody 
to its antigen 4 % PFA (Sigma, UK) followed by a washing step in PBS. Supernatants 
were discarded and the cell pellets resuspended in blocking buffer (PBS supplemented 
with 0.1% (w/v) bovine serum albumin [BSA]). The cells were incubated at 4 ºC for 1 hr 
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with saturating concentrations of the following primary human specific monoclonal 
antibodies: with an appropriate concentration of By2 (anti-CD74), ab55445 (anti-MIF), 
156-3C11 (anti-CD44), W6/32 (anti-HLA-A, B, C), and LN3 (anti-HLA-DR). The cells 
were washed twice with PBS and incubated with secondary antibody fluorescein 
isothiocyanate (FITC) conjugated goat anti-mouse IgG at 4 ºC for 1 hr. Cells were used 
with either only secondary antibody or neither primary nor secondary antibody as 
negative controls. For intracellular staining, cells were permeabilised with 200 µl 
permeabilisation buffer (PBS supplemented with 0.1% (v/v) [Triton X-100 (Sigma, UK)]) 
for 20 minutes to facilitate the entry of antibodies inside the cells. The staining procedure 
for intracellular staining was the same as for the surface staining. Samples (10,000 cells) 
were analysed using a BDFACS Aria flow cytometer and a 488 nm beam for detection of 
the fluorochrome attached to the secondary antibody (PE, FITC). The results were 
analysed using FlowJo version 8.8.6 (Tree Star Inc., Ashland, OR, USA). 
2.2.7 Laser scanning confocal microscopy  
2.2.7.1 Principle 
Confocal laser scanning microscopy is a valuable technique that has the ability to produce 
high resolution images of very small objects and produce a three-dimensional image of a 
specimen. There are many advantages of confocal microscopy over the conventional 
microscope due to many factors; firstly its ability to control the depth of the field, 
secondly the reduction of background interference away from the focal plane and thirdly 
its ability to analyse serial sections from thick specimens.  
2.2.7.2 Colocalisation analysis 
Colocalisation describes the presence of two or more types of molecules at the same 
physical location. Colocalisation of fluorescent signals from two or more different 
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proteins is an indicator of their association and potential interaction. Within the context of 
a cell or sub-cellular protein, often the molecules are attached to the same receptor, while 
in the context of digital imaging, the colours emitted by the fluorescent molecules occupy 
the same pixel in the image (Bolte and Cordelieres, 2006; Adler and Parmryd, 2010). 
Colocalisation does not refer to the likelihood that fluorochromes with similar emission 
spectra will appear as overlapped in the composite image. It is important to note that 
cross-talk or “bleed-through” may occur if the emission spectra of the two fluorochromes 
are similar. Accurate colocalisation determination can only occur if emission spectra are 
sufficiently separated between fluorochromes and the correct filter sets are used during 
the acquisition step. To achieve this aim, red and green wavelengths are usually selected, 
and usually those dyes representing these wavelengths are carefully matched to the power 
spectrum of the illumination source to obtain maximum excitation wavelengths while still 
maintaining a degree of separation between the emission wavelengths. Often, 
colocalisation is assessed qualitatively, for example by showing yellow regions as the 
overlap between dual colour fluorescence images from green and red channels. If 
quantitation is sought, global statistical methods to determine overlap on a pixel-per-pixel 
basis are commonly chosen. (Press et al., 1992; Manders et al., 1993). Measuring the 
colocalisation can be divided into two main methods: pixel-based and object- based. 
Pixel-based methods look at all pixels in an image and determine various correlations 
between the channels. Object-based methods first segment the images into objects, and 
then make some comparison between the objects in the channels (Bolte and Cordelieres, 
2006; Adler and Parmryd, 2010). 
The Pearson correlation coefficient and Mander's overlap coefficient are the most 
common colocalisation measurement for pixel-based approaches. However, Adler and 
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Parmryd (2010) have reported that the Pearson correlation coefficient is superior to the 
Mander's overlap coefficient. The PCC is a well-established measure of correlation, 
originating with Galton in the late 19th century but named after a colleague, and has range 
of −1 (perfect correlation) to +1 (perfect but negative correlation) with 0 denoting the 
absence of a relationship (Adler and Parmryd, 2010). 
Bolte and Cordelieres (2006) also describe object-based approaches, which allow more 
spatial information to be inferred about colocalisation, helpful in determining in which 
subcellular compartment(s) of the cell the stains may colocalise. Proper segmentation is 
very important in object-based methods, since different segmentations will give different 
colocalisation results. Pre-processing of the image, including filtering or illumination 
correction, may be necessary for proper segmentation. Once images have been properly 
segmented (that is, the cells and subcellular compartments correctly identified in both 
channels), Bolte and Cordelieres (2006) described several methods by which to compare 
the colocalisation. The first was to compare the centroids of the identified objects and 
define colocalised objects as those whose centroids are within some specified distance 
(usually, less than the optical resolution of the microscope). Another method was to 
multiply the two channels by one another after pre-processing and then to segment the 
structures of interest; the result of the multiplication is composed of only pixels present in 
both channels. However, we applied segmentation using regional maximum detection 
tools followed by manual threshold (Manders, 1997; Lachmanovich et al., 2003; Bolte 
and Cordelieres 2006; Rizk et al., 2014) 
2.2.7.3  Experimental protocol 
Cell monolayer culture and double staining: CAMA-1 and MDA-MB-231 cell lines were 
separately cultured in LabTek 8 well chambers (Thermo Fisher Scientific) at a density of 
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10 × 103 cell per well, for two days following seeding. For the staining procedure, all the 
steps were carried out at room temperature. The cells were fixed with 4% PFA (Sigma, 
UK) for 20 minutes and blocked with 2% (w/v) BSA (Bovine serum albumin) prepared in 
1X PBS for 1 hr at room temperature. For intracellular staining, the cells were 
permeabilized with 0.1% Triton X-100 and then blocked as described above. The 
incubation steps were also carried out at room temperature. For staining, the cells were 
incubated with specific monoclonal antibody for 1 hr and washed three times with PBS. 
For the secondary antibody, anti-mouse IgG conjugated with Alexa Fluor® 488 or Alexa 
Fluor® 555 (Invitrogen, Carlsbad, CA, USA) was used for 1h. For double staining, cells 
were blocked again for 1h and stained with specific monoclonal antibody for 1 hr. After 3 
washes cells were incubated with anti-mouse IgG TRITC conjugated antibody for 1h. 
Isotype controls were stained with only secondary antibody. Cells were then thoroughly 
washed and chambers were removed from the slide. Slides were rinsed in a beaker 
containing 1XPBS and dried. The cells were mounted with anti-fade mounting medium 
and carefully covered with the cover slip avoiding any air bubbles. Edges of the cover slip 
were sealed with transparent nail polish and dried in air. Prepared slides were stored at 
4oC in the dark for further analysis. The slides were then examined under a Bio-Rad 
confocal microscope using an x 60 oil immersion objective (numerical aperture 1.4) and 
FITC filter for Alexa Fluor® 488 and PE filter for Alexa Fluor® 555. The images 
obtained were then analysed using the Fiji software and NIS elements. 
2.2.7.4 Image acquisition 
For image acquisition, a Nikon A1si confocal microscope was used with a plan-
apochromatic VC1.4 N.A. 60x magnifying oil-immersion objective. The software used 
for image acquisition was NIS-Elements AR 4.13.01 (Build 916). Three dimensional (3D) 
images were acquired in three channels, using one-way sequential line scans. DAPI was 
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excited at 398.7 nm with laser power 1.6 arbitrary units, and its emission collected at 450 
nm with a PMT gain of 86. Alexa Fluor® 488 was excited at 488 nm with laser power 
5.8, its emission collected at 525 nm with a PMT gain of 117. Alexa Fluor® 555 was 
excited at 560.5 nm with laser power 3.7, and collected at 595 nm with a PMT gain of 98, 
the scan speed was ¼ frames/s (galvano scanner). The pinhole size was 35.76 µm, 
approximating 1.2 times the Airy disk size of the 1.4 N.A. objective at 525 nm. Scanner 
zoom was cantered on the optical axis and set to a lateral magnification of 60 nm/pixel. 
Axial step size was 105 nm, with 80-100 image planes per z-stack.  
2.2.7.5 Image processing 
NIS-Elements software (version 3.21.03, build 705) was used for image processing. MIF 
(green) and CD74 (red) or CD74 (green) and CD44 (red) channels were segmented using 
regional maximum detection tools followed by manual threshold. The generated binary 
areas were visually inspected; the overlap of the green and red channels was generated by 
the overlay tool, resulting in a new layer (yellow) that represents the intersection of CD74 
and MIF or CD74 and CD74. Finally, automated volume measurement was carried out for 
CD74, MIF, CD44 and their intersection by volume measurements tool. 
2.2.8 Preparation of total protein 
For Lysate preparation, a pellet of 1 × 106 cells for control, untreated and treated cells were 
collected and washed twice in ice cold 1X PBS. Following this, 500 µl of cell lysis mixture 
(Cell Lytic™ MT Reagent and Protease Inhibitor, Sigma, UK) was added. The pellet was 
resuspended by gentle pipetting and incubated on ice for 20 minutes. Then, the lysate was 
clarified by centrifugation at 15,000 rpm for 20 minutes. Finally, the protein containing 
supernatant was moved to a chilled test tube and the lysate was stored at -80°C for long-term 
use.  
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2.2.8.1 Bradford assay 
This method is used for calculating the protein concentration in the lysate so as to calculate 
the amount of protein that should be loaded into each well before running the gel. This assay 
was based on the principal that when the Coomassie Blue Dye is bound to the protein in an 
acidic medium, a shift in absorbance occurs from 465 nm to 595 nm resulting in a colour 
change from brown to blue. The amount of complex now present in the solution is a measure 
for the protein concentration by means of an absorbance reading. Standard concentrations of 
BSA (Bovine Serum Albumin) 0.015, 0.031, 0.06, 0.125, 0.50, 1, and 2 mg/ml were 
prepared. A series of dilutions for the sample were prepared in PBS. 5 µl of the standards and 
samples respectively were added to the 96 well-plate. 250 µl of Bradford reagent was added 
to each well and the plate was left for incubation at room temperature for 5 minutes. The 
Micro-titre plate reader was switched on and set up to an absorbance of 595 nm. The plate 
was read and results were read three times to minimise experimental error. A graph for 
concentration vs. absorbance was plotted on Microsoft Excel and the protein concentration 
was found out using the y = mx + c equation.  
2.2.9 One dimensional gel electrophoresis  
2.2.9.1 SDS- PAGE 
Electrophoresis is currently the most commonly technique used for the isolation and 
identification of proteins. This technique is based on the unique idea of separating 
polypeptides based on their molecular weight. The ability of a molecule to move across 
an electric field is inversely proportional to molecular friction (which depends on the 
shape and size of the molecule) and directly proportional to the voltage and the charge of 
the molecule.  Total protein complexes can then be separated electrophoretically 
according to molecular weight in gels containing sodium dodecyl sulphate (SDS), in a 
semi-solid matrix at a set voltage. In the presence of SDS (sodium dodecyl sulphate), 
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proteins bind the SDS anions, and all become negatively charged and thus separated 
within a matrix of polyacrylamide gel in an electric field according to their molecular 
weights. The polyacrylamide gel concentration used determines the effective separation 
range of SDS-PAGE. For example, low porosity gels 15 % (w/v) total acrylamide 
concentration are suitable for analysis of small proteins (less than 50 kD), whereas high 
porosity gels 5% (w/v) total acrylamide concentration should be used for large molecular 
weight proteins (above 100 kD). 
In this study, the protein samples were separated in 12 % resolving gels and 4% stacking 
gels and prepared in sterile universals, using a BioRad Mini PROTEAN Electrophoresis 
system. Care was taken during the addition of TEMED (tetrametylethylenediamine) and 
APS (ammonium persulfate) were added as they enhance the process of polymerization. 
Thus, these two components were only added after the system was completely set up. 
Once the resolving and stacking gels were polymerised completely, they were loaded with 
electrophoresis buffer into to the system. The previously measured protein lysate was 
used in sample preparation. The samples were diluted in 5X SDS-sample buffer and 
heated for 4 minutes at 95oC before loading on 12 % SDS-PAGE. The mixture of 5 µl of 
sample buffer was added to 20 µl of the lysate loaded into each well. The sample and 
protein markers thus prepared were loaded into the wells of the gel. The system was 
connected to a power supply unit and run at 60V until the samples crossed the stacking 
gel and then increased to 120V until the samples reached the bottom of the resolving gel 
for approximately 2 hr. Following separation by SDS-PAGE, the gels were stained with 
sliver or Coomassie Blue to check the success of the transfer or processed for 
immunoblotting. Recipes for buffers and solutions are in the (Appendix 2 Buffer 
Recipes). 
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2.2.9.2  Coomassie blue staining 
The polyacrylamide gel was carefully removed from between the plates and then placed 
into coomassie blue stain, covering the gel completely, for 2 hr at RT on a rocking table. 
Following that, the gel was placed into 100 ml of destain solution and replaced with fresh 
one until the gel was clear and the stained protein bands were visible. Recipes for buffers 
and solutions are in the (Appendix 2 Buffer Recipes). 
2.2.9.3 Western transfer 
Following protein separation by electrophoresis, proteins were moved to polyvinylidene 
fluoride (PVDF) membrane (Immobilon-FL, Merck Millipore, Merck KGaA, Darmstadt, 
Germany) by opening the gel system and placing the gels in a transfer buffer. Two 
cassettes were lined with a sponge and the gels were positioned on a filter paper above the 
sponge. The methanol pre-soaked PVDF membrane was positioned above the gel while 
an additional filter paper and sponge were stacked above. A glass pipette was rolled over 
to eliminate air bubbles, and the two cassettes were positioned into the Bio Rad Mini 
PROTEAN Electrophoresis system. Then a cooling unit and transfer buffer were added, 
and the system was run overnight at 30V. At the end of the transfer period, the system 
was disconnected from a power supply unit and the gel also stained with coomassie blue 
stain to check the success of the transfer. 
2.2.9.4 Immunoblotting 
This technique is used to detect a target protein in a sample through the monoclonal or the 
polyclonal antibody specific to that protein. The blocking method was the first step to this 
procedure. A membrane was incubated in a 5% semi skimmed milk solution with PBS-
Tween-20 (Sigma-Aldrich) for 1 hr to prevent non-specific protein binding between the 
membrane and the antibody. The primary antibody was then diluted in PBS-T. Since the 
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primary antibody was specific for the protein, it would not bind to any other protein on 
the membrane. After incubation, the membrane was washed about 3 times with PBS-T at 
10 minutes intervals to eliminate any unbound primary antibody. The membrane was then 
incubated with a secondary antibody to bind with the primary antibody. The membrane 
was washed again to remove unbound secondary antibody. Finally, the membrane was 
scanned with ODYSSEY Infrared Imaging System from LI-COR Biosciences. To 
estimate the molecular weight of the proteins being studied we used the PageRuler™ Plus 
Prestained Protein Ladder (#26619) from Fermentas (Thermo Fisher Scientific). 
2.2.10 Co-immunoprecipitation  
Immunoprecipitaion techniques are very sensitive methods to reveal molecular weights of 
specific antigens. Immunoprecipitaion is often used to study the interaction of different 
proteins with each other as part of a complex. As with most other proteins, clock proteins 
physically interact with one another. Immunoprecipitation is a useful method for isolating 
proteins of interest from cellular extracts using specific antibodies. Co-
immunoprecipitation (Co-IP) is the most straightforward technique to study protein-
protein interactions in vivo, if antibodies against the proteins of interest are available. To 
perform coIP, first an antibody against a target protein was coupled to Sepharose beads 
through protein A or G, and then the complexes containing the target protein were 
immunoprecipitated with the antibody-coupled beads by centrifugation. Protein 
components in the complexes were visualized by western blotting using antibodies 
specific to the different components. In this study, we utilized co-immunoprecipitation to 
investigate the interaction of CD74 along with other partners such as MIF and CD44 
(Kaboord and Perr, 2008; van der Geer, 2013). 
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2.2.10.1 Experimental protocol 
During this procedure, cells were lysed with RIPA lysis buffer system (Santa Cruz 
Biotechnology, USA) and incubated for 20 minutes. This was achieved by mixing the 
following: 1 ml of RIPA lysis buffer with 10 µl of protease inhibitor cocktail in DMSO, 
(200mM) PMSF (phenylmethylsulfonyl fluoride) in DMSO (Dimethyl sulfoxide) and 
(100mM) sodium orthovanadate in water. After incubation, cells were centrifuged at 
14,000 rpm for 15 minutes, and the total protein concentration was determined by 
Bradford assay. 1 mg/ml of each sample was incubated with 4 µg of specific primary 
antibody for the protein overnight at 4°C. Then, 40 µl of protein A/G PLUS- Agarose 
(Santa Cruz Biotechnology, USA) was added and kept overnight on a rotator at 4°C. 
After incubation, the samples were spun down for 30 seconds and the supernatant was 
discarded. Beads were then washed twice using PBS and the samples were boiled at 
100°C after adding 50 µl of SDS-PAGE sample loading buffer containing Dithiothreitol 
(DTT). Then, 20 µl of each sample was loaded in each well of the gel and they were left 
for 1 hr and 30 minutes at 120V. After electrophoresis, protein was transferred to a 
polyvinylidene fluoride (PVDF) membrane (Immobilon-FL, Merck Millipore, Merck 
KGaA, Darmstadt, Germany). Membranes were blocked with 5% skimmed milk in PBS-
Tween-20 (Sigma) for 1 hr at room temperature and incubated in primary antibody 
specific for protein co-immunoprecipitation (Co-IP) followed by washing in PBS-T for 30 
minutes. The membranes were then incubated with secondary antibody, the IRDye 
800CW Donkey anti-Mouse IgG (Li-Cor Bioscience, Licoln, NE, USA) for 1 hr and then 
by washed in PBS-T for 30 minutes. Signals were detected using the ODYSSEY Infrared 
Imaging System (Li-Cor Biosciences). 
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2.2.11 siRNA transfection 
2.2.11.1 Principle 
Mammalian cell transfection is a technique commonly used to express exogenous DNA 
or RNA in a host cell line (for example, for generating RNAi probes). Transfection is the 
introduction of foreign material into eukaryotic cells. It typically involves the opening of 
transient pores or 'holes' in the cell plasma membrane to allow the uptake of molecules, 
such as supercoiled plasmid DNA or siRNA constructs. There are many different ways to 
transfect mammalian cells, depending on the cell line characteristics, desired effect, and 
downstream applications such as transient transfection, stable transfection and siRNA 
transfection. In this study, siRNA transfection was used as described below. 
2.2.11.2 siRNA transfection protocol 
CAMA-1 and MDA-MB-231 cell lines were seeded in six well plate at density of 2 × 105 
per well in 2 ml normal growth medium supplemented with 10% FCS. The cells were 
then allowed to grow until they reached 60-80% confluency. For each transfection, 4 µl of 
CD74 siRNA duplex at dose of 80 pmols (sc-35023) (Santa Cruz Biotechnology, USA) 
was diluted and 4 µl of siRNA transfection regent was added at dose of 80 pmols (sc-
29528) (Santa Cruz Biotechnology, USA) into 100 µl of siRNA transfection medium (sc-
36868) (Santa Cruz Biotechnology, USA) separately without serum or antibiotics. Both 
diluents were mixed together and incubated for 15-45 minutes at room temperature. Cells 
were then washed with 2 ml of siRNA transfection medium. The siRNA transfection 
regent mixture was then added to each well and the volume made up to 1 ml by adding 
800 µl of siRNA transfection medium (Santa Cruz Biotechnology, USA). In the same 
manner, this was applied for negative control siRNA (sc-44230) (Santa Cruz 
Biotechnology, USA). The cells were then incubated overnight at 37ºC in a CO2 
incubator for 18-24 hr. Following incubation, the medium was aspirated and replaced 
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with fresh 1X normal growth medium. Cells were assayed using the appropriate 
manufacturer’s protocol 24-72 hr after the addition of fresh medium in the step above. 
Transfection efficiency was confirmed by western blot and microscopy. Once the 
transfection was confirmed, the effect of CD74 siRNA on the proliferation and apoptosis 
of CAMA-1 and MDA-MB-231 could then be studied. 
2.2.12 Apoptosis assay 
2.2.12.1 Principle 
Apoptosis, or programmed cell death, is a normal physiological process occurring to 
remove unwanted cells. An early apoptotic event is the translocation of membrane 
phosphatidylserine (PS) from the inner side of the plasma membrane to the surface. 
Annexin V, a Ca2+-dependent phospholipid-binding protein, has high affinity for PS, and 
fluorochrome-labelled Annexin V can be used for the detection of exposed PS using flow 
cytometry. 
2.2.12.2 Experimental protocol 
CAMA-1 and MDA-MB231 cell lines were cultured in 6 well plate at a density of (15 × 
103 cell/well) at 37°C, and then transfected with CD74 siRNA duplex as explained 
previously. The cells were then washed twice with 1X PBS and incubated with 2 µl of 
Annexin V-FITC (BioLegend, UK) at room temperature for 20 minutes in the dark. Cells 
were then thoroughly washed and then fixed with 4 % PFA followed by washing steps in 
PBS. Finally the samples were read using BD FACSAria and analysed by FlowJo 8.8.6. 
2.2.13 Two-Dimensional gel electrophoresis 
2.2.13.1 Preparation of cell lysate 
Untreated and IFN-γ treated CAMA-1 and MDA-MB-231 cells cultured in 100 mm cell 
culture dishes (Nunc, UK), and 1 × 107 cells were used per sample to make cell lysate. 
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Cells were detached from culture dishes using accutase, counted and washed with 1X 
PBS as described earlier. The cell pellet was resuspended in 1 ml of the protein extraction 
buffer containing 7M urea, 2M Thiourea, 4% CHAPS, 1X protease inhibitor cocktail, 20 
mM DTT, 1% ampholyte, and Bensonase. All reagents were purchased from Sigma, UK. 
Cells were vortexed and sonicated for 5 minutes at 4°C. Cell lysates were spun at 20,000 
rpm for 10 minutes, supernatant was collected into a clean micro-centrifuge tube and 
stored at -80°C for later use. The protein concentration of cell lysates was estimated using 
the Coo Assay (Uptima, Interchim, France) following manufacturer's instructions. 
2.2.13.2 First dimensional gel isoelectric focusing (IEF) 
The Immobiline dry strip gel pH 3-10NL, 18cm (GE Healthcare Bio-Sciences AB) used 
in this study was rehydrated in an immobiline dry strip reswelling tray. The dry strip was 
rehydrated for 24 hr at room temperature in 350 µl of rehydration buffer (7M urea, 2M 
thiourea, 4% CHAPS, 1X protease inhibitor cocktail, 20 mM DTT, 1% ampholyte, 0.1% 
bromophenol blue, 0.05% SDS) containing 80 µg of sample proteins. The IPG strip was 
overlaid using approximately 3 ml of immobiline PlusOne dry strip cover fluid (GE 
Healthcare Bio-Sciences AB). After rehydration, the IPG strip was briefly rinsed with 
ultrapure water to remove crystallized urea. 
For isoelectric focusing, the IPG-Phor was cleaned with Strip holder cleaning solution 
(GE Healthcare Bio-Sciences AB). The Ettan IPG Phor3 was switched on and connection 
with the IPG Phor3 control software was established. IPG Phor mainfold was covered 
with 108 ml of Immobiline PlusOne dry strip cover fluid and the rehydrated strips were 
then placed in individual lanes of Ettan IPG strip holder (GE Healthcare Bio-Sciences 
AB) under the fluid using tweezers with the positive end towards the anode end of the 
mainfold. Hydrated filter wicks were placed between the IPG strips and the electrodes. 
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The cathodic (-ve) filter wick was rehydrated with 150 µL of 100 mM DTT. The anodic 
(+ve) filter wick was hydrated with 150 µL miliQ water. The lid was closed and IPG-Phor 
programme was run according to the programme below. A holding step at the end was 
added to so that it could be left overnight. 
Step 1  200 V  500 V hr 
Step 2  500 V  500 V hr 
Grad 3  1000 V 800 V hr 
Grad 4  10,000 V 16,500 V hr 
Step 5  10,000 V 6,200 V hr 
Step 6  200 V  24 hr 
At the end of the programme, the computer was disconnected and IPG-Phor was stopped. 
The paper wicks were removed with tweezers and discarded. The IPG strips were placed 
in a petri dish, rinsed briefly with deionized water, labelled and stored at –80 °C for later 
use. 
2.2.13.3 SDS-PAGE gel preparation 
For second dimension gel electrophoresis, the PROTEAN® II System (BIO-RAD, UK) 
was used. Glass plates were cleaned with 70% ethanol, dried, assembled with 2 mm 
spacers and clipped into the casting frame. Purite water was poured between the plates to 
check for leakage. Assemblies that leaked were taken apart and re-clipped and the process 
was repeated. Upon establishing a non-leaking system, the water was removed and the 
system was dried in situ with pressurized airflow. The gel solution 12% SDS PAGE was 
made with water, 1.5 M Tris-HCl and 30% acrylamide solution. These were placed in a 
flask and degassed for 15 minutes at ambient temperature. The TEMED, APS and SDS 
were added and mixed by stirring. The gel solution was poured in between glass plates, 
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avoiding any air bubbles, to 1 cm below the lowest plate. The top of the gels was covered 
with overlay buffer (water saturated isopropanol 80%) and allowed to polymerise 
overnight. 
2.2.13.4 Equilibration of the IPG strips 
Prior to the second dimension gel run, the Immobilized pH Gradient (IPG) strips 
containing isoelectrically focussed proteins were equilibrated and reduced. For each strip, 
two vials of 10 ml aliquots of frozen equilibration buffer were thawed at room 
temperature. In one vial of equilibration buffer 100 mg of DTT was added while in the 
other 400 mg of iodo-acetamide was added and allowed to mix gently. The IPG strips 
were first equilibrated in equilibration buffer containing 1% DTT, then in a buffer 
containing 4% iodo-acetamide for 15min each at room temperature. The IPG strips were 
rinsed with 1X electrophoresis buffer before placing on second dimension gel. 
2.2.13.5 Assembly and running of second dimensional gel 
Agarose sealing solution was heated to liquefy. IPG strips were trimmed from each end 
up to 0.6 cm thus giving a final length of 16 cm. A small square of paper electrode wick 
(2 × 3 cm half thickness) was loaded with 10 µl of molecular weight marker and placed 
on the top of left hand corner of the gel. The IPG strip was placed into the well of the 
12% SDS PAGE gel with the acidic side facing the glass plate hinge and sealed with 
agarose solution, avoiding any air bubbles. The electrophoresis tank was filled with 1.5 L 
of gel running buffer. The gels with strips were removed from the casting assembly and 
clipped onto the core unit of the protean tank. The core unit was lifted into the tank, 
running buffer was added to the top of the upper buffer chamber and air bubbles were 
removed with a glass rod. The lid was fitted to the tank and cables were connected to the 
power Pac (Bio-Rad, Power Pac 1000). Electrophoresis was carried out first at 50V for 30 
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minutes and then at 150V for about 4.5 hr or until the bromophenol blue dye front had 
reached to the lower end. The core unit was then removed from the tank disassembled and 
gels were removed from the clamps. The spacers were loosened and one edge of the glass 
plate was lifted up with a spatula. The gel was then placed in a glass container containing 
gel fixing solution. 
2.2.13.6 Silver staining 
For visualization of protein spots a modified silver staining protocol was used as 
previously described (Yan et al., 2000; Yan and Chen, 2005). Briefly, after 
electrophoresis gels were fixed for half an hour in fixing solution they were sensitized for 
30 minutes and washed with ultrapure water. Staining was carried out using 2.5% silver 
nitrate solution for 20 minutes followed by a careful wash with ultrapure water for a 
maximum of 1 min. The gels were developed for 10-15 minutes until spots appeared, and 
the reaction was stopped by washing with stop solution for 10 minutes. The gels were 
washed 3 times with ultrapure water and stored in gel preserving solution at 4°C.  
2.2.13.7 Gel image capture and spot analysis 
Gels were scanned using the scanner (Epson image scanner III) with LabScan 6.0 
software. First the scanner was calibrated and set to use the transparent settings at 300 dpi 
with the blue filter. The scanner surface was cleaned with 70% ethanol and a little purite 
water was poured on the surface. The gel was placed directly on the scanner, previewed 
and air bubbles were smoothed out if any were present. The scan area of the gel was then 
selected and scanned. Gel images were saved as mel and tiff files. Scanned gel images 
were characterised with Progenesis SameSpot software package (Nonlinear Dynamics 
Limited, UK). 
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2.2.13.8 Statistical analyses 
All results in this research were carried out in at least triplicate experiments. The mean of 
each set of data was calculated and the standard error (±SD) was also included in order to 
present the reliability of the mean reading. 
 
  
 
100 
 
 
  
 
 
 
 
 
 
 
 
 Immunophenotyping of CD74, MIF and CD44 expression Chapter 3
on human breast cancer derived cell lines 
Chapter 3 Results  
 
 
101 
3.1 Introduction  
In the light of numerous instances of the breakdown of immunologic self-tolerance, the 
former paradigm that the primary function of the immune system is to discriminate 
between self and non-self (e.g. foreign antigens or mutated self-antigens) has recently 
been queried. The identification of a handful of potentially immunogenic cancer antigens 
shows that they are not truly foreign. Although the boundary between self and non-self is 
not well defined, this first look at cancer antigens fits more with a self/altered self 
paradigm than with the non-self paradigm for antigens recognized in infectious diseases 
(Houghton, 1994). Resultantly, the likelihood that the immune system does not recognize 
between self and non-self has led to the proposal of the “Danger” model of the immune 
system (Matzinger, 1994, 2001; Fuchs and Matzinger, 1996; Aickelin and Cayzer, 2008). 
This model suggests that the immune system may be concerned with the detection of 
damaged cells rather than recognition of non-self (Matzinger, 2001, 2002). Tumour cells 
might exemplify the “Danger” model, threatening the host immune system. The 
contemporary self-non-self discrimination model assumes that immune system protects 
the organism against everything, which is foreign, thus immune responses are directed 
towards external entities, which are non-self antigens. According to the danger model the 
immune system detects and then responds to anything dangerous and not necessarily 
foreign (Matzinger, 1994; 1998; Fuchs & Matzinger, 1996). The whole model is based on 
the principle that the presence or absence of the so called second signal determines 
immune responsiveness or tolerance. Whereas the first signal comes from specific antigen 
recognition, the second signal is generated from either help delivered by T-helper 
lymphocytes or co-stimulation from professional antigen presenting cells (Kowalczyk, 
2002). 
As described previously, tumour antigens are identified and eliminated through the 
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process known as immunoediting (based on tumour immune surveillance). In fact, tumour 
immune surveillance is considered an important process that prevents the formation of 
cancers and maintains cellular homeostasis (Dunn et al., 2002, 2004). It has been 
suggested that the immune system recognizes tumour cells as “non-self” and then rejects 
them. Tumours that arise from non-virally transformed cells are considered, as “self”, and 
therefore the immune system cannot recognize the tumours as “non-self” (Klein and 
Klein, 2005; Swann and Smyth, 2007).  
Based on the above, efforts have been made to manipulate the immune system in order to 
identify tumour cells that are carrying ‘foreign antigens’. One way to achieve this is to 
monitor the expression of selected molecules that are required for immunological 
responses. In this context, MHC class II molecules that are normally found only on APCs, 
are considered to be significant molecules due to their role in antigen presentation (Vyas 
et al., 2008; Neefjes et al., 2011). In contrast, MHC class I molecules are expressed by all 
nucleated cells and present fragment of cytosolic and nuclear origin at the cell surface 
allowing for cytotoxic cell based elimination upon infection or transformation (Neefjes et 
al., 2011). However, a previous study was carried out on the breast cancer cell lines 
TD7D and ZR75-1, which showed low expression of MHC class I molecules and no 
expression of MHC class II molecules. Surprisingly, the expression of MHC molecules 
can be found in non-professional antigen presenting cells such as epithelial cells 
(Tsunawaki et al., 2002). Since most breast cancers are considered adenocarcinomas and 
arise from epithelial cells, it is believed that these cells could express MHC molecules 
normally however these molecules may behave differently (Elenbaas et al., 2001; Dimri 
et al., 2005; Kumar et al., 2005). It is suggested that high levels of CD74 expression is 
associated with class II MHC expression and might prevent tumour antigen presentation 
by blocking the peptide-binding cleft, thus leading to a lack of recognition of tumour cells 
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by immune cells (Beswick and Reyes, 2009; Borghese and Clanchy, 2011; Zheng et al., 
2012). 
A number of molecules play a key role in to play a crucial role in tumour progression. 
These include CD74, MIF and CD44 (Meyer-Siegler et al., 2004).  These molecules have 
been identified in several types of cancers and are believed to play a role in 
immunotolerance (Becker-Herman et al., 2005).  CD74 expression has been observed in 
several types of cancer, including multiple myeloma, as well as in solid tumour cancers, 
such as gastric cancer, kidney and small-cell lung cancer (Ishigami et al., 2001; Young et 
al., 2001; Burton et al., 2004; Butrym et al., 20013).  CD74, along with CD44, has been 
suggested to mediate MIF signalling pathway in bladder and prostate cancer cell lines 
(Meyer-Siegler et al., 2004; Meyer-Siegler et al., 2006). MIF has a critical role in 
tumourigenesis due to its overexpression by cancer cells; it is widely documented that 
MIF is overexpressed in breast cancer, prostate cancer and colon carcinoma tumours 
(Conroy et al., 2010). CD44 is able to promote tumour cell invasiveness, self-renewal and 
sustained survival, and for these reasons has the ability to prompt many types of cancer 
(Toole and Slomiany, 2008; Fedorchenko et al., 2013). 
The key aim of this study was to investigate the expression profile of CD74, MIF and 
CD44 molecules on the breast cancer derived cell lines CAMA-1, MDA-MB-231 and 
MDA-MB-435. To validate this study the expression of CD74, MIF and CD44 on the 
normal breast cell line 266LDM, whole cell lysate obtained from adult normal breast 
tissue and normal breast tissue section were investigated. In order to test this flow 
cytometry, Western blotting and microscopy were employed. 
 
Chapter 3 Results  
 
 
104 
3.2 Results 
3.2.1 Granularity, viability and size of malignant and non-malignant cells 
The viability and granularity of the breast cancer cell lines CAMA-1, MDA-MB-231 and 
MDA-MB-435 and normal breast cells (226LDM) were tested using flow cytometry. This 
was achieved using cells with no staining. The obtained results show that all breast cells, 
whether they were malignant or benign, were the same cell size and almost all the cells 
showed the same viability, which was around 88% to 92 %.  Figure 3-1 shows results 
obtained from a flow cytometer. 
3.2.2 Cell-surface expression of HLA-A, B, C and HLA-DR 
The expression of HLA-A, B, C and HLA-DR molecules on the cell-surface of CAMA-1, 
MDA-MB-231 and MDA-MB-435 cells and normal breast cells was tested to examine 
the immunogenicity of these cell lines as models of malignant and non-malignant cells. 
Figure 3-2 shows results obtained from a flow cytometer. The results showed that MDA-
MB-231 and MDA-MB-435 cells express the same level of HLA-A, B, C and HLD-DR 
respectively. In contrast, CAMA-1 and 266LDM cells did not express HLA-A, B, C and 
HLA-DR or the expression was very weak. 
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Figure 3-1: Scatter plots displaying forward scatter (FSC) (X-axis) and side scatter 
(SSC) (Y-axis) of breast cancer cell lines CAMA-1, MDA-MB-231 and MDA-MB-435 
and normal breast cell lines (226LDM).  
The FCS scatter data provide information on the relative size of the cells whereas SSC scatter data estimate 
the granularity. The units indicate the level of light scatter brightness with 0 being the dullest and 1000 
being the brightest. Each dot is a cell ranked by its brightness. Data is representative of three independent 
experiments. 
 
 
Figure 3-2: Analysis of the expression of cell-surface of HLA-A, B, C and HLA-DR 
in the breast cancer cell lines CAMA-1, MDA-MB-231 and MDA-MB-435 and in the 
normal breast cell line (226LDM).  
Flow cytometry analysis showing HLA-A, B, C and HLA-DR expression (empty histograms), displayed as 
mean fluorescence intensity at the cell-surface for CAMA-1, MDA-MB-231, MDA-MB-435 and 226LDM 
cells. Negative controls were performed by using an isotype-matched control antibody (blue-filled 
histograms). Data is representative of three independent experiments. 
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3.2.3 Identification and quantification of CD74, MIF and CD44  
The cell-surface and intracellular expression of CD74, MIF and CD74 was analysed in 
CAMA-1, MDA-MB-231 and MDA-MB-435 cells. Non-permeabilized and 
permeabilized cells with 0.1 % Triton x-100 were stained with an appropriate 
concentration of By2 (anti-CD74), ab55445 (anti-MIF) and 156-3C11 (anti-CD44) 
antibodies followed by 1 µl RAM-FITC secondary antibody. Cells without staining and 
isotype cells, stained with only secondary antibody, were used as a negative control. 
CD74, MIF and CD44 expression was detected on the cell-surface and cytoplasmic of 
CAMA-1, MDA-MB-231 and MDA-MB-435 cells (Figures 3-3, 3-4 and 3-5). 
Monocytes, Raji cells, cervical cancer HeLa cells and lymphocytes, (Jurkat) cells, were 
used as a positive control as they express high levels of CD74, CD44 and MIF 
respectively.  
Results are shown as histograms where mean fluorescence intensity (MFI) is along the 
horizontal axis (x-axis) versus total cell count on vertical axis (y-axis). This is displayed 
in (Figures 3-3 A, 3-4 A and 3-5 A) where empty histograms show CD74, MIF or CD74 
protein expression as indicated while blue histograms represent isotype-matched negative 
control. Mean fluorescence intensity (MFI) values were further used to plot the bar graphs 
and CAMA-1, MDA-MB-231 and MDA-MB-435 cell lines under study were compared 
for the level of CD74, MIF and CD44 expression separately (Figures 3-3 B, 3-4 B and 3-5 
B).  
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Figure 3-3: Analysis of the expression of cell-surface and intracellular CD74 in the 
breast cancer cell lines CAMA-1, MDA-MB-231 and MDA-MB-435. 
(A) Flow cytometry analysis showing CD74 expression (empty histograms), displayed as mean 
fluorescence intensity, on the cell-surface and intracellularly for CAMA-1, MDA-MB-231 and MDA-MB-
435 cells. Surface and intracellular expression of CD74 in Rji cells are shown as a positive control. 
Negative controls were performed by using an isotype-matched control antibody (blue-filled histograms). 
(B) Graphical representation of CD74 surface and intracellular protein expression on CAMA-1, MDA-MB-
231 and MDA-MB-435 cells. Bar graphs represent level of each protein in mean values ± SD in each cell 
line. Data is representative of three independent experiments. 
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Figure 3-4: Analysis of the expression of cell-surface and intracellular MIF in the 
breast cancer cell lines CAMA-1, MDA-MB-231 and MDA-MB-435.  
(A) Flow cytometry analysis showing MIF expression (empty histograms), displayed as mean fluorescence 
intensity, on the cell-surface and intracellularly for CAMA-1, MDA-MB-231 and MDA-MB-435 cells. Cell 
-surface and intracellular expression of MIF in Jurkat cells are shown as a positive control. Negative 
controls were performed by using an isotype-matched control antibody (blue-filled histograms). (B) 
Graphical representation of MIF surface and intracellular protein expression on CAMA-1, MDA-MB-231 
and MDA-MB-435 cells. Bar graphs represent the levels of each protein in mean values ± SD in each cell 
line. Data is representative of three independent experiments. 
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Figure 3-5: Analysis of the expression of cell-surface and intracellular CD44 in the 
breast cancer cell lines CAMA-1, MDA-MB-231 and MDA-MB-435.  
 (A) Flow cytometry analysis showing CD44 expression (empty histograms), displayed as mean 
fluorescence intensity, on the cell-surface and intracellularly for CAMA-1, MDA-MB-231 and MDA-MB-
435 cells. Surface and intracellular expression of CD44 in HeLa cells are shown as a positive control. 
Negative controls were performed by using an isotype-matched control antibody (blue-filled histograms). 
(B) Graphical representation of CD44 surface and intracellular protein expression on CAMA-1, MDA-MB-
231 and MDA-MB-435 cells. Bar graphs represent the levels of each protein in mean values ± SD in each 
cell line. Data is representative of three independent experiments.  
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3.2.4 Immunoblot analysis of CD74, MIF and CD44 
CD74, MIF and CD44 protein expression in CAMA-1, MDA-MB-231 and MDA-MB-
435 cells was analysed by Western blot analysis using By2 (anti-CD74), D-2 (anti-MIF), 
156-3C11 (anti-CD44), and TU-02 (anti- α-Tubulin) and Poly6221 (anti β-Actin). By2 
(anti-CD74) is specific for CD74 isoforms 31-45 kDa and 156-3C11 (anti-CD44) is a 
mouse mAb that detects endogenous levels of total CD44 protein and is specific for most 
isoforms (80-90 kDa). The MIF-specific antibody, D-2, is a mouse monoclonal antibody 
mapping an epitope between amino acids 7 to 39 at the N-terminus of the MIF protein.  
THP-1 monocytic cells, Jurkat cells and cervical cancer HeLa cells were used as a 
positive control, expressing high levels of CD74, MIF and CD44.  
The results obtained show that the molecular weight of CD44, α-tubulin, β-actin, CD74 
and MIF are 80-90 kDa, 50-55 kDa, 42 kDa, 33-41 kDa and 12 kDa respectively. β-actin 
and α-tubulin were used as a loading control, since their expression not affected by any 
treatments such as IFN-γ or LPS. CAMA-1, MDA-MB-231 and MDA-MB-435cell lines 
expressed CD74 isoforms, MIF and CD44 however CAMA-1 cells expressed two 
isoforms of CD44 (CD44s and CD44v) (Figure 3-6 A). To evaluate the differences in 
protein loading during the experiment, the percentage of regulation was calculated after 
the intensity of each band was adjusted according to its respective β-Actin band intensity 
(Figure 3-6 B) using the Image Studio Lite software (LI-COR Biosciences).  
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Figure 3-6: Semi-quantitative Western blot analysis of CD74, MIF, CD44 and β-
Actin expression, detected according to their molecular weight in CAMA-1, MDA-
MB-231 and MDA-MB-435. 
(A) 12% SDS-PAGE was performed under reducing conditions, followed by Western blotting with primary 
monoclonal antibodies Poly 6221 (anti β-Actin as loading control), By2 (anti-CD74), 156-3C11 (anti-
CD44), D-2 (anti-MIF). β-Actin is detected at a molecular weight of 42 kDa. Monocytes (THP-1 cells), 
cervical cancer HeLa cells and Jurkat cells were used as a positive control as they express high levels of 
CD74, CD44 and MIF respectively. CD44, CD74, β-Actin and MIF on untreated CAMA-1, MDA-MB-231 
and MDA-MB-435 cells are also shown. CD44 isoforms were detected at expected molecular weights; 90 
and 80 kDa, CD74 at 33, 35 and 41 kDa and MIF at 12 kDa. The expression of target proteins was 
normalised according to its respective β-actin band intensity using the Image Studio Lite software (LI-COR 
Biosciences). (B) Graphical representation of CD74, CD44 and MIF protein expression on CAMA-1, 
MDA-MB-231 and MDA-MB-435 cells. Bar graphs represent the level of each protein in mean values ± 
SD in each cell line. A representative immunoblot of three independent experiments. 
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3.2.5 Confocal microscopy  
Cell-surface staining of CD74, MIF and CD44 in THP-1, Jurkat and HeLa cell lines as 
positive controls was performed as per the protocol for breast cancer cell lines since they 
express high level of above mentioned molecules (Figure 3-7). Negative control samples 
stained with IgG isotype and secondary antibodies were also imaged using the same 
acquisition protocol as for all data sets, where no signals above background fluorescence 
were observed (Figure 3-8), thus minimising false positive signals.  
Cell-surface and intracellular expression of CD74, CD44 and MIF proteins was visualized 
by laser scanning confocal microscopy using different wavelengths.  The CAMA-1, 
MDA-MB-231 and MDA-MB-435 cell lines all exhibited expression of CD74, CD44 and 
MIF on the surface and intracellular membranes of cells (Figure 3-9 A, B). CD74 or MIF 
was labelled with Alexa Fluor® 488 (green), CD44 Alexa Fluor® 555 (red) and cell 
nuclei were stained with 4 ', 6-diamidino-2-phenylindole (DAPI) (blue).  
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Figure 3-7: Cell-surface staining of CD74, MIF and CD44 of THP-1, Jurkat and 
HeLa cells as visualised by confocal laser scanning microscopy.  
All cells were cultured in LabTek 8-well chambers at a density of 6 × 103 cells per well overnight. Cells 
were stained either with CD74 or MIF labelled with Alexa Fluor® 488 (green). CD44 was labelled with 
Alexa Fluor® 555 (red), cell nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI), which is 
shown in blue. Fluorochromes were acquired separately to evaluate the expression of CD74, CD44 and MIF 
using the Fiji software. Photomicrographs are representative of three independent experiments. Scale bar 10 
µm.  
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Figure 3-8:Confocal microscopy images of CAMA-1, MDA-MB-231 and MDA-MB-
435 cells as isotype- negative controls. 
The isotype control comprised cells stained with isotype control IgG primary and Alexa Fluor® 488 and 
Alexa Fluor® 555 secondary antibodies, visualised by using green 488 nm and red 555 nm wavelength 
lasers to measure non-specific antibody binding. Blue colour shows DAPI stained cell nuclei, red and green 
show the merged image, whereas DIC is the differential interference contrast image of corresponding cells. 
Scale bar 10 µm. 
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Figure 3-9: (A) Cell-surface and (B) intracellular staining of CD74, CD44 and MIF 
on CAMA-1, MDA-MB-231 and MDA-MB-435 cell, as visualised by confocal laser 
scanning microscopy.  
All cells were cultured in LabTek 8-well chambers at a density of 10 × 103 cells per well overnight. Cells 
were stained either with CD74 or MIF labelled with Alexa Fluor® 488 (green). CD44 was labelled with 
Alexa Fluor® 555 (red). Cell nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI) that is shown 
in blue. Fluorochromes were acquired separately to evaluate the expression of CD74, CD44 and MIF using 
the Fiji software. Photomicrographs are representative of three independent experiments. Scale bar 10 µm. 
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3.2.6 Validation study of tumour antigens  
In order to validate this study, the expression of CD74, MIF and CD74 in immortalized 
normal breast luminal cells (226LDM) was investigated. Cell-surface and intracellular 
expression of CD74, CD44 and MIF was assessed using flow cytometry (Figure 3-10 A). 
Total protein of CD74, MIF and CD44 was detected by Western blotting and α-Tubulin 
was used as a loading control (Figure 3-10 B). Confocal laser scanning microscopy was 
used to study the intracellular staining of CD74, MIF and CD44 in 226LDM cells (Figure 
3-10 C). The results show that 226LDM cells do not seem to express CD74, but they do 
express MIF and CD44. Flow cytometry data show that MIF was not detectable and 
CD44 was very weak on the cell-surface but was higher intracellularly.  
In the same manner, the expression of CD74, MIF and CD44 on normal breast lysate and 
tissues (available commercially) was examined. The results revealed that CD74 was not 
expressed on normal breast lysate and tissues in contrast to MIF and CD44 (Figure 3-11 
A, B). Although normal breast lysate and tissues expressed MIF and CD44, the level was 
low compared to that in CAMA-1, MDA-MB-231 and MDA-MB-435 breast cancer cells. 
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Figure 3-10: The expression of CD74, MIF and CD44 proteins in immortalized 
normal breast luminal cells (226LDM).  
(A) Cell-surface and intracellular expression of CD74, MIF and CD44 was acquired by flow cytometry 
using By2 (anti-CD74), 156-3C11 (anti-CD44) and D-2 (anti-MIF).  Empty histograms represent the 
226LDM cells stained with indicated antibody as displayed. Negative controls were performed by using an 
isotype-matched control antibody (blue-filled histograms). (B) Total protein of CD74, MIF and CD44 was 
detected by Western blotting and α-Tubulin was used as a loading control. (C) Intracellular staining of 
CD74, MIF and CD44 in 226LDM cells, visualised by confocal laser scanning microscopy. Data is 
representative of three independent experiments. Scale bar 10 µm 
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Figure 3-11: The detection of CD74, MIF and CD44 proteins in normal human 
breast lysate and tissues.  
(A) Total protein of CD74, MIF and CD44 was detected by Western blot and α-Tubulin was used as a 
loading control. (B) Histological immunostaining of CD74, MIF and CD44 in normal breast tissue cells, as 
visualised by confocal laser scanning microscopy. Scale bar 10 µm. 
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3.3 Conclusions 
The determination and identification of tumour antigens that are highly immunogenic in 
human tumours is important for the development of cell- and vaccine-based tumour 
therapies  (Parmiani et al., 2007).  The characterisation of tumour cells in terms of 
mapping the immunological molecules on those cells can provide further insight into 
whether these cells have the ability to be utilised by the immune system to work as non 
professional antigen-presenting cells.  
This study has examined the immunophenotyping of HLA-A, B, C, HLA-DR, CD74, 
MIF and CD44 expression in the human breast cancer derived cell lines CAMA-1, MDA-
MB-231 and MDA-MB-435. The expression of CD74, MIF and CD44 was studied in 
breast cancer cell lines, the immortalized normal breast luminal cell line 226LDM, 
normal breast tissues and lysate, and in THP-1 cells, Jurkat cells and HeLa cells which 
were used as a positive control. From the obtained results it is concluded that all breast 
cancer cells overexpress CD74 isoforms, MIF and CD44, in contrast to the normal cell 
lines and normal breast tissues, which express only CD44 and MIF in low levels. The data 
shown in this chapter also represents the first evidence of breast cancer cell lines 
expressing three different isoforms of CD74. Taken together, the results of the present 
study indicate a crucial role of CD74 in breast cancer cells along with MIF and CD44. 
The results also suggest that CAMA-1, MDA-MB-231 and MDA-MB-435 cells are 
poorly immunogenic, expressing low levels of HLA-A, B, C and HLA-DR.  
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4.1 Introduction 
Tumour immunogenicity is the ability of a tumour to induce the immune response to 
prevent tumour growth and single-cell transplantation experiments have been widely used 
to study the immunogenicity of tumour cells. Cancer cells that are rejected in naive 
syngeneic mice (which are known as ‘regressors’) are considered highly immunogenic 
(Blankenstein et al., 2012). However, low immunogenicity of cancer cells has often been 
attributed to selective immune processes in the primary tumour-bearing host. The possible 
reasons for the poor immunogenicity of some tumour cells in allogeneic systems include 
the inability to produce, or to cause accessory cells to produce, the necessary 
‘costimulators’ i.e. interleukin (IL)-1 and/or IL-2, a qualitative or quantitative deficiency 
of MHC encoded alloantigens, and the production of inhibitory molecules such as 
prostaglandins (Ashman, 1987). Although most tumour cells express antigens that can 
mediate recognition by host CD8+ T cells, tumour cells can evade anti-tumour immune 
responses to grow progressively (Gajewski et al., 2013). The regulation of the tumour 
immunogenicity by tumour cells is believed to be through either tumour-specific (non-
self) antigens (TSAs) or tumour-associated (self) antigens (TAAs) (B Janakiram, 2012; 
Blankenstein et al., 2012; Burgess, 2012; Gajewski et al., 2013).   
Several mechanisms of immunomodulation within tumour cells have been described that 
render the cells less sensitive to immune attack (resistance) or inhibit anti-tumour immune 
responses (immunosuppression) (Uyttenhove et al., 2003; Gajewski et al., 2006; 
Mantovani et al., 2008). Tumour cells that directly suppress anti-tumour immune 
responses, or induce other cells to do so, are likely selected for by the spontaneous 
occurrence of anti-tumour immune responses. The most common cause of resistance is 
decreased antigenicity owing to HLA class I and II molecule downregulation or loss, 
which frequently occurs in human tumours (Garrido et al., 2010). It is also believed that 
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tumour formation in immunocompetent hosts is dependent on the ability of tumour cells 
to evade the immune system, as suggested by alterations in the expression of MHC 
molecules and other related molecules, such as CD74, in a number of cancers (Rangel et 
al., 2004). However, defects in HLA molecules can be reversed by cytokines, such as 
IFN-γ (Pandha et al., 2007).  In consideration of these defects, it is believed that studying 
the expression of HLA molecules and related molecules would help to characterise the 
ability of tumour cells to be recognised by the immune system or to be utilized as APS 
(Dodson et al., 2011). Therefore, investigating the effect of proinflammatory and 
inflammatory conditions on the expression of HLA molecules by tumour cells might 
assist with targeting specific molecules for immunotherapy if inflammatory events in 
tumour microenvironments could be created. In this context, several researches have 
investigated the expression of HLA molecules and CD74 in tumour cells (Moldenhauer et 
al., 1999; Rangel et al., 2004; Burton et al., 2010; Greenwood et al., 2011). Rangel et al. 
(2004) demonstrated that ovarian cancer cells overexpress HLA-DR-α and HLA-DR-β, 
class II transcriptional transactivator (CIITA) and CD74. Matsushita et al. (2006) have 
also shown that overexpression of HLA-DR molecules in cancer cells relates to better 
prognosis of colorectal cancer patients. The immunogenicity of tumour cells is suggested 
to be regulated by HLA molecules; Malmberg et al. (2002) have shown that IFN-γ 
regulates the immunogenicity of target cells by increasing their expression of HLA class I 
molecules. Similarly, Propper et al. (2003) have also shown that low-dose IFN-γ induces 
tumour MHC expression in metastatic malignant melanoma, increasing the 
immunogenicity of tumour cells. Zheng et al. (2012) showed that LPS stimulation can 
greatly induce MIF and surface CD74 expression and enhance the MIF/CD74 pathway. 
Wu et al. (2014) also observed that the expression of CD74 in lung tissue was 
significantly increased after LPS induction in a mouse model.  
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 The main aim of the present study was to investigate the role of CD74, the cell-surface 
form of the invariant chain, in respect to immunological molecules in breast cancer cell 
lines. This was achieved by studying the effect of IFN-γ or LPS on the expression of 
CD74 on CAMA-1 and MDA-MB-231 cells and by quantifying the cell-surface 
expressed CD74 receptors as well as proliferation and cell migration. To evaluate the 
response of the cells to stimulation, the cell- surface expression of HLA-A, B, C and 
HLA-DR was investigated after IFN-γ treatment. To achieve the aim of this study, RT-
PCR, flow cytometry and Western blotting were employed. 
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4.2 Results 
4.2.1 Effect of IFN-γ and LPS on the proliferation and invasion of CAMA-1 and 
MDA-MB-231 cells 
The effect of varying concentrations of IFN-γ (100, 500 and 1000 IU/ml) for 72 hr or LPS 
(100, 500 and 1000 ng/ml) for 24 hr on proliferation of CAMA-1 and MDA-MB-231 
cells was examined. Cells without IFN-γ or LPS treatment served as the control group. 
IFN-γ could inhibit the proliferation of CAMA-1 and MDA-MB-231 cells (Figure 4-1 A, 
B). Both cell lines showed a similar pattern of decreasing the proliferation. In contrast, 
LPS treatment positively affected the proliferation of CAMA-1 cell lines, since 
proliferation increased compared to untreated control cells. MDA-MB-231 cell lines 
showed a weak proliferative response to LPS treatment in comparison to CAMA-1 cells. 
In the same manner, the ability of non-invasive CAMA-1 and highly invasive MDA-MB-
231 cells to migrate was measured in the presence and absence of 10% FCS, as controls, 
using a transwell insert from Corning Life Science (Figure 4-1 C). The result showed that 
both cell lines had a tendency to migrate towards the serum. However, MDA-MB-231 
cells migrated more than CAMA-1 cells. The migration of both CAMA-1 and MDA-MB-
231 cells cultured with IFN-γ or ng/ml LPS for 24 hr was also evaluated. In the absence 
of 10% FCS, 1000 IU/ml of IFN-γ or 1000 ng/ml LPS were added in the upper chambers 
of the transwell insert. The results confirmed that both cell lines migrate against IFN-γ or 
LPS even in the absence of FCS, which functions as an effective chemoattractant for cells 
in the culture.  This suggests that IFN-γ or LPS have a clear effect in the migration of 
both cell lines.  
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Figure 4-1: Effect of IFN-γ and LPS on proliferation and cell migration of human 
breast cancer cell lines.  
(A and B) Validity of IFN-γ or LPS treated CAMA-1 and MDA-MB-231 cells. CAMA-1 and MDA-MB-
231 cells were seeded in 96 well-plates and treated with indicated concentrations of IFN-γ (100-1000 
IU/ml) for 72 hr or LPS (100-1000 ng/ml) for 24 hr. Untreated cells of both cell lines were used as positive 
controls. Each data point represents a mean of at least three independent experiments with triplicate wells 
and error bars represent SEM from three separate experiments. (C) CAMA-1 and MDA-MB-231 cells were 
cultured with an appropriate medium in the presence or absence of 10% FCS and were allowed to migrate 
overnight through the transwell membrane; 24 mm diameter inserts and a pore size of 0.4 µm. The negative 
control showed that there was no indication of cell migration in the absence of FCS in contrast to the 
positive control, which showed that CAMA-1, and MDA-MB-231 cells strongly migrated toward FCS. The 
migration of CAMA-1 and MDA-MB-231 cells was also evaluated in the presence of IFN-γ or LPS. 1000 
IU/ml of IFN-γ or 1000 ng/ml LPS were added in the upper chambers of transwell insert in the absence of 
10% FCS. Both cell lines migrated against IFN-γ or LPS. 
  
       (0% FCS)                      (10% FCS)               IFN-γ 1000 IU/ml           LPS 1000 ng /ml 
C
A
M
A
-1
  
 M
D
A
-M
B
-2
31
 
0 
20 
40 
60 
80 
100 
120 
0 100 500 1000 
Pr
ol
ife
ra
tio
n 
of
 C
el
ls
  %
 
IFN-γ IU/ml  
CAMA-1 
MDA-MB-231 
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
0 100 500 1000 
Pr
ol
ife
ra
tio
n 
of
 C
el
ls
 %
 
LPS ng/ml 
CAMA-1 
MDA-MB-231 
A B 
C 
Chapter 4 Results  
 
 
 
126 
4.2.2 Effect of IFN-γ on the expression of HLA-A, B, C, and HLA-DR 
The cell-surface expression of HLA-A, B, C and HLA-DR was analysed in untreated and 
IFN-γ-treated CAMA-1 and MDA-MB-231 cells. Non-permeabilized cells were stained 
with an appropriate concentration of w6/32 (anti-HLA-A, B, C) and L243 (anti- HLA-
DR) primary antibody followed by 1 µl RAM-FITC secondary antibody. Cells without 
staining and isotype cells, stained with only secondary antibody, were used as a negative 
control.  
Weak expression of HLA-DR was detected on the cell-surface membrane of untreated 
CAMA-1 and MDA-MB-231 cells. In contrast to CAMA-1 cells, which showed a weak 
expression of HLA-A, B, C molecules, MDA-MB-231 cells showed high expression of 
the same molecules.  It was observed that the expression of HLA-A, B, C and HLA-DR 
increased when CAMA-1 and MDA-MB-231 cells were incubated with (100, 500 and 
1000 IU/ml) IFN-γ for 72 hr (Figures 4-2 and 4-3). However, maximum HLA-A, B, C 
and HLA-DR expression was detected in CAMA-1 cells treated with 1000 IU/ml of IFN-
γ.  In the same manner, MDA-MB-231cells treated with 1000 IU/ml of IFN-γ showed the 
maximum expression of HLA-A, B, C and HLA-DR molecules.  
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Figure 4-2: Cell-surface expression of HLA-A, B, C and HLA-DR on IFN-γ treated 
CAMA-1 cells.  
CAMA-1 cells were cultured in the presence of the indicated concentrations of IFN-γ (100-1000 IU/ml) for 
72 hr and were acquired by flow cytometry using w6/32 (anti-HLA-A, B, C) and L243 (anti- HLA-DR). 
Empty histograms represent the cells with indicated concentrations of IFN-γ and antibody. Blue-filled 
histograms show negative controls. Cells were labelled with an FITC-labelled secondary anti-mouse 
antibody. Cell-surface expression of HLA-A, B, C and HLA-DR on untreated and IFN-γ treated CAMA-1 
cells is also displayed. The results show that HLA-A, B, C and HLA-DR expression increases upon IFN-γ 
treatment. 
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Figure 4-3: Cell-surface expression of HLA-A, B, C and HLA-DR on IFN-γ treated 
MDA-MB-231 cells. 
 MDA-MB-231 cells were cultured in the presence of the indicated concentrations of IFN-γ (100-1000 
IU/ml) for 72 hr and were acquired by flow cytometry using w6/32 (anti-HLA-A, B, C) and L243 (anti- 
HLA-DR). Empty histograms represent the cells with indicated concentrations of IFN-γ and antibody. Blue-
filled histograms show negative controls. Cells were labelled with an FITC-labelled secondary anti-mouse 
antibody.  Cell-surface expression of HLA-A, B, C and HLA-DR on untreated and IFN-γ treated CAMA-1 
cells is also displayed. The results show that HLA-A, B, C and HLA-DR expression increases upon IFN-γ 
treatment. 
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4.2.3 Gene expression 
4.2.3.1 RNA extraction  
To investigate the RNA expression of CD74 and β-actin in Raji, CAMA-1 and MDA-
MB-231 cell lines, RT-PCR was performed. In order to achieve this, RNA was extracted 
and then measured using a NanoDrop spectrophotometer. The samples were then checked 
on a 0.1 % agarose gel, (Figure 4-4 A, B). Since the results showed that the extracted 
RNA was cross contaminated with DNA, DNAse treatment was carried out for RNA 
using a DNase treatment kit (Life technologies, UK). RNA was then converted to cDNA 
according the manufacturer’s instructions. β-actin and CD74 primers were then evaluated 
with the cDNA to check the quality of the cDNA. 
4.2.3.2 Effect of IFN-γ and LPS on CD74 mRNA expression in CAMA-1 and MDA-
MB-231 cells 
RNA extracted from IFN-γ or LPS treated CAMA-1 and MDA-MB-231 cells was reverse 
transcribed into cDNA using reverse transcriptase. This was achieved by converting an 
equal amount of each sample (2 µg of RNA). The resulting cDNA was used as a template 
for subsequent PCR amplifications using β-actin and CD74 primers.  The results 
confirmed that the extracted RNA was converted successfully, using β-actin as a 
housekeeping gene. The CD74 amplicon migrated consistently as a single band at the 
appropriate molecular size (384 bp). These results served to confirm the expression of 
CD74 that was observed in untreated and treated CAMA-1 and MDA-MB-231 cells with 
IFN-γ or LPS. The results are illustrated in (Figure 4-5 A, B). 
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Figure 4-4: Total RNA extracted using TRIzol reagent.  
RNA samples isolated from 1 × 106 Raji, CAMA-1 and MDA-MB-231 cells. Samples were subjected to 
electrophoresis in agarose gels to check the integrity of the RNA. According to this analysis, distinct 
ribosomal RNA bands 28s and 18s could be seen, indicating that all samples were in tact. Lane 1 represents 
the RNA for untreated (A) CAMA-1 and (B) MDA-MB-231 cells. RNA from (A; upper panel) CAMA-1 
and (B; lower panel) MDA-MB-231 cells treated with indicated concentrations of IFN-γ for 72 hr is shown 
in lanes 2, 3 and 4 respectively. Lane 5, 6 and 7 shows the RNA samples isolated from CAMA-1 and MDA-
MB-231 cells treated with indicated concentration of LPS for 24 hr. Lane 8; Raji cells used as a positive 
control. Data is representative of three independent experiments. 
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Figure 4-5: CD74 mRNA expression in CAMA-1 and MDA-MB-231 cells by RT-
PCR.  
Submaximal amplification (27 cycles) of cDNA from a representative subset of the positive control (Raji 
cells) and CAMA-1 and MDA-MB-231 cells treated with IFN-γ or LPS is shown for β-actin and CD74. β-
actin was included as housekeeping gene. (A and B) The presence of bands corresponding to indicated 
molecular weights according to the DNA marker shows CD74 mRNA expression levels in untreated 
CAMA-1 and MDA-MB-231 cells as well as in cells treated with IFN-γ or LPS. (A) The band intensity of 
CD74 shows that mRNA expression increased when CAMA-1 cells were incubated with IFN-γ for 72 hr or 
LPS for 24 hr and maximum expression was detected in CAMA-1 treated with 500 IU/ml of IFN-γ or 1000 
ng/ml of LPS. (B) CD74 mRNA expression in MDA-MB-231 cells increased upon the treatment of IFN-γ 
for 72 hr or LPS for 24 hr and the highest band intensity was obtained in cells treated with (500 IU/ml of 
IFN-γ or 1000 ng/ml of LPS). Data is representative of three independent experiments. 
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4.2.4 Flow cytometry 
4.2.4.1 Effect of IFN-γ and LPS on the expression of CD74 on CAMA-1 and MDA-
MB-231 cells  
The cell-surface and intracellular expression of CD74 was analysed in untreated and IFN-
γ or LPS treated CAMA-1 and MDA-MB-231 cells as explained in section 2.2.2. Cells 
permeabilized with 0.1 % of Triton X-100 and non-permeabilized cells were stained with 
an appropriate concentration of the By2 (anti-CD74) primary antibody followed by 1 µl 
RAM-FITC secondary antibody. Cells without staining and isotype cells stained with 
only secondary antibody were used as a negative control.  
 CD74 was found to be moderately expressed on the cell-surface membrane and 
intracellularly in untreated CAMA-1 and MDA-MB-231 cells. The expression of CD74 
increased when CAMA-1 and MDA-MB-231 cells were incubated with (100, 500 and 
1000 IU/ml) IFN-γ for 72 hr (Figures 4-6 A and 4-8 A).  In the same manner, the 
expression of CD74 increased when CAMA-1 and MDA-MB-231 cells were incubated 
with (100, 500 and 1000 ng/ml) LPS for 24 hr  (Figures 4-6 B and 4-8 B). However, 
maximum CD74 expression was detected in CAMA-1 and MDA-MB-231 cells treated 
with either 500 or 1000 IU/ml of IFN-γ or 1000 ng/ml of LPS. (Figures 4-7 A, B and 4-9 
A, B) show cell-surface and intracellular expression of CD74 depicted by graphical 
representation of mean fluorescence intensity (MFI) in IFN-γ or LPS treated CAMA-1 
and MDA-MB-231.  
 
Chapter 4 Results  
 
 
 
133 
 
Figure 4-6: Cell-surface and intracellular expression of CD74 in IFN-γ or LPS 
treated CAMA-1 cells. 
CAMA-1 cells were cultured in the presence of the indicated concentrations of IFN-γ (100, 500 and 1000 
IU/ml) for 72 hr or LPS (100, 500 and 1000 ng/ml) for 24 hr and were acquired by flow cytometry using 
By2 (anti-CD74). Empty histograms represent the expression of CD74 on untreated CAMA-1 and IFN-γ or 
LPS treated CAMA-1 cells whereas blue-filled histograms show negative controls. Cells were labelled with 
an FITC-labelled secondary anti-mouse antibody. (A) Cells-surface and intracellular expression of CD74 in 
untreated CAMA-1cells and in IFN-γ treated cells. (B) The expression of CD74 after LPS treatment with 
indicated concentration. The results show that CD74 expression increases upon IFN-γ or LPS treatment. 
Maximum CD74 expression was detected in CAMA-1 cells treated with 1000 IU/ml of IFN-γ or 1000 
ng/ml of LPS. Data is representative of three independent experiments. 
 
 
 
IFN-γ  treated CAMA-1 cells   
Untreated                     100 IU/ml                       500 IU/ml                  1000 IU/ml   
 In
tr
ac
el
lu
la
r 
   
   
   
   
 C
el
l S
ur
fa
ce
 
R
el
at
iv
e 
ev
en
t n
um
be
r 
Log Fluorescence (FITC) 
A 
LPS treated CAMA-1 cells   
  Untreated                     100 ng/ml                         500 ng/ml                1000 ng/ml   
 In
tr
ac
el
lu
la
r 
   
   
   
   
 C
el
l S
ur
fa
ce
 
B 
Chapter 4 Results  
 
 
 
134 
 
Figure 4-7: Graphical representation of CD74 surface and intracellular protein 
expression in untreated CAMA-1 and IFN-γ or LPS treated CAMA-1 cells.  
(A and B) CAMA-1 cells cultured in RPMI-1640 supplemented with 10% FCS and treated with indicated 
concentrations of IFN-γ (100, 500 and 1000 IU/ml) for 72 hr or LPS (100, 500 and 1000 ng/ml) for 24 hr. 
Cells were stained with primary mouse anti-human (anti-CD74) mAb clone (By2) followed by staining with 
goat-anti-mouse secondary antibody labelled-FITC. The expression levels were analysed by flow cytometry 
(Aria cell sorter) and FlowJo 8.8.6 software was used to analyse the data. Mean fluorescence intensity 
(MFI) values were measured based on geometric means. Mouse IgG was used as a negative control. Blue 
bars represent cell-surface expression and red bars represent intracellular expression of CD74 in untreated 
and IFN-γ or LPS treated CAMA-1 cells. The results show the expression levels of cell-surface and 
intracellular levels of CD74 in untreated and LPS treated CAMA-1 cells. The increase in both blue and red 
bars confirms that the expression of CD74 was upregulated after exposing the cells to LPS. Maximum 
expression levels were detected when cells were incubated with 1000 ng/ml of LPS on the cell-surface and 
intracellularly. Bar graphs represent level of each protein in mean values ± SD in each cell line. It was noted 
that the level of CD74 expression increased after IFN-γ or LPS treatment. Data is representative of three 
independent experiments. 
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Figure 4-8: Cell-surface and intracellular expression of CD74 on IFN-γ or LPS 
treated MDA-MB-231 cells. 
MDA-MB-231 cells were cultured in the presence of the indicated concentrations of IFN-γ (100, 500 and 
1000 IU/ml) for 72 hr or LPS (100, 500 and 1000 ng/ml) for 24 hr and were acquired by flow cytometry 
using By2 (anti-CD74). Empty histograms represent the expression of CD74 in untreated CAMA-1 and 
IFN-γ or LPS treated CAMA-1 cells whereas blue-filled histograms show negative controls. Cells were 
labelled with an FITC-labelled secondary anti-mouse antibody. (A) Cell-surface and intracellular 
expression of CD74 in untreated MDA-MB-231 and in IFN-γ treated cells. (B) The expression of CD74 
after LPS treatment with indicated concentration. The results show that CD74 expression increases upon 
IFN-γ or LPS treatment. Maximum CD74 expression was detected in CAMA-1 cells treated with 1000 
IU/ml of IFN-γ or 1000 ng/ml of LPS. Data is representative of three independent experiments. 
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Figure 4-9: Graphical representation of CD74 surface and intracellular protein 
expression in untreated MDA-MB-231 and IFN-γ or LPS treated MDA-MB-231 
cells.  
(A and B) MDA-MB-231 cells were cultured in D-MEM supplemented with 10% FCS and treated with 
indicated concentrations of IFN-γ (100, 500 and 1000 IU/ml) for 72 hr or LPS (100, 500 and 1000 ng/ml) 
for 24 hr. Cells were stained with primary mouse anti-human (anti-CD74) mAb clone By2, followed by 
staining with goat-anti-mouse secondary antibody labelled-FITC. The expression levels were analysed by 
flow cytometry (Aria cell sorter) and FlowJo 8.8.6 software was used to analyse the data. Mean 
fluorescence intensity (MFI) values were measured based on geometric means. Mouse IgG was used as a 
negative control. Blue bars represent cell-surface expression and red bars represent intracellular expression 
of CD74 in untreated and IFN-γ or LPS treated CAMA-1 cells. The results show the expression levels of 
cell-surface and intracellular levels of CD74 in untreated and LPS treated CAMA-1 cells. The CD74 
expression was upregulated after exposing the cells to LPS. Maximum expression levels were detected 
when cells were incubated with 1000 ng/ml of LPS on the cell-surface and intracellularly. Bar graphs 
represent level of each protein in mean values ± SD in each cell line. It was noted that level of CD74 
expression increased after IFN-γ or LPS treatment. Data is representative of three independent experiments. 
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4.2.5  Western blotting 
CD74 protein expression in Raji, CAMA-1 and MDA-MB-231 cells was studied by 
Western blot analysis using By2 (anti-CD74) and TU-02 (anti- α-Tubulin) mAbs. By2 
(anti-CD74) is specific for 31-45 kDa CD74 isoforms. Results confirmed that the 
molecular weight of CD74 and α-tubulin are 33-41 kDa and 55 kDa respectively. α-
tubulin was used as a loading control since it is expressed at the same level and it is not 
affected by the suggested treatments. Almost all cell lines expressed CD74 isoforms even 
though the expression varied before and after treatment with IFN-γ and LPS. To evaluate 
the differences in protein loading during the experiment, the percentage of regulation was 
calculated after the intensity of each band was adjusted according to its respective α-
tubulin band intensity using the Image Studio Lite software (LI-COR Biosciences). 
4.2.5.1  The effect of IFN-γ and LPS on total protein expression of CD74 on 
CAMA-1 and MDA-MB-231 cells  
Total cell lysate was extracted and loaded on a gel from untreated and IFN-γ or LPS 
treated CAMA-1 and MDA-MB-231 cells, cultured in the presence of the indicated 
concentrations of IFN- γ (100, 500 and 1000 IU/ml) for 72 hr or LPS (100, 500 and 1000 
ng/ml) for 24 hr (Figures 4-10 A, C and 4-11 A, C).  The presence of bands 
corresponding to the expected molecular weight of CD74 confirmed its expression. The 
differences in band intensity between untreated and treated CAMA-1 or MDA-MB-231 
cells confirmed that CD74 was upregulated in cells incubated with IFN-γ or LPS. CD74 
isoforms were detected at expected molecular weights; 33 and 41 kDa. Maximum CD74 
isoform expression was detected in CAMA-1 cells treated with 500 IU/ml of IFN-γ or 
with 1000 ng/ml of LPS.  Density of the bands was normalized with internal α-tubulin 
loading control (Figures 4-10 B, D and 4-11 B, D). 
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Figure 4-10: CD74 and α-Tubulin expression according to their molecular weight in 
IFN-γ or LPS treated CAMA-1 cell lines.  
SDS-PAGE (12%) was performed under reducing conditions, followed by Western blotting with primary 
monoclonal antibodies TU-02 (anti α-Tubulin as loading control) and By2 (anti-CD74). α-Tubulin was 
detected at a molecular weight of 55 kDa. The monocyte cell line Raji was used as a positive control as it 
expressed high levels of CD74 without any stimulation of cytokines. CAMA-1 cells, cultured in the 
presence of the indicated concentrations of IFN- γ for 72 hr or LPS for 24 hr. (A and C) α-Tubulin, CD74 
on untreated CAMA-1 and IFN-γ or LPS treated CAMA-1 cells with indicated concentrations. (B and D) 
Relative levels of CD74 in IFN-γ or LPS treated CAMA-1 cells. CD74 levels are normalized against α-
tubulin to account for the difference in protein loading during the experiment. The percentage of regulation 
was calculated after the intensity of each band was adjusted according to its respective α-Tubulin band 
intensity using Image Studio Lite software (LI-COR Biosciences). Comparison of CD74 expression in 
untreated CAMA-1 and IFN-γ or LPS treated CAMA-1 cells were assessed using densitometry analysis. 
CD74 isoforms were detected at expected molecular weights; 33, 35 and 41 kDa. Maximum CD74 isoform 
expression was detected in CAMA-1 cells treated with 500 IU/ml of IFN-γ or 1000 ng/ml of LPS. A 
representative immunoblot of three independent experiments. 
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Figure 4-11: CD74 and α-Tubulin expression according to their molecular weight in 
IFN-γ or LPS treated MDA-MB-231 cell lines. 
SDS-PAGE (12%) was performed under reducing conditions, followed by Western blotting with primary 
monoclonal antibodiesTU-02 (anti α-Tubulin as loading control) and By2 (anti-CD74). α-Tubulin is 
detected at a molecular weight of 55 kDa. The monocyte cell line Raji was used as a positive control as it 
expressed high levels of CD74 without any stimulation of cytokines. MDA-MB-231 cells, cultured in the 
presence of the indicated concentrations of IFN- γ for 72 hr or LPS for 24 hr. (A and C) α-Tubulin, CD74 
on untreated MDA-MB-231 and IFN-γ or LPS treated MDA-MB-231 cells with indicated concentrations. 
(B and D) Relative levels of CD74 in IFN-γ or LPS treated MDA-MB-231 cells. CD74 levels are 
normalized against α-Tubulin to account for the difference in protein loading during the experiment; the 
percentage of regulation was calculated after the intensity of each band was adjusted according to its 
respective α-Tubulin band intensity using Image Studio Lite software (LI-COR Biosciences). Comparison 
of CD74 expression in untreated MDA-MB-231 and IFN-γ or LPS treated MDA-MB-231 cells were 
assessed using densitometry analysis. CD74 isoforms were detected at expected molecular weights; 33, 35 
and 41 kDa. Maximum CD74 isoform expression was detected in MDA-MB-231 cells treated with 500 
IU/ml of IFN-γ or 1000 ng/ml of LPS. A representative immunoblot of three independent experiments. 
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4.3 Conclusions 
The characterization of the determinants of tumour immunogenicity may potentially help 
to inform the development of cell-based vaccines. The present study sought to map 
immunological molecules and related molecules in breast cancer cells to investigate the 
involvement of CD74 in proinflammatory and inflammatory pathways.  As it was 
explained above, CD74 is a receptor for the proinflammatory cytokine, MIF. This 
ligand/receptor complex initiates survival pathways and cell proliferation, and it triggers 
the synthesis and secretion of major proinflammatory factors and cell adhesion molecules 
(Le Hiress et al., 2015). CD74 has been also suggested to be involved in tumour escape 
and dissemination (Chao et al., 2012). For this reason the influence of IFN-γ or LPS on 
the behaviour of the breast cancer derived cell lines CAMA-1 and MDA-MB-231 was 
studied. It is suggested that overexpression of CD74 by tumour cells might enhance their 
escape from immunoediting during the cancer immunoediting process (Kim et al., 2008; 
Chao et al., 2012).  Recent studies by Fan et al. (2011) and Chao et al. (2012) have found 
evidence to link CD74 to tumour survival, suggesting that systemic inflammation and 
postoperative infections lead to cancer recurrence and survival. Therefore, investigation 
of the role of IFN-γ or LPS in the expression of CD74 in breast cancer cell lines has 
become critical.  
The obtained results from this study showed the MIF-receptor CD74 could serve as a new 
putative prognostic factor, opening up possibility for further research. Growing interest 
focuses on the role of inflammatory signals in the initiation and development of breast 
cancer diagnosis and prognosis. Therefore, following profiling of CD74 expression, the 
effect of IFN-γ and LPS on CD74 expression in breast cancer cell lines was examined. It 
was found that CD74 positivity is significantly increased after incubation with IFN-γ or 
LPS.  The results indicate that IFN-γ and LPS can play a key role in modulating the 
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expression of CD74 in the breast cancer cell lines CAMA-1 and MDA-MB-231as well as 
on the proliferation and the migration of both cell lines. This suggests that CD74 might 
play a role in tumour immunogenicity as well as in cancer immunoediting of breast 
cancer cells. Further research into CD74 and its effect on cellular processes, including the 
complex interactions between CD74 and its binding partners, such as MIF and CD44, will 
undoubtedly translate into clinical benefit for patients. However, on the whole, the present 
data support a role for CD74 in the inflammatory cascade during tumourigenesis. Its 
biological functions, and its association with surrogate markers, such as invasion and 
migration, could implicate CD74 as a potential therapeutic target in breast cancer therapy. 
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5.1 Introduction  
Several studies have suggested that a small proportion of intracellular CD74 is modified 
by the addition of chondroitin sulfate (CD74-CS), a form of CD74. Chondroitin sulfate is 
a sulfated glycosaminoglycan usually found attached to proteins as part of a proteoglycan. 
CD74-CS is expressed on the surface of immune cells and can bind MIF, mediating 
MIF’s signalling pathway (Naujokas et al., 1993; Matza et al., 2003; Binsky et al., 2010). 
Cell-surface expression of CD74 is not strictly dependent on the expression of class II 
MHC molecules in term of antigen presentation (Henne et al., 1995; Starlets et al., 2006), 
and numerous non-class II positive cells express CD74, in which it functions as a receptor 
for the initiation of different signalling cascades (Stumptner-Cuvelette and Benaroch, 
2002; Maharshak et al., 2010). MIF has been found to be the natural ligand of CD74 and 
binds to the extracellular domain of CD74 with high affinity (KD = 1.40 Å~ 10-9 M) and 
initiates a signalling cascade (Leng et al., 2003).  
When bound to the extracellular domain of CD74, MIF promotes signalling pathways, 
including cell proliferation and apoptosis (Leng et al., 2003; Shi et al., 2006; Starlets et 
al., 2006; Bach et al., 2009; Fan et al., 2011; Tillmann et al., 2013).  The short 
cytoplasmic tail of CD74 lacks a signal-transducing intracellular domain, although serine 
phosphorylation, takes place in the P35 variant of CD74, requiring CD44, a polymorphic 
transmembrane protein with kinase activating properties  (Zernecke et al., 2008; Borghese 
and Clanchy, 2011). CD74 forms a complex with CD44, which is essential for the MIF-
induced signalling cascade (Gore et al., 2008; Shi et al., 2006). This cascade induces 
phosphorylation of ERK1 and ERK2, which then activates various effector proteins 
involved in inflammatory processes and cell proliferation. ERK1 and ERK2 remains 
phosphorylated for many hours and hence this cascade continues for up to 2 to 3 hours 
(Mitchell et al., 1999; Lue et al., 2006; Wortzel and Seger, 2011; Roskoski, 2012).  
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Concurrently, MIF binding to CD74 activates the P13K-Akt pathway, leading to 
phosphorylation of BAD and BAX proteins, involved in apoptosis (Lue et al., 2007). In 
addition, this cascade augments Bcl-2 expression, further supporting cell survival 
(Starlets et al., 2006; Lantner et al., 2007; Gore et al., 2008; Sapoznikov et al., 2008; 
Gordin et al., 2010; Cohen et al., 2012). Thus, the binding of MIF to the CD74/CD44 
complex initiates a pathway resulting in proliferation of the mature B cell population and 
their rescue from death. In addition to activating the P13K-Akt pathway, MIF binding to 
CD74 induces a signalling pathway that involves the Syk tyrosine kinase  (Gore et al., 
2008; Starlets et al., 2006), induction of CD74 intramembrane cleavage, and the release of 
the CD74 intracellular domain (CD74-ICD) (Matza et al., 2002; Schneppenheim et al., 
2013). CD74-ICD translocates to the nucleus where it induces activation of transcription 
mediated by the NF-κB p65/RelA homodimer and its co-activator, TAFII105, resulting in 
regulation of transcription of genes that control B cell proliferation and survival (Gore et 
al., 2008; Matza et al., 2001; Starlets et al., 2006). Therefore, the CD74-MIF-CD44 
complex initiates a pro-survival signal leading to the increase of proliferation and 
inhibition of apoptosis. 
The key question of this study was to investigate the interaction of CD74 as a related 
molecule to MIF and CD44 in CAMA-1, MDA-MB-231 and MDA-MB-435 cells. This 
was achieved by studying the colocalisation of CD74 and MIF as well as CD74 and CD44 
by confocal microscopy and immunoprecipitation. Two different colocalisation analysis 
methods, pixel-based and object- based, were applied to study the interaction between 
CD74-MIF-CD44 complexes. Cell proliferation and apoptosis in CD74 siRNA 
transfected cells (CAMA-1 and MDA-MB-231) were also studied to address the 
hypothesis that blocking CD74 or MIF would affect apoptosis and cell proliferation.
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5.2 Results 
5.2.1 Colocalisation of CD74 and MIF  
To investigate whether CD74 colocalised with MIF on CAMA-1, MDA-MB-231 and 
MDA-MB-435 cells, all cell lines were immunostained with an appropriate primary 
antibody followed by a secondary antibody. CD74 was labelled with Alexa Fluor® 
(red) and MIF Alexa Fluor® (green). MDA-MB-435 cells were used as a model in this 
study since they express high level of CD74, MIF and CD44. CAMA-1, MDA-MB-231 
and MDA-MB-435 cells showed clear expression of CD74 and MIF. Merging green 
and red channels assessed the colocalisation and the Pearson’s product-moment 
correlation coefficient (PCC) was used to analyse the degree of colocalisation. Figure 
5-1 shows the colocalisation of CD74 and MIF on positive control THP-1 cells by 
merging green and red channels. 3D images are depicted in Figure 5-2, which were 
acquired in stack, with z-direction step size 0.14 µm using NIS element. Figure 5-3 
shows the colocalisation analysis of CD74 and MIF which is performed on a pixel by 
pixel basis and based on the PCC using a scatter plot on the THP-1, CAMA-1, MDA-
MB-231 and MDA-MB-435 as a comparison of colocalisation in all cell lines versus 
the (positive control; THP-1). It was found that CD74 and MIF were highly colocalised 
in the breast cancer cell lines CAMA-1, MDA-MB-231 and MDA-MB-435 compared 
to THP-1 cells, serving as positive control (Figures 5-1 and 5-3). The images used to 
calculate the Pearson's correlation coefficients of MIF and CD74 are presented in 
(Appendix 1; Figure A1.6). For more accuracy, the total colocalised volume of CD74 
and MIF was acquired in stack, with z-direction and segmented by NIS-Elements 
program (Nikon).  
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Figure 5-1: Colocalisation of CD74 and MIF on the cell-surface of THP-1 cells. 
THP-1 cells were cultured in LabTek 8-well chambers at a density of 10 × 103 cells per well overnight. 
Colocalisation of CD74 and MIF on the cell-surface of THP-1 cells is shown. THP-1 cells were double 
stained with MIF primary antibody labelled with (FITC) Alexa Fluor® 488 (green) or with CD74 primary 
antibody labelled with (TRITC) Alexa Fluor® 555 (red). Colocalisation is shown as yellow fluorescence, 
the result of merging green and red channels; highly colocalised area of MIF and CD74 is shown.  The 
Pearson’s product-moment correlation coefficient was used to analyse the degree of colocalisation. The 
images represent three different experiments. 
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Figure 5-2: Colocalisation of CD74 and MIF on the cell-surface of CAMA-1, MDA-
MB-231 and MDA-MB-435 cells, determined by confocal microscopy analysis. 
CAMA-1, MDA-MB-231 and MDA-MB-435 cells were cultured in LabTek 8-well chambers at a density of 
10 × 103 cells per well overnight. Cells were stained with MIF labelled with Alexa Fluor® 488 (green) or 
CD74 labelled with Alexa Fluor® 555 (red). Cell nuclei were stained with 4', 6-diamidino-2-phenylindole 
(DAPI) (blue). Fluorochromes were acquired separately to evaluate the expression of CD74 and MIF. 
Yellow/orange fluorescence reveals the potential colocalisation of the two antigens. 3D images were 
acquired in stack, with z-direction step size 0.14 µm using NIS element. Single-plane of z-stack is shown in 
three directions as xy, yz and zx. Data represents three different experiments. 
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Figure 5-3: Colocalisation analysis of CD74 and MIF performed on a pixel by pixel 
basis and based on Pearson’s product-moment coefficient correlation using a scatter 
plot on THP-1, CAMA-1, MDA-MB-231 and MDA-MB-435 cells. 
(A) Each pixel in the image was plotted in the scatter diagram based on its intensity level in each channel. 
The colour in the scatterplot represents the number of pixels plotted in that region. In this example, green is 
shown on the x-axis and red is shown on the y-axis. The scatterplot shows high colocalisation and no bleed 
through either green or red channels. The scatter plot provides the rate of the area of association of two 
fluorochromes, calculated by linear regression. The scatter plot comprised of dots, appearing as cloud, 
indicates complete colocalisation. (B) Graphical representation of colocalisation analysis based on the 
Pearson product-moment correlation coefficient (PCC) on each cell. The value for PCC ranges from +1 and 
−1 inclusive. A value of +1 would mean the total positive correlation, every pixel that contains Alexa 
Fluor® 488 (FITC) also contains Alexa Fluor® 555 (TRITC), while a value of −1 would mean the total 
negative correlation, every pixel that contains Alexa Fluor® 488 does not contain Alexa Fluor® 555 and 
vice versa. The PCC was calculated based on different images and indicates strong colocalisation of CD74 
and MIF on CAMA-1, MDA-MB-231 and MDA-MB-435 cells. THP-1 cells, serving as positive control. 
Data represents three different experiments. 
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5.2.2 Colocalisation of CD44 and MIF  
The colocalisation of CD44 with MIF on the cell-surface of CAMA-1, MDA-MB-231 
and MDA-MB-435 cells was also investigated. All cell lines were immunostained with an 
appropriate primary antibody followed by a secondary antibody. MIF was labelled with 
Alexa Fluor® (green) 488 and CD44 was labelled with Alexa Fluor® 555 (red). CAMA-
1, MDA-MB-231 and MDA-MB-435 cells showed expression of MIF and CD44. 
Confocal microscopy confirmed that MIF and CD44 were not colocalised on the cell-
surface so further analysis was not carried out. Figure 5-4 shows a weak colocalisation of 
CD44 and MIF on the cell-surface of CAMA-1, MDA-MB-231 and MDA-MB-435. 3D 
images of negative control samples stained with secondary antibodies were acquired in 
stack, with z-direction step size 0.14 µm using NIS element, the same acquisition protocol 
as for all data sets (Figure 5-5).  
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Figure 5-4:Colocalisation of MIF and CD44 on the cell-surface of CAMA-1, MDA-
MB-231 and MDA-MB-435 cells, determined by confocal microscopy analysis. 
CAMA-1, MDA-MB-231 and MDA-MB-435 cells were cultured in LabTek 8-well chambers at a density of 
10 × 103 cells per well overnight. The cells were stained with MIF labelled with Alexa Fluor® 488 (green) 
or CD44 labelled with Alexa Fluor® 555 (red). Cell nuclei were stained with 4', 6-diamidino-2-
phenylindole (blue). Fluorochromes were acquired separately to evaluate the expression of CD44 and MIF. 
Yellow/orange fluorescence reveals the potential colocalisation of two antigens.  The images represent three 
different experiments. 
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Figure 5-5: Confocal microscopy images of negative control samples of CAMA-1, 
MDA-MB-231 and MDA-MB-435 cells.  
Isotype control representing cells stained with isotype control IgG primary and Alexa Fluor® 488 and 
Alexa Fluor® 555 secondary antibodies, visualised by using green 488 nm and red 555 nm wavelength 
lasers to measure non-specific antibody binding. Blue colour shows DAPI stained cell nuclei. Red Green 
shows merged image. 3D images were acquired in stack, with z-direction step size 0.14 µm using NIS 
element. Single-plane of z-stack is shown in three directions as xy, yz and zx. Scale bar 10 um.  
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5.2.3 Segmentation and colocalisation of CD74 and MIF 
For more accuracy, 3D images were acquired in stack, with z-direction and segmented by 
NIS elements using regional maximum detection tools followed by manual threshold to 
calculate the exact percentage of colocalised molecules of CD74 with MIF against the 
total volume in each image. CD74 (red) and MIF (green) channels were segmented and 
the generated binary areas were visually inspected; the overlap of the green and red 
channels was generated by an overlay tool, resulting in a new layer (yellow) that 
represented the intersection of CD74 and MIF. Finally, automated volume measurement 
was carried out for CD74, MIF and their intersection with a volume measurements tool. 
The overlapped percentage of the green and red channels (yellow) in that CAMA-1, 
MDA-MB-231 and MD-MB-435 was calculated by NIS-Elements with values presented 
as a pie chart  (20%, 15% and 22% respectively). The result of 3D images and pie charts 
are presented in (Figure 5-6 A, B and C).  It was found that CAMA-1, MDA-MB-231 and 
MD-MB-435 cells labelled with CD74 and MIF displayed significantly high levels of 
colocalisation. This suggests that CD74 might serve important regulatory roles in 
signalling pathways along with MIF and CD44. 
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Figure 5-6: Colocalisation of CD74 with MIF, quantified on segmented 3D images by 
maximum intensity projections. 
Maximum intensity projections of CAMA-1, MDA-MB-231 and MDA-MB-435 cells are represented in 
panels A, B and C.  MDA-MB-435, MDA-MB-231 and CAMA-1 cells were stained with CD74 labelled 
with Alexa Fluor® 555 (red) and MIF labelled with Alexa Fluor® 488 (green). Cell nuclei were stained 
with 4', 6-diamidino-2-phenylindole (blue). Segmentation results from both channels were merged with the 
DAPI. The percentages of the total volumes of CD74, MIF and the colocalisation from each image are 
represented on pie charts. CAMA-1 cells have the highest correlation between CD74 and MIF followed by 
MDA-MB-435 and MDA-MB231. Data represents three different experiments. 
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5.2.4 Colocalisation of CD74 and CD44 
To investigate whether the intra-cytoplasmic domain of CD74 colocalises with CD44 on 
the intracellular membranes of CAMA-1, MDA-MB-231 and MDA-MB-435 cells, cell 
lines were immunostained with an appropriate primary antibody followed by a secondary 
antibody. CD74 was labelled with Alexa Fluor® 488 (green) and CD44 was labelled with 
Alexa Fluor®  (red). CAMA-1, MDA-MB-231 and MDA-MB-435 cells show expression 
of CD74 and CD44. Merging green and red channels revealed colocalisation of CD74 and 
CD44, and the PCC was used to analyse the percentage of colocalisation. Figure 5-7 
shows colocalisation of CD74 and CD44 in positive control THP-1 cells. 3D images are 
shown in in Figure 5-8, which were acquired in stack, with z-direction step size 0.14 µm 
using NIS element. Figure 5-9 shows colocalisation analysis of CD74 and CD44, which 
was performed on a pixel by pixel basis and based on the PCC. This analysis used a 
scatter plot for the assessment of the THP-1, CAMA-1, MDA-MB-231 and MDA-MB-
435 to compare colocalisation in all cell lines versus the (positive control; THP-1). It was 
found that CD74 and CD44 were highly colocalised in the breast cancer cell lines 
CAMA-1, MDA-MB-231 and MDA-MB-435 compared to THP-1 cells (Figure 5-7). For 
more accuracy, the total colocalised volume of CD74 and CD44 was acquired in stack, 
with z-direction and segmented by NIS elements. The images used to calculate the 
Pearson's correlation coefficients are presented in (Appendix 1; Figure A1.7). 
Colocalisation of CD74 and CD44 was also investigated on the cell-surface membrane. 
Confocal microscopy confirmed that CD74 and CD44 were not colocalised on the cell-
surface, so further analysis was not carried out. The merged images of CD74 and CD44 
on the breast cancer cell lines are shown in Figure 5-10. 
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Figure 5-7: Colocalisation of CD74 and CD44 at intracellular level in THP-1 cells. 
THP-1 cells were cultured in LabTek 8-well chambers at a density of 10 × 103 cells per well overnight.  
THP-1 double were stained with CD74 primary antibody and labelled with (FITC) Alexa Fluor® 488 
(green), and with CD44 primary antibody and labelled with (TRITC) Alexa Fluor® (red). Colocalisation is 
shown as yellow fluorescence, the result of merging green and red channels; highly colocalised area of 
CD74 and CD44 is shown Pearson’s correlation coefficient was used do analyse the degree of 
colocalisation.  The images shown represent three different experiments. 
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Figure 5-8: Intracellular colocalisation of CD74 and CD44 in CAMA-1, MDA-MB-
231 and MDA-MB-435 cells, determined by confocal microscopy analysis. 
CAMA-1, MDA-MB-231 and MDA-MB-435 cells were cultured in LabTek 8-well chambers at a density of 
10 × 103 cells per well overnight. Cells were stained with CD74 labelled with Alexa Fluor® 488 (green) 
and CD44 labelled with Alexa Fluor® 555 (red). Cell nuclei were stained with 4', 6-diamidino-2-
phenylindole (DAPI) (blue). Fluorochromes were acquired separately to evaluate the expression of CD74 
and CD44. Yellow/orange fluorescence shows the potential colocalisation of two antigens.  3D images were 
acquired in stack, with z-direction step size 0.14 µm, using NIS element. Single-plane of z-stack is shown in 
three directions as xy, yz and zx. Data represents three different experiments. 
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Figure 5-9: Colocalisation analysis of CD74 and CD44 is performed on a pixel by 
pixel basis and based on Pearson’s product-moment coefficient correlation using a 
scatter plot on THP-1, CAMA-1, MDA-MB-231 and MDA-MB-435 cells.   
(A) Each pixel in the image is plotted in the scatter diagram based on its intensity level in each channel. The 
colour in the scatterplot represents the number of pixels that are plotted in that region. Green intensity is 
shown on the x-axis and red intensity is shown on the y-axis. The scatterplot shows high colocalisation and 
no bleed through.  It depicts the area of association of two fluorochromes, as calculated by linear regression.  
Dots, appearing as cloud, indicate complete colocalisation. (B) Graphical representation of colocalisation 
analysis based on the Pearson product-moment correlation coefficient (PCC) of each cell. The value for 
PCC can range from −1 to +1. A value of +1 would mean that the patterns are perfectly similar; i.e. pixels 
that contain Alexa Fluor® 488 (FITC) also contain Alexa Fluor® 555 (TRITC). A value of −1 would mean 
that the patterns are perfectly opposite; i.e. pixels that contain Alexa Fluor® 488 do not contain Alexa 
Fluor® 555 and vice versa.  The PCC, derived from three different images, indicates a strong colocalisation 
of CD74 and CD44 on CAMA-1, MDA-MB-231 and MDA-MB-435 cells. THP-1 cells, serving as positive 
control. Data represent three different experiments.  
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Figure 5-10: Colocalisation of CD74 and CD44 on the cell-surface of CAMA-1, 
MDA-MB-231 and MDA-MB-435 cells, determined by confocal microscopy analysis. 
CAMA-1, MDA-MB-231 and MDA-MB-435 cells were cultured in LabTek 8-well chambers at a density of 
10 × 103 cells per well overnight.  Cells were stained with CD74 labelled with Alexa Fluor® 488 (green). 
Alexa Fluor® 555 (red) and CD44 labelled with Alexa Fluor® 555 (red). Cell nuclei were stained with 4', 
6-diamidino-2-phenylindole (blue). Fluorochromes were acquired separately to evaluate the expression of 
CD74 and CD44. Yellow/orange fluorescence reveals the potential colocalisation of two antigens.  3D 
images were acquired in stack, with z-direction step size 0.14 µm using NIS element. Single-plane of z-
stack is shown in three directions as xy, yz and zx. Data represents three different experiments. 
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5.2.5 Segmentation and colocalisation of CD74 and CD44 
For more accuracy, 3D images were acquired in stack with z-direction and segmented by 
NIS elements using regional maximum detection tools followed by manual threshold to 
calculate the exact percentage of colocalised CD74 with CD44. CD74 (green) and CD44 
(red) channels were segmented and the generated binary areas were visually inspected. 
The overlap of the green and red channels was generated by the overlay tool, resulting in 
a new layer (yellow) that represents the intersection of CD74 and CD44. Finally, 
automated volume measurement was carried out for CD74, CD44 and their intersection 
using the volume measurement tool. The overlapped percentage of the green and red 
channels (yellow) in that CAMA-1, MDA-MB-231 and MD-MB-43 was calculated by 
NIS-Elements with values presented as a pie chart  (20%, 22% and 23% respectively). 
The resulting 3D images and pie charts are presented in (Figure 5-11 A, B and C).  MDA-
MB-435, MDA-MB-231 and CAMA-1 labelled with CD74 and CD44 displayed a 
significantly high level of colocalisation, suggesting that CD74 might play important 
regulatory roles in signalling pathways along with MIF and CD44.  
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Figure 5-11: Colocalisation of CD74 with CD44, quantified on segmented 3D images 
by maximum intensity projections.  
Maximum intensity projections of CAMA-1, MDA-MB-231 and MDA-MB-435 cells are represented in 
panels A, B and C. Cells were stained with CD74 labelled with Alexa Fluor® 488 (green) and CD44 
labelled with Alexa Fluor® 555 (red). Cell nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI, 
blue). Segmentation results from both channels merged with the DAPI. The percentages of the total 
volumes of CD74, CD44 and the colocalisation from each image are represented in pie charts. The result 
shows that CAMA-1 cells have the highest correlation between CD74 and CD44, followed by MDA-
MB435 and MDA-MB231. Data represents three different experiments. 
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5.2.6 Interaction of CD74 with MIF and CD44 
To determine whether a physical association exists exclusively between the human-
specific CD74 isoforms (P41, P35 and P33) and MIF as well as CD44 variant (CD44v) 
and CD44 standard (CD44s), a coimmunoprecipitation technique was used. Cell lysate 
was extracted from CAMA-1, MDA-MB-231 and MDA-MB-435 cells cultured in the 
presence of 10% of FCS with appropriate medium. The extracted lysate was incubated 
with anti-CD74 or anti-CD44 antibody and loaded on a gel. The probe was then incubated 
either with anti-CD74, anti-MIF or anti-CD44 antibodies as instructed.  
CD74 or CD44 were first pulled down by immunoprecipitation in all breast cancer cell 
lines, as shown in (Figures 5-12 A and 5-13 A). CD74-MIF and CD74-CD44 interactions 
in cell lysates, as demonstrated by coimmunoprecipitation, showed that CD74 interacted 
with MIF and CD44 in breast cancer cells CAMA-1, MDA-MB-231 and MDA-MB-435 
(Figure 5-12 B and C). The data also revealed that CD74 interacted with MIF, CD44s and 
CD44v in CAMA-1 cells. Figure 5-13 A, which demonstrates the pull of CD44, shows 
that MDA-MB-231 and MDA-435 cells expressed only CD44s, so were interacting with 
CD74 in the same manner, but in contrast to CAMA-1 cells, which expressed CD44v and 
CD44s. Co-IP of CD44-CD74 and CD44-MIF was performed to test whether CD44s and 
CD44v interacted exclusively with all isoforms of CD74 and MIF. The results showed 
that CD44s and CD44v bind only to P41 of CD74 (Figure 5-13 B and C). In contrast, no 
evidence was obtained for a cell-surface or intracellular interaction between CD44 and 
MIF (Figure 5-13). Bands at 55 and 25 kDa, corresponding to the heavy chain and light 
chain of the antibody coupled to the magnetic beads, were observed in all the samples and 
could be considered as a loading control. Additionally, no band was observed with protein 
G beads alone, which were loaded as the negative control.  
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Figure 5-12: Co-immunoprecipitation (Co-IP) to study the interaction of CD74 with 
MIF and CD44 in CAMA-1, MDA-MB-231 and MDA-MB-435 cells. 
Cell lysates from breast cancer cell lines were used for immunoprecipitation and immunoprecipitated 
proteins were separated by 12% SDS-PAGE. Blots were probed with mouse anti-CD74, anti-MIF or anti-
CD44 antibodies. (A) Immunoprecipitation was subjected to pull down CD74 from breast cancer cells 
lysate. The blots were probed with mouse anti-CD74, anti-MIF or anti-CD44 antibodies. Molecular mass in 
kDa is shown on the left-hand side. The antibody (Ab) heavy and light chain bands are indicated so that Ab 
heavy and light chain fragments can be observed at approximately 55 and 25 kDa respectively. Lane 1 
shows beads without added Ab, used in Co-IP as a negative control. (B and C) Co-IP applied to study the 
interaction of CD74/MIF and CD74/CD44. (B) The Co-IP of CD74/MIF confirmed that CD74 interacts 
with MIF. (C) The Co-IP of CD74/CD44 confirmed that all CD44 isoforms, including CD44s and CD44v, 
interact with CD74. No CD74 Co-IP was observed with Protein G beads alone, used as the negative control. 
The data represent three different experiments. 
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Figure 5-13: Co-immunoprecipitation (Co-IP) to study the interaction of CD44 with 
CD74 and MIF in CAMA-1, MDA-MB-231 and MDA-MB-435 cells.  
Cell lysates from breast cancer cell lines were used for immunoprecipitation and immunoprecipitated 
proteins were separated by 12% SDS-PAGE. Blots were probed with mouse anti-CD74, anti-MIF or anti-
CD44 antibodies. (A) Immunoprecipitation was subjected to pull down CD44 from breast cancer cells 
lysate. Molecular mass in kDa is shown on the left-hand side. The antibody (Ab) heavy and light chain 
bands are indicated so that Ab heavy and light chain fragments can be observed at approximately 55 and 
25 kDa respectively. Lane 1 shows G beads without added antibody used in Co-IP, used as the negative 
control. (B and C) Co-IP was applied to study the interaction of CD44/CD74 and CD44/MIF. (B) The Co-
IP of CD44 /CD74 confirmed that only P41 of CD74 interacts with CD44. (C) The Co-IP of CD44/MIF 
confirmed that there is no clear interaction between MIF and CD44 as no band consistent with MIF was 
observed. No CD74 Co-IP was observed with the negative control. Data represent three different 
experiments. 
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5.2.7 Knockdown of CD74 expression in CAMA-1 and MDA-MB-231 cells by 
siRNA CD74  
Prior studies have reported that CD74 is over-expressed in human breast 
adenocarcinomas, and, along with MIF and CD44, has a role in tumour progression. The 
expression of CD74 in CAMA-1 and MDA-MB-231 cells was therefore evaluated. The 
expression of CD74 was found to be highest in CAMA-1 cells compared to MDA-MB-
231 cells (Figure 5-14). In pilot experiments, it was found that a concentration of 80 
pmol/ml for 24 hr of specific CD74 siRNA was optimal for disrupted expression of 
CD74. Therefore, a dose of 80 pmol/ml was selected for optimal transfection of CAMA-1 
and MDA-MB-231 cells with siRNA for all subsequent experiments.  
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Figure 5-14: CD74 knockdown by CD74 siRNA transfection reagent in CAMA-1 
and MDA-MB-231 cells.  
(A and B) siRNA-mediated knockdown of CD74 expression in CAMA-1 and MDA-MB-231 cells detected 
by Western blot. An approximately two to five (siRNA) fold weaker signal of CD74 protein expression is 
apparent, as compared to the negative control siRNA group normalized to the expression of α-Tubulin. (C 
and D). Confocal images of CAMA-1 and MDA-MB-231 cells transfected with CD74 siRNA, untreated 
control and negative control siRNA. Data represent three different experiments. 
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5.2.8 Knockdown of functional CD74 expression promotes apoptosis 
In the light of the observations indicating apoptotic modes of cell death in CAMA-1 and 
MDA-MB-231 cells treated with CD74 siRNA (Figure 5-14), next, multi-parameter flow 
cytometric analysis of siRNA-transfected CAMA-1 and MDA-MB-231 cells was pursued 
to obtain more sensitive and quantitative details of a possible apoptotic mode of cell 
death. Following 24 hr of culture of CD74 siRNA-transfected CAMA-1 and MDA-MB-
231 cells, flow cytometry was used to detect the expression of annexin V in the absence 
of PI staining  (Figure 5-15 A). Annexin V is a non- quantitative probe used to detect 
phosphatidylserine expressed on the cell-surface, an indication of apoptosis. CAMA-1 
and MDA-MB-231 cells treated with CD74 siRNA displayed significantly higher levels 
of annexin V staining (± 55% and 58% respectively) compared with negative control 
siRNA-treated counterparts (± 8% and ± 13% respectively) (Figure 5-15 A). These 
observations indicate that CD74 might play important regulatory roles in apoptosis.  
5.2.9 Determination of the effects of CD74 siRNA on CAMA-1 and MDA-MB-231 
cell proliferation  
CAMA-1 and MDA-MB-231 cell proliferation and viability was determined using the 
MTT metabolic and viability assay  (Figure 5-15 B). CAMA-1 and MDA-MB-231 cells 
treated with CD74 siRNA displayed significantly reduced proliferation compared to cells 
treated with the negative control siRNA control sequence.  
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Figure 5-15: Effect of CD74 siRNA on the apoptosis and proliferation of CAMA-1 
and MDA-MB-231 cells. 
(A) Flow cytometric determination of the effect of CD74 siRNA on apoptosis of CAMA-1 and MDA-MB-
231 cells. Cultured CAMA-1 and MDA-MB-231 cells were divided into three groups: nontransfected cells, 
cells transfected with negative control siRNA and cells transfected with CD74 siRNA. After a 24 hr 
treatment, the cells were harvested for quantitation of apoptosis by determining changes in the cell-surface 
expression of annexin V. Displayed is also a description of the observed frequency of cells undergoing 
apoptosis, which was found to be much higher in the CD74 siRNA treated cells than in the negative control 
treated group of CAMA-1 and MDA-MB-231 cells, respectively. (B) Effect of CD74 siRNA on the 
proliferation of CAMA-1 and MDA-MB-231 cells. MTT assay showed that treatment of CAMA-1 and 
MDA-MB-231 cells with CD74 siRNA inhibited their proliferation. Each point in the curve represents the 
arithmetic mean OD values ± SD from representative experiments that were performed in triplicate. 
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5.3 Conclusions  
As it was suggested that co-expression CD74/MIF and CD44 might play a significant role 
in breast tumour progression and survival (Leng et al., 2003; Shi et al., 2006). This study 
found that CD74, MIF and CD44 were expressed in breast cancer cell lines; they were 
also associated with cell proliferation and apoptosis. Correlation analysis revealed that 
CD74 was positively correlated with MIF and both proteins were also associated with 
CD44. CD74 colocalise with MIF on the cell-surface and intra-cytoplasmic domain of 
CD74 colocalise with CD44 in CAMA-1, MDA-MB-231 and MDA-MB-435 cells, 
regardless of the degree of colocalisation.  It was observed that the interaction of CD74 
with MIF and CD74 with CD44 could be a potential tumour marker for breast cancer 
cells. Moreover, level of co-expression of MIF and CD74 or CD74 and CD44 could be a 
surrogate marker for the efficacy of anti-angiogenic drugs, particularly in breast cancer 
tumours. Also, knockdown of CD74 by CD74 siRNA significantly reduced CAMA-1 and 
MDA-MB-231 cell proliferation and increased the level of apoptotic cells.  
In summary, by applying a pixel-based and object-based colocalisation quantification 
technique, it was possible precisely to quantify and detect subtle differences in the 
distribution of CD74, MIF and CD44 proteins. The breast cancer cell lines CAMA-1, 
MDA-MB-231 and MDA-MB-435 served as a good study model to develop this 
approach and to investigate baseline information on potential associations of CD74, MIF 
and CD44 molecules. It is concluded that CD74, MIF and CD44 molecules colocalise 
with each other, forming preferential associations on breast cancer derived cells. There 
appeared to be favoured combinations of certain CD74-MIF-CD44 complexes, and these 
may enhance cell-to-cell apposition. It is reasonable to assume that an immune-effector 
mechanism initiated a pro-survival signal, leading to the increase of proliferation and 
inhibition of apoptosis. 
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6.1 Introduction  
Proteomics is the large-scale study of localisation, identification, structure and function of 
the proteome. A proteome is the complete set of proteins expressed and modified by an 
organism under a specific set of environmental conditions. The application of mass 
spectrometry (MS) in proteomics analysis has made it a powerful tool for protein 
characterization (Cravatt et al., 2007). The classical method for the quantitative analysis 
of complex protein mixtures is the separation of proteins by two-dimensional gel 
electrophoresis (2-DE), and identification of resolved proteins by MS or tandem mass 
spectrometry (MS/MS) (Issaq and Veenstra, 2008). 2-DE accommodates a large mass 
range and permits the analysis of the entire set of proteins. Also, proteins are separated 
with high resolution by isoelectric point (pI) and molecular mass. Resolved protein spots 
are used for comparison among different samples and can be used for MS analysis. 
However, this method has some disadvantages such as the occurrence of gel to gel 
variation, a limited dynamic range, and difficulty in detection of basic or hydrophobic 
proteins and low range of molecular weights and limited range pIs of proteins (Zhu et al., 
2009). Recent developments of non-gel-based and label-free shotgun proteomics 
techniques have rendered quantitative protein study faster, cleaner and simpler (Old et al., 
2005; Chen and Yates, 2007; Patel et al., 2009).  
Proteomics studies provide global analysis of protein expression and function. In contrast 
to the genome, the proteome is very dynamic in nature because of post-translational 
modifications (Aebersold and Cravatt, 2002; Aebersold and Mann, 2003). Therefore, in 
order to recognize the physiological and pathological events that occur in health and 
disease, it is important to detect and analyse the proteins from their native proteome. 
Taking into consideration the importance of proteomics, 2-DE was applied in the context 
of the breast cancer model system to investigate the effect of cytokines such as IFN-γ on 
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breast cancer cells.  The ExPASy tool (http://web.expasy.org/tagident/) was used to 
identify and quantify breast cancer cell membrane proteins expressed in response to IFN-
γ. This investigation will be a potential aid in developing our understanding of the 
molecular aspects breast cancer and drug discovery. 
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6.2 Results  
6.2.1 Two dimensional gel analysis of CAMA-1 and MDA-MB-231 cells  
CAMA-1 and MDA-MB-231 cells were used in this study as a model for breast cancer 
and differential expression of the breast cancer proteome in response to proinflammatory 
cytokines such as IFN-γ. This was investigated by 2-DE followed by protein spot 
analysis. The total proteome is separated by first dimension iso-electric focusing on the 
basis of the isoelectric points (pI) of the various proteins. The isoelectrically focused 
proteins were resolved by second dimension SDS-PAGE, as shown in Figure 6-1 and 
Figure 6-3. Silver stained protein spots in untreated CAMA-1 and MDA-MB-231 cells 
and IFN-γ treated cells, as well as a third unchallenged control group, are shown in 
(Figure 6-2 A-D and Figure 6-4 A-D). Gel images from three independent experiments 
were then analysed using Progenesis SameSpot software (Nonlinear Dynamics Limited), 
where a control untreated sample gel was used as a reference to identify differentially 
expressed proteins. Differentially expressed protein spots from CAMA-1 and MDA-MB-
231 cells are shown in (Figure 6-1 and Figure 6-3) surrounded by a blue line and a spot 
number is given to each spot. Some selected differentially expressed spots are also 
indicated with red arrows in all four conditions: control cells only; in 10% FCS medium, 
cells treated with 100 IU/ml IFN-γ, cells treated with 500 IU/ml IFN-γ and cells treated 
with 1000 IU/ml IFN-γ (Figure 6-2 A-D and Figure 6-4 A-D). These data were used to 
gather preliminary results to discover the potential of differential protein expression in 
response to infections in the model system. An example of a 3D spot graph analysed by 
Progenesis SameSpot software is shown in Figure 6-5. Table 6-1 represents a summary of 
data obtained from a reference image showing all differentially expressed spots on an 
untreated control of CAMA-1 and MDA-MB-231 cells by PI and molecular weight. 
Representation and comparison of the number of spots in the untreated control of CAMA-
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1 or MDA-MB-231 and IFN-γ treated CAMA-1 or MDA-MB-231 cells was identified by 
Progenesis SameSpot software and is shown in (Table 6-2 and Table 6-3). 
 
Figure 6-1: Representation of reference image showing an example image of spot 
detection on untreated CAMA-1 cells control.  
Reference image used for image analysis that was carried out with Progenesis SameSpot software. 
Isoelectric point pI range is shown at the top, while the direction of the second dimension SDS-PAGE is 
represented by an arrow on the left. 
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Figure 6-2: Representative 2D gel images of total cell proteins from CAMA-1 cells 
untreated and treated with IFN-γ.  
(A) Control (untreated) cells only, in 10% FCS medium. (B) Cells treated with 100 IU/ml IFN-γ. (C) Cells 
treated with 500 IU/ml IFN-γ. (D) Cells treated with 1000 IU/ml IFN-γ. All incubations were for 72 hr. In 
the first dimension, 80 µg total soluble protein was separated on immobiline IPG strips (18 cm, pH 3-10 
NL). Isoelectric focussing was performed using a IPG phor unit. The second dimension was performed on 
12% SDS-PAGE gels, with image analysis carried out using Progenesis SameSpot software. M-Molecular 
mass standards are shown on the left side (kDa- kilo Daltons). Differentially expressed, user selected 
protein spots in four gels are marked by red arrows. 
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Figure 6-3:Representation of reference image showing an example image of spot 
detection on untreated of MDA-MB-231 cells control.  
Reference image used for image analysis that was carried out with Progenesis SameSpot software. 
Isoelectric point pI range is shown at the top, while the direction of the second dimension SDS-PAGE is 
represented by an arrow on the left. 
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Figure 6-4: Representative 2D gel images of MDA-MB-231 total cell proteins from 
cells untreated and treated with IFN-γ.  
(A) Control (untreated) cells only in 10% FCS medium. (B) Cells treated with 100 IU/ml IFN-γ. (C) Cells 
treated with 500 IU/ml IFN-γ. (D) Cells treated with 1000 IU/ml IFN-γ. Incubations were for 72  hr. In the 
first dimension, 80 µg total soluble protein was separated on immobiline IPG strips (18 cm, pH 3-10 NL). 
Isoelectric focussing was performed on an IPG phor unit. The second dimension was performed on 12% 
SDS-PAGE gels, with image analysis carried out with Progenesis SameSpot software. M-Molecular mass 
standards are shown on the left side (kDa- kilo Daltons). Differentially expressed, user selected protein 
spots in four gels are marked by red arrows. 
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Figure 6-5:  Example of 3D spot graph analysed by Progenesis SameSpot software. 
Three-dimensional spot graph showing the difference between untreated (control) and treated CAMA-1 
cells treated with different doses of IFN-γ. The images show the effect of IFN-γ on breast cancer cells.  
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Table 6-1: Summary of data obtained form reference image showing all 
differentially expressed spots on untreated CAMA-1 and MDA-MB-231 cells 
controls by PI and molecular weight.  
CAMA-1 cells  MDA-MB-231 cells   
Spot 
Number 
PI 
(pH) 
Molecular Weight 
(kDa) 
Spot 
Number 
PI  
(pH) 
Molecular Weight 
(kDa) 
2610 6 16 1720 4 20 
2708 7 12 1765 6 18 
2561 7 18 1597 7 18 
2611 8 17 1671 5 35 
2715 7 16 2277 3 10 
3018 7 12 2299 5 10 
3033 8 11 1784 5 22 
2718 5 15 1845 8 22 
3013 10 12 1493 3 30 
2500 4 18 663 9 65 
2086 9 25 837 6 60 
2167 8 22 392 4 110 
1387 3 30 656 6 63 
1741 6 25 1234 4 35 
2266 9 20 1503 7 20 
2361 7 20 826 7 60 
2410 8 18 905 5 55 
2347 3 20 
2354 5 22 
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Table 6-2: Representation and comparison of the number of spots in untreated 
CAMA-1 cells control and in IFN-γ treated CAMA-1 cells, identified by Progenesis 
sameSpot software. 
CAMA-1 cells were either untreated or treated with the indicated concentration of IFN-γ for a period of 72 
hr. Both untreated and treated cell lysates were then subjected to isoelectric focusing. The second dimension 
was resolved with 12% SDS-PAGE.  A plus sign (+) indicates the presence of spots or increase of spot size 
before or after treatment with IFN-γ. A minus sign (-) indicates the absence of spots before or after 
treatment with IFN-γ. Five spots out of the 19 polypeptide spots (highlighted in bold); generated from the 
CAMA-1 cell sample were randomly selected and analysed using ExPASy tool 
(http://web.expasy.org/tagident/). 
 Average normalised volumes of CAMA-1 cells spot  
Spot 
Number 
Untreated 
CAMA-1 
(Control) 
CAMA-1 treated 
with 100 IU/ml of 
IFN-γ 
CAMA-1 treated 
with 500 IU/ml of 
IFN-γ 
CAMA-1 treated with 
1000 IU/ml of IFN-γ 
2610 Spot - Spot - Spot + Spot - 
2708 Spot - Spot - Spot + Spot - 
2561 Spot - Spot - Spot + Spot - 
2611 Spot - Spot - Spot + Spot - 
2715 Spot - Spot ++ Spot + Spot - 
3018 Spot - Spot - Spot + Spot - 
3033 Spot - Spot - Spot + Spot - 
2718 Spot - Spot - Spot + Spot - 
3013 Spot - Spot - Spot + Spot - 
2500 Spot - Spot - Spot + Spot - 
2086 Spot + Spot - Spot - Spot - 
2167 Spot + Spot - Spot - Spot - 
1387 Spot + Spot - Spot - Spot - 
1741 Spot - Spot + Spot + Spot - 
2266 Spot + Spot - Spot - Spot - 
2361 Spot + Spot - Spot - Spot - 
2410 Spot + Spot - Spot - Spot - 
2347 Spot + Spot - Spot - Spot - 
2354 Spot - Spot - Spot + Spot - 
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Table 6-3: Representation and comparison of the number of spots in untreated 
MDA-MB-21 cells control and in IFN-γ treated MDA-MB-231 cells, identified by 
Progenesis SameSpot software. 
MDA-MB-231 cells were either untreated or treated with the indicated concentration of IFN-γ for a period 
of 72 hr. Both untreated and treated cell lysates were then subjected to isoelectric focusing. The second 
dimension was resolved with 12% SDS-PAGE.  A plus sign (+) indicates the presence of spots or increase 
in spot size before or after treatment with IFN-γ. A minus sign (-) indicates the absence of spots before or 
after treatment with IFN-γ. Five spots out of the 17 polypeptide spots (highlighted in bold); generated from 
the MDA-MB-231 cell sample were randomly selected and analysed using ExPASy tool 
(http://web.expasy.org/tagident/). 
Average normalised volumes of MDA-MB-231 cells spots 
Spot 
Number 
Untreated 
MDA-MB-231 
(Control) 
MDA-MB-231 
treated with 100 
IU/ml of IFN-γ 
MDA-MB-231 
treated with 500 
IU/ml of IFN-γ 
MDA-MB-231 treated 
with 1000 IU/ml of 
IFN-γ 
1720 Spot ++ Spot + Spot - Spot - 
1765 Spot - Spot - Spot - Spot + 
1597 Spot + Spot + Spot + Spot - 
1671 Spot - Spot - Spot - Spot + 
2277 Spot ++ Spot + Spot - Spot - 
2299 Spot ++ Spot + Spot + Spot - 
1784 Spot +++ Spot ++ Spot + Spot + 
1845 Spot ++++ Spot +++ Spot ++ Spot + 
1493 Spot ++++ Spot +++ Spot ++ Spot - 
663 Spot ++ Spot - Spot +++ Spot + 
837 Spot ++ Spot + Spot ++ Spot + 
932 Spot + Spot + Spot + Spot +++ 
656 Spot - Spot - Spot + Spot + 
1234 Spot - Spot ++ Spot +++ Spot +++ 
1503 Spot + Spot + Spot + Spot + 
826 Spot + Spot ++ Spot +++ Spot +++ 
905 Spot + Spot ++ Spot +++ Spot +++ 
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6.3 Conclusions  
Two-dimensional gel electrophoresis is considered as one of the most powerful tools for 
protein separation and fractionation since its first introduction in 1975 (Klose, 1975; 
O'Farrell, 1975; Fernandez et al., 1990). The method has been improved over time to 
make it a more robust tool for proteome analysis.  However, 2-DE is a robust technique 
only if samples are of low complexity and if subcellular fractions are used. This study 
made use of 2-DE to investigate breast cancer cell responses to proinflammatory cytokines 
such as IFN-γ through analysis of their proteome, and compared results with untreated 
conditions. Whole cell lysates of IFN-γ-stimulated and non-stimulated CAMA-1 and 
MDA-MB-231 breast cancer cells were used.  Thus, 2-DE was utilized to obtain 
information about potential differential protein expression. Protein spots in the gels were 
visualized by silver staining and analysed by Progenesis SameSpot as previously used in a 
number of previous studies (Amiour et al., 2012; Brasier et al., 2012; Brunelli et al., 2012; 
Magdeldin et al., 2012; Brioschi et al., 2013). While results obtained from this analysis 
were used as preliminary data to identify differences between untreated and IFN-γ-treated 
samples, they were not used for further MS analysis. 
The present proteomics study of the breast cancer cell lines CAMA-1 and MDA-MB-231 
revealed that breast cancer cells respond to cytokines, including IFN-γ. Differentially 
expressed proteins in IFN-γ-stimulated and non-stimulated (control) CAMA-1 and MDA-
MB-231 breast cancer cells were identified and quantified. Sub-cellular localisation, 
expression, and functions of the listed proteins have been discussed briefly. The data 
described and discussed here can be utilized for further data validation projects, and could 
assist the discovery of new breast cancer related proteins and molecular pathways. 
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7.1 Overview  
Tumour immunology aims to investigate tumour markers that may affect normal immune 
function (Bissell and Radisky, 2001; Kindt et al., 2007).  The field also seeks to identify 
tumour antigens that play a role in the immune response (Graziano and Finn, 2005). The 
present study has contemplated a number of issues associated with breast cancer, cancer 
immuoediting, immunogenicity and tumorigenicity in cases of health and disease.  The 
non-invasive and invasive cell lines CAMA-1, MDA-MB-231 and MDA-MB-435 were 
employed as a study model because many of their biological and biochemical 
characteristics are shared with breast cancer (Holliday and Speirs, 2011).  This study also 
employed 226LDM cells, immortalized normal breast luminal cells, as a model of healthy 
and normal breast tissue (Docquier et al., 2009). 
7.1.1 Analysis and profiling of the expression of CD74, MIF and CD44 
To further understand the immunogenicity and tumorigenicity of breast cancer cells, the 
expression of HLA-A, B, C and HLA-DR molecules in CAMA-1, MDA-MB-231, MDA-
MB-435 and 226LDM cells was investigated. HLA-A, B, C expression was detected in 
MDA-MB231 and MDA-MB435 cells, but not in CAMA-1 and 226LDM cells. 
Conversely, HLA-DR was not detectable in any of the cell lines except MDA-MB-435 
cells, which showed weak expression, as shown in (Figure 3-2). The expression of MHC 
class I and II in cancer cells, including lung, liver, melanoma, colon and breast cancer, 
has been previously observed (Moldenhauer et al., 1999; Kaczmarek et al., 2007; Huang 
et al., 2010; Thibodeau et al., 2012). Notably, Jabrane-Ferrat et al., (1990a,b) reported 
that four out of five different breast adenocarcinoma cell lines expressed cell-surface 
MHC class I proteins. On the other hand, MHC class I was either not expressed or 
downregulated in primary breast cancer tissue (Pistillo et al., 2000).  
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In this respect, it has been reported that coordinate expression of HLA-DR, CD74 and 
HLA-DM by tumour cells is an indicator of improved prognosis in breast carcinoma. 
Several groups have suggested that the expression of HLA molecules improves 
immunogenicity of tumour cells and therefore can induce an anti-tumour T-cell response 
(Meazza et al., 2003; Humphreys et al., 2004; Oldford et al., 2006). Thus, the expression 
of HLA-A, B, C and HLA-DR molecules in breast cancer cell lines could be of 
considerable value for tumour immunity, potentially leading to efficient tumour antigen 
processing and presentation to T cells  (Feinmesser et al., 2000). In the tumour 
immunotherapy design field, MHC class II presentation has received much recent 
attention  (Rajnavölgyi and Lanyi, 2003; Velders et al., 2003).  
Recent published data show that CD74, MIF and CD44 can play a role in the 
pathogenesis of various solid tumours (Meyer-Siegler et al., 2004; 2006; Gore et al., 
2008). The data obtained have confirmed that cell-surface and intracellular CD74, MIF 
and CD44 molecules are detectable by flow cytometry and by confocal microscopy on 
CAMA-1, MDA-MB-231 and MDA-MB-435 cells. The Western blotting results revealed 
that breast cancer cells express total protein of CD74, MIF and CD44.  Significantly, 
Western blot analysis revealed that the CAMA-1, MDA-MB-231 and MDA-MB-435 cell 
lines express three different isoforms of CD74, the P33, P35 and P41 isoforms, which 
were detected at the expected molecular weights, the major form being the 33 kDa 
isoform (Figure 3-6 A) (Liu and Lin, 2014). These findings differ from those obtained by 
Verjans et al. (2009) who found that MDA-MB-231 and MDA-MB-468 cells express one 
CD74 isoform however it was not specified which isoform.  Similarly, Metodieva et al. 
(2013) found that MDA-MB-435 also express P35 isoform of CD74.  Using Western blot 
analysis, Martín-Ventura et al. (2009) found THP-1 cells to express the P33 and P43 
isoforms of CD74. The cell-surface and the total protein expression of CD74 were also 
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studied in the MCF-7 cell line. Data obtained from flow cytometry showed that MCF-7 
cells express a moderate level of CD74 compared to the positive control Raji cell lines. 
Western blot results confirmed that MCF-7 cells express the total protein of CD74. 
However, MCF-7 cells expressed the P33 and P41 isoforms of CD74, in contrast to breast 
cancer cells (Appendix 1; Figure A1.1). Theoretically, an additional 43 kDa form of 
CD74, the longest isoform, could be expected, but it has not yet been unequivocally 
detected in immunoprecipitates from human cells. The P33 and P35 isoforms are believed 
to be involved in regulating class II MHC antigen presentation while the P41 isoform may 
play a key role in T cell selection in the thymus (Mun et al., 2013; Liu and Lin, 2014). It 
is generally accepted that CD74 facilitates the export of MHC II/CD74 complexes from 
the endoplasmic reticulum, while blocking premature loading of peptides on to the MHC 
II molecules (Weenink and Gautam 1997; Datta et al., 2000; Neefjes et al., 2011; 
Bergmann, 2012; Genève et al., 2012). However, it has been recently suggested that high 
levels of CD74 expression might prevent tumour antigen presentation by blocking the 
MHC class II peptide-binding cleft, thus preventing binding of antigenic peptides for 
presentation to T cells, rendering tumours less immunogenic (Beswick and Reyes, 2009; 
Zheng et al., 2012).  In humans, 80% of the CD74 protein pool is composed of the P33 
isoform. However, P35 is considered the most enigmatic isoform (Bergmann, 2012). 
Genève et al. (2012) have suggested that P33 and P35, together, facilitate antigen 
presentation, and that this process does not require the co-expression of any other CD74 
isoform (Beswick and Reyes, 2009; Genève et al 2012).  
Western blotting also demonstrated that CAMA-1 cells express two different isoforms of 
CD44; CD44 variant (CD44v) and CD44 standard (CD44s) (Figure 3-6 A). Jung et al. 
(2009) showed that some breast cancer cell lines, such as MDA-MB-468 and SUM149, 
express several isoforms of CD44s and CD44v.  It is possible that CD44 expression in 
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breast cancer is associated with highly aggressive breast tumour subtypes or highly 
invasive breast cancer cells (Montgomery et al., 2012). 
To validate the present study, immortalized normal breast luminal cells (226LDM), breast 
(human) whole cell lysate obtained from adult normal tissue, and normal breast tissue 
slides were used as a model. The expression of CD74, MIF and CD44 was investigated by 
flow cytometry, Western blot and microscopy. The findings confirmed that 226LDM cells 
did not express CD74 on the cell-surface or intracellularly, while they do express MIF 
and CD44, although in low levels compared to breast cancer cells (Figure 3-10). In the 
same manner, the results obtained from Western blotting of normal breast lysate and 
histological immunostaining of breast tissue slides showed only positive detection of MIF 
and CD44 but not CD74 (Figure 3-11). This result was expected because it has been 
confirmed that the expression of CD74 is restricted to antigen-presenting cells, including 
B cells, monocytes, macrophages and dendritic cells (e.g. langerhans cells) (Gold et al., 
2011). 
7.1.2 The role of IFN-γ and LPS in the expression of CD74  
This study investigated if IFN-γ or LPS played a role in the proliferation and migration of 
CAMA-1 and MDA-MB-231 cells. To determine the level of IFN-γ and LPS that is toxic 
to the cells, the MTT assay was performed, using concentrations of IFN-γ ranging from 
100 to 1000 IU/ml and of LPS ranging from 100 to 1000 ng/ml. The results showed that 
the viability of CAMA-1 and MDA-MB-231 cells decreased after treatment with IFN-γ in 
contrast to that of cells treated with LPS, which enhanced cell proliferation of breast 
cancer cells. In this system, it was observed that 1000 IU/ml of IFN-γ or 1000 ng/ml of 
LPS was the optimal concentration. The results from migration assays indicated that 
MDA-MB-231 cells migrated towards FCS at a higher level than CAMA-1 cells. This 
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was carried out as an evaluation of the ability of cells to display migratory properties in 
an in vitro assay. The effect of the optimal concentration 1000 IU/ml of IFN-γ or 1000 
ng/ml of LPS on cell migration and invasion was also investigated. The results showed 
that both cell lines migrated against IFN-γ or LPS (Figure 4-1).  
In this context, Zhao et al. (2013) have shown that AGS, HGC-27 and GES-1 gastric 
cancer cells that were exposed to IFN-γ had significantly reduced colony formation, cell 
proliferation and migration ability. However, flow cytometry showed no effect of IFN-γ 
on apoptosis of the cells and no effect on cell ageing as assessed by beta-galactosidase (β-
gal) staining. In contrast, results obtained from flow cytometry revealed that IFN-γ 
arrested the cells in the transition stage (G1/S) phase. It has also been shown that IFN-γ 
induces apoptosis in ovarian cancer cells in vivo and in vitro (Wall et al., 2003). Tate Jr et 
al. (2012) have shown that IFN-γ inhibits the proliferation of carcinoma cells.  
This study has also demonstrated that LPS can induce the proliferation and migration of 
CAMA-1 and MDA-MB-231 cells. In this context, Goodier and Londei (2000) have 
shown that LPS stimulates the proliferation and expansion of human CD56+CD3− NK 
cells. Wang et al. (2013a) also demonstrated that LPS can induce the signalling of TLR-4, 
resulting in promotion of cell survival and proliferation in hepatocellular carcinoma. LPS 
has been found to induce NF-κB-dependent expression of antiapoptotic and prometastatic 
genes in tumour cells (Luo et al., 2004). However, Hsu et al. (2011) observed no 
proliferative or apoptotic changes in vitro after 4 hr of LPS treatment of colorectal cancer 
cells, despite evidence that LPS may alter proliferation and apoptosis in cancer cells. 
The expression of CD74 can be induced in tumour cells upon their exposure to 
proinflammatory cytokines such as MIF and IFN-γ  (Moldenhauer et al., 1999; Beswick 
and Reyes; 2009). Several researches have shown that IFN-γ reduces tumourgenicity in 
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vivo by upregulating the expression of MHC and related molecules such as CD74. IFN-γ 
in cancer cells can be modified by epigenetic changes in the promoter region of class II, 
major histocompatibility complex, transactivator (CIITA) (Beatty and Paterson, 2000). 
This may potentially disrupt the IFN-γ signalling pathway and impair T-cell activation, 
thus representing a possible tumour escape mechanism of cancer cells from 
immunosurveillance,  (Matsushita et al., 2006). In the same manner, it is suggested that 
systemic inflammation and postoperative infections lead to cancer recurrence (Hsu et al., 
2011). It has been shown that CD74 expression is increased by chronic inflammatory 
conditions and  Helicobacter pylori  infection  (Beswick and Reyes, 2009; Zheng et al., 
2012). Thus, to evaluate tumour cell responsiveness to treatment with different reagents, 
the expression of HLA-A, B, C and HLA-DR molecules on the surface of CAMA-1 and 
MDA-MB-231 cells, following their exposure to IFN-γ, was examined, as studied by flow 
cytometry. The results confirmed the viability of the cells in response to external reagents 
such as IFN-γ (Figures 4-2 and 4-3). The data also showed that CD74 expression 
increased upon treatment with IFN-γ or LPS in both the CAMA-1 and MDA-MB-231 cell 
lines. 
A clear shift of CD74 mRNA expression was observed when the cells were incubated 
with 100, 500 or 1000 IU/ml of IFN-γ for 72 hr  (Figure 4-5). Also, using flow cytometry 
and Western blotting, following IFN-γ treatment of the cells CD74 expression was found 
to increase both on the cell-surface and intracellularly (Figures 4-6, 4-8, 4-9 and 4-10). 
Verjans et al. (2009) showed that expression of the MIF receptor CD74 was elevated in 
MDA-MB-231 compared to non-invasive MDA-MB-468 and ZR-75-1 breast cancer 
cells. In contrast, the observations of this study revealed that the expression of CD74 was 
higher in non-invasive CAMA-1 cells compared to invasive MDA-MB-231 cells.  
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Using real-time PCR and immunostaining techniques, Maubach et al. (2007) observed 
that CD74 expression in hepatic stellate cells (HSCs) was upregulated after the cells were 
treated with IFN-γ for 30 hr. Similarly, Martín-Ventura et al. (2009) found the expression 
of CD74 to increase in human vascular smooth muscle cells (VSMCs) and THP-1 cells 
after IFN-γ treatment. Moldenhauer et al. (1999) have also shown that the expression of 
CD74, HLA-DR and HLA-A, B, C increased when colon carcinoma cell lines (HT-29 
cells) were incubated with rIFN-γ for 72 hr. More specifically, Greenwood et al. (2012) 
revealed that the triple negative breast cancer cell lines MDA-MB-435, MDA-MB-231, 
MCF-7 and ZR-75 showed higher expression of CD74 after IFN-γ treatment for 72 hr 
using Western blot techniques. There are several potential explanations for increasing 
CD74 expression after IFN-γ treatment. It has been suggested that IFN-γ may directly 
induce CD74 intramembrane cleavage and release to the nucleus, or alternative indirect 
mechanism via cathepsin S upregulation or by an as yet unknown mechanism (Maubach 
et al., 2007; Martín-Ventura et al., 2009).  
CD74 is classified as MIF receptor, which suggests that its expression might be induced 
directly after cytokine treatment (Beswick and Reyes; 2009; Borghese and Clanchy; 
2011). For example, MIF induces the expression of CD74 via Bcl-2 and Bcl-XL (proteins 
family involved in the regulation of apoptosis) in tumour cells such as bladder cancer, 
prostate cancer, gastric cancer and breast cancer (Meyer-Siegler et al., 2004, 2006; Burton 
et al., 2004; Zheng et al., 2012). Verjan et al. (2009) confirmed that the expression of 
CD74 and MIF is somehow associated, since the cell lines that express high levels of MIF 
show higher expression of CD74 compared to those that have low expression of MIF. 
This might indicate that IFN-γ induces CD74 expression directly via the JAK-STAT-1 
pathway, even though the exact mechanism is not well known yet. 
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It has been suggested that CD74 is upregulated directly via CITTA after IFN-γ treatment. 
When IFN-γ binds to its receptors; interferon gamma receptor (IFNAR1 and IFNGR2), it 
causes dimerization and the activation of JAK1 and JAK2 by tyrosine phosphorylation. 
Tyrosine phosphorylation of receptors in cytoplasmic regions allows for interaction to 
occur with STAT-1. STAT-1 is then activated by tyrosine phosphorylation, which also 
leads to dimerization causing STAT-1 to move to the nucleus. At the nucleus STAT-1 
binds to the GAS element of the CIITA promoter IV and is stabilized by its interaction 
with USF-1 (upstream stimulatory factor-1). This then leads to the activation of the 
transcription of CIITA mRNA. CIITA then operates as the essential mediator of MHC-II 
gene induction and activates MHC II gene expression and related genes such as CD74 as 
a co-activator interacting with the promoter – bound transcription factors (Muhlethaler-
Mottet et al., 1998). 
Several studies have suggested that the expression of CD74 upon IFN-γ treatment might 
be induced via cathepsin S (Martín-Ventura et al., 2009). There are many different 
proteases involved in the processing of CD74 during antigen presentation. The most 
effective proteases involved in the last step of this process are cathepsins S and L. These 
enzymes release the class II-associated peptide (CLIP) region of the invariant chain from 
the lip10 (leupeptin induced polypeptide) (Maubach et al., 2007). Significantly, cathepsin 
S overexpression has been linked to human malignant tumour tissues and cells (Chang et 
al., 2007). Cathepsin S is involved in MHC class II expression and CD74 processing in 
human T-cell leukaemia cell lines (HuT-78) and keratinocyte cell lines (HaCaT) 
(Schönefuß et al., 2009). Schönefuß et al. (2009) showed that the expression of MHC 
class II and CD74 was downregulated after inhibition of cathepsin S with CATS-inhibitor 
in HuT-78 and HaCaT cells, even with IFN-γ treatment. This indicates that the expression 
of CD74 might be regulated by cathepsin S via IFN-γ treatment.  
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Recently, it was confirmed that most cytokines that alter MHC class II and CD74 
expression, such as IFN-γ, tumour necrosis factor (TNF-α), transforming growth factor-β, 
IL-1, IL-4 and IL-10, either upregulate or downregulate CIITA and both MHC class II 
and CD74 accordingly. CIITA is known to respond to different proinflammatory stimuli 
and to induce the expression of the classical MHC class II molecules as well as the 
accessory molecule invariant chain CD74 (Harton and Ting; 2000; Maubach et al., 2007). 
Interestingly, Maubach et al. (2007), using real time PCR, have shown that mRNA 
expression of CIITA and CD74 increased in HSC cells upon treatment with IFN-γ. 
Following induction by inflammatory stimuli (IFN-γ), CD74 associates with class II alpha 
and beta chains. This is followed by the stepwise processing of CD74 into the CLIP 
starting from the C-terminus. In contrast, it has also been confirmed that mRNA 
expression of CIITA, HLA-DR and CD74 is not found in trophoblast cell lines such as 
JAR and JEG-3, even after treatment with IFN-γ (Murphy and Tomasi; 1998). Holtz et al. 
(2003) have shown that CD74 is not expressed in JAR and JEG-3 due the absence of the 
CIITA gene. 
In terms of infection (chronic inflammatory conditions), accumulating evidence indicates 
that systemic inflammation and postoperative infections can lead to cancer recurrence 
(Tsujimoto et al., 2010). The mechanisms by which postoperative Gram-negative 
bacterial infections promote cancer recurrence are poorly understood (Hsu et al., 2011). It 
has been reported that the expression of CD74 is increased by inflammatory processes 
triggered by H. Pylori infection.  This bacterium can also use CD74 as a point of 
attachment to gastric cancer cell lines (Beswick and Reyes; 2009; Zheng et al., 2012). 
Therefore, the dramatic increase in CD74 expression during infection suggests that 
H.Pylori can use CD74 as a receptor (Zheng et al., 2012). Zhang et al. (2013) have 
reported that CD74 is induced by LPS, polyinosinic acid: (polyI:C), and infection with 
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porcine circovirus type 2 (PCV2) in vitro. These findings suggest that CD74 may play a 
potential role in inflammatory diseases including cancer. 
In this context, data obtained have shown that CD74 is overexpressed in both the CAMA-
1 and MDA-MB-231 cell lines after LPS treatment. Maximum CD74 mRNA expression 
was detected when the cells were incubated with 1000 ng/ml of LPS for 24 hr (Figure 
4-5). Similar findings were obtained from flow cytometry and Western blotting (Figures 
4-7, 4-10 and 4-11). Relatedly, LPS treatment increased the expression of CD74 in 
MKN45 cells and the highest expression was found when the cells were incubated with 
1000 ng/ml of LPS. It has been suggested that the expression of CD74 increases via MIF 
induction (Zheng et al., 2012).   Zhang et al. (2013) have reported that LPS and polyI:C in 
porcine kidney (PK-15) cells induce CD74 when PK-15 cells are cultured and maintained 
with 1 µg/ml LPS or 10 µg/ml polyI:C  for 48 hr. 
Beswick et al. (2006) reported that H.Pylori binds CD74 on gastric epithelial cells and 
induces NF-κB, ERK1 and ERK2 activation and IL-8 predication. Another study has 
demonstrated that the stimulation of surface CD74 could induce a signalling cascade that 
results in the activation of Akt, NF-κB, and cell proliferation (Starlets et al., 2006). In 
addition, it was found that CD74 is processed in the endocytic compartments, which 
ensures its intramembrane cleavage to liberate the intracellular domain of CD74. This 
cleavage process is followed by nuclear translocation and transcriptional activation, 
including that of NF-κB (Brown et al., 2000). Induction of CD74 by LPS, leading to 
upregulation of the inflammation factors IL-6, IL-8 and COX-2, has also been proposed. 
Thus, it is believed that CD74 enhances the inflammatory response by regulating the NF-
κB signalling pathway (Zhang et al. 2013). Interestingly, it has been found that diabetic 
patients overexpress MIF and CD74. Similarly, high glucose also upregulated MIF and 
CD74 expression in cultured HK2 human proximal tubular cells (Sanchez-Niño et al., 
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2009). This suggests that the interaction between CD74 and LPS might take place in the 
polysaccharide core of the LPS. H.pylori is thought to bind directly to CD74 on the 
surface of cells via urease, a common bacterial protein involved in the catalysis of urea to 
CO2 and NH3 (Beswick and Reyes, 2009; Borghese and Clanchy, 2011).  
The effect of concentrations of IFN-γ ranging from 100 to 1000 IU/ml and LPS ranging 
from 100 to 1000 ng/ml on the expression of CD44 in CAMA-1 and MDA-MB-231 cells 
was also studied. The expression of CD44 was found not affected upon IFN-γ and LPS 
treatment  (Appendix 1; Figures A1.2, A1.3, A1.4 and A1.5).  This result was not 
expected, since CD44 has been shown to be associated with inflammation conditions. 
However, CD44 has been linked to cancer due to its ability to increase tumour cell 
proliferation and invasiveness  (Götte and Yip, 2006; Barshack et al., 1998). 
7.1.3 The interrelation of CD74 with MIF and CD44 
Several groups have studied the association of CD74 with MIF and CD44 in cancers since 
it was reported that CD74 and CD44 are involved in signalling with MIF (Shi et al., 2006; 
Gore et al., 2008; Borghese and Clanchy, 2011). In addition, it was shown that the 
formation of a molecular complex between MIF, CD74 and CD44 in prostate carcinoma 
cells lines (DU-145) could mediate signal transduction including (gene regulation, 
apoptosis and cell proliferation) in prostate cancer (Meyer-Siegler et al., 2006). So, the 
present study aimed to investigate the role of CD74 and its interrelation to MIF and CD44 
in breast cancer cells. This was achieved by studying the colocalisation of CD74, MIF 
and CD44 molecules in the breast cancer cell lines CAMA-1, MDA-MB-231 and MDA-
MB-435 and in THP-1 cells. THP-1 cells were used as a model in this study based on 
Leng et al.’s (2003) finding that MIF colocalises with CD74 with high affinity. THP-1 is 
a human leukemia monocytic cell line, which has been extensively used to study 
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monocyte/macrophage functions, mechanisms, signalling pathways, and nutrient and drug 
transport (Chanput et al., 2014). The results obtained from confocal microscopy 
demonstrated that CD74 and MIF are highly colocalised on the cell-surface of all breast 
cancer cells as well as THP-1 cells (Figures 5-2 and 5-3). Pearson’s correlation 
coefficient and scatter plot  (Figure 5-3) were used to analyse the colocalisation of CD74 
and MIF (Bolte and Cordelieres, 2006). The colocalisation of CD74 and MIF was 
additionally investigated by segmentation methods using regional maximum detection of 
the images (Figure 5-6). These accurately depict the percentage of colocalised CD74 and 
MIF molecules.  
One previous immunofluorescence study has confirmed the colocalisation of MIF and 
CD74 in non-small cell lung cancer (McClelland et al., 2009). Additionally, using 
correlation analysis, Zheng et al. (2012) identified a positive correlation between MIF and 
CD74 in gastric cancer cells. Correspondingly, Starlets et al. (2006) showed that, in 
malignant B cells obtained from patients with chronic lymphocytic leukemia (CLL), MIF 
binds to the extracellular domain of CD74 to initiate a signalling cascade leading to cell 
proliferation and survival. The interaction of MIF with CD74 and CD44 has been 
reported, suggesting that MIF in association with CD74 and CD44 as a complex plays a 
significant role in bladder cancer cell proliferation (Meyer-Siegler et al., 2004). Similarly, 
Meyer-Siegler et al. (2006) reported that the interaction between MIF and CD74 activates 
the ERK1 and ERK2 signalling pathway, presumably through interaction with CD44, in 
the prostate cancer cell lines DU-145 and LNCaP, but not in normal human prostate 
epithelial cells (PrEC) or benign prostate epithelial cells (BPH-1). However, human 
benign prostate hyperplasia epithelial cells (BPH-1) and PrEC prostate cancer cells do not 
express CD74 on the cell-surface, so for this reason, both cells do not interact with MIF 
and CD44 (Meyer-Siegler et al., 2006). Correspondingly, Shi et al. (2006) showed that 
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mammalian COS-7 cells do not bind MIF unless engineered to express the extracellular 
domain of CD74. 
Using confocal microscopy, the present study investigated the colocalisation of CD74 
with CD44, intracellularly, in CAMA-1, MDA-MB-231 and MDA-MB-435 cells. The 
results obtained show that CD74 and CD44 are highly colocalised intracellularly in all 
breast cancer cells as well as THP-1 cells (Figures 5-8 and 5-9). Figure 5-9 showed the 
colocalisation of CD74 and CD44 by scatter plot and the Pearson’s correlation coefficient 
(Bolte and Cordelieres, 2006). Colocalisation of CD74 and CD44 was also investigated 
by segmentation methods using regional maximum detection of the images, which shows 
the percentage of colocalised CD74 and CD44 molecules  (Figure 5-11). 
It has been confirmed that CD74 alone is sufficient to mediate MIF binding to COS-7 
cells. However, CD74 on its own is insufficient to signal with MIF in the absence of 
CD44. Shi et al. (2006) demonstrated that COS-7 cells are not capable of being involved 
in signalling when engineered to express CD74 and a truncated CD44 lacking its 
cytoplasmic signalling domain. Moreover, Shi et al. (2006) also observed that the 
phosphoserine content of CD74 increased only in cells that expressed CD74 and full-
length CD44, which is consistent with the hypothesis that MIF-mediated phosphorylation 
of CD74 is dependent on the activity of the CD44 intracytoplasmic domain. Further, Gore 
et al. (2008) demonstrated that CD74 binds to CD44 to initiate a signalling pathway 
involving MIF in monocytes and macrophages. It has also been found that CD44-
deficient cells are not able to participate in MIF-induced signalling cascade like 
MAPK/ERK pathway (Gore et al., 2008; Cohen and Shachar, 2014.). 
In the light of the above findings, whether CD74 and CD44 colocalise on the cell-surface 
as well as CD44 with MIF was also studied by confocal microscopy. In this context, no 
evidence for the existence of cell-surface interaction between CD44 and CD74 or MIF 
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was obtained. Concomitantly, Shi et al. (2006) did not obtain evidence for a specific 
interaction between MIF and CD44 in COS-7/M6 cells. However, CD44 was suggested to 
mediate signalling of MIF by binding to a MIF that has undergone conformational 
modification as a result of binding to CD74. CD74 alone mediated MIF binding. 
However, MIF-induced ERK1 and ERK2 kinase phosphorylation required the co-
expression of CD44 (Shi et al., 2006).  
To confirm the colocalisation of CD74 with MIF and CD44 co-immunoprecipitation was 
performed, utilizing CAMA-1, MDA-MB-231 and MDA-MB-435 cells.  So, either CD74 
or CD44 was incubated with CAMA-1, MDA-MB-231 and MDA-MB-435 lysates. CD74 
or CD44 was immunoprecipitated by the CD74 or CD44 antibody along with proteins 
bound to it. Western blotting using anti-MIF or anti-CD44 mAb revealed that CD74 was 
co-precipitated with MIF, and CD74 was co-precipitated with CD44. The result obtained 
from Co-IP confirmed that CD74 interacted with MIF and both CD44s and CD44v. 
However, Co-IP of CD44/74 showed that CD44s and CD44v interacted only with the P41 
isoform of CD74, which is found to be the largest isoform present in breast cancer cells of 
this study. Moreover, this study confirmed there is no clear association between CD44 
and MIF, which was further, supported by Co-IP data (Figures 5-12 and 5-13).   
Meyer-Siegler et al. (2004) showed that CD44 binds to the P35 form of CD74 in bladder 
cancer cells, although P35 has been suggested to be involved in the antigen presentation 
process (Genève et al., 2012). However, Meyer-Siegler et al. (2006) did not study 
whether bladder cancer cells express different isoforms of CD74 or not. In the same 
manner, in prostate cancer cells (DU-145), CD44v interacts with CD74 and MIF, creating 
a complex. Moreover, BPH-1 and LNCaP cells do not express surface CD74; so both cell 
lines do not interact with CD44. LNCaP cells, however, have been demonstrated to 
interact with MIF (Meyer-Siegler et al., 2006). Zheng et al. (2012) have found a positive 
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correlation between MIF and CD74 and TLR4 in gastric cancer through correlation 
analysis. Therefore, the data suggest that MIF-CD74 interaction activates the ERK1 and 
ERK2 signalling pathway, presumably through interaction with CD44, as suggested by 
Naujokas et al, (1993). Interestingly, no information has been reported to show other 
pathways and/or signalling molecules (aside from ERK activation) that are affected by 
MIF-CD74 interaction, although a recent report suggests that MIF engagement of CD74 
augments B cell survival by increasing the expression of Bcl-xL (Starlets et al., 2006; Xu 
et al., 2013). However, CD74 has been found to promote HLA-DR internalization by 
active physical association. So, this proposed a model for the dual role of CD74 as a 
molecule that promotes HLA-DR internalization by physical interaction with CD74 and 
as a ligand for MIF (Karakikes et al., 2012).  
To investigate the role of CD74 in apoptosis and proliferation, siRNA that targeted CD74 
was used. Western blot results  (Figure 5-14 A and B) showed that CD74 expression was 
strongly knocked down in CAMA-1 and MDA-MB-231 cells in comparison with the 
control and CD74 siRNA. Microscopic results also confirmed that CD74 expression was 
strongly knocked down in both cell lines (Figure 5-14 C and D). When CD74 expression 
was knocked down, apoptosis was observed in CAMA-1 and MDA-MB-231 cells.  Both 
cell lines, when treated with CD74 siRNA, displayed significantly higher levels of 
annexin V staining (± 55% and ± 58% respectively) compared to negative control siRNA-
treated counterparts (± 8% and ± 13% respectively). In the same manner, it was found 
that in CAMA-1 and MDA-MB-231 cells treated with CD74 siRNA, a significantly 
reduced proliferation was observed compared to cells treated with the negative control 
siRNA control sequence and untreated cells.  
Likewise, it has been reported that knockdown of MIF or CD74 expression by RNA 
interference inhibits DU-145 cell proliferation and downstream MIF signalling (Meyer-
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Siegler et al., 2006; Ren et al., 2006). Guo et al. (2013) also reported that knockdown of 
the functional expression of MIF markedly decreased H460 cell proliferation and induced 
apoptosis, as seen by augmented expression of annexin A5 following treatment of H40 
cells by MIF siRNA. In particular, Verjans et al. (2009) showed that anti-MIF and anti-
CD74 antibodies potently blocked cell proliferation of non-invasive MDA-MB-468 and 
invasive MDA-MB-231 breast cancer cells however this was not observed in non-
tumorous MCF-12A cells.  This could be explained by the absence of the cell-surface 
portion of CD74 in MCF-12A cells. Berkova et al. (2014) reported that CD74 regulates 
Fas death receptor signalling in lymphomas by decreasing the levels of Fas receptors on 
the cell-surface. In the same manner, Liu et al. (2008) have shown that CD74 promotes 
tumour growth, angiogenesis, and cancer cell metastasis in vivo. The effect of CD74 in 
tumour growth and cell proliferation was studied by blocking the activity of MIF or CD74 
in HEK/ CD74 or a renal cell carcinoma (Caki-1) cells. The data showed that CD74-
upregulated vascular endothelial growth factor D (VEGF-D) positively regulates the 
expression of cyclin D and E, which results in the promotion of cell cycle progression 
(Liu et al., 2008). It was reported that G1/S phase proteins cyclin D and cyclin E, were 
upregulated by CD74 and promoted cell cycle progression (Starlets et al., 2006). In the 
light of this, it is here assumed that persistent high expression of CD74 in the intracellular 
compartment and on the cell-surface could impair MHC class II antigen presentation by 
tumour cells; it could also contribute to immune escape and tumour metastasis (Xu et al., 
2000). Figure 7-1 shows proposed signal transduction pathway of MIF with CD74 and 
CD44. 
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Figure 7-1: Diagram illustrating the proposed signal transduction pathway of MIF 
with CD74 and CD44 in human breast cancer cells CAMA-1, MDA-MB-231 and 
MDA-MB-435. 
(A) MIF, CD74 and CD44 are key molecules in the immune system through the role that they have on their 
own or when they associate to form a multimeric complex. MIF/CD74/CD44 complex regulates the 
adaptive immune response by maintaining the mature B cell population and B cell activation and 
differentiation. However, when tumour cells express this complex, it shows different functions that are 
believed to be against the immune system. (B) Shows proposed model of an association between MIF and 
cluster of differentiation CD74 and CD44 based on the correlation analysis revealed on this study, which 
shows that MIF is positively correlated with CD74 and CD44. It was hypothesised that CD74 colocalise 
with MIF on the cell-surface and intra-cytoplasmic domain of CD74 colocalise with CD44 in CAMA-1, 
MDA-MB-231 and MDA-MB-435 cells. It is reasonable to assume that the MIF-CD74-CD44 complex 
formation activates Src-family kinase and (ERK1 and ERK2/MAPK), resulting in the activation of cyclin 
D1 and PI3K/Akt, to the downstream effects on cell cycle, cell proliferation, gene expression and inhibition 
of apoptosis on tumour cells however detailed mechanisms are not fully understood. (C) As it is proposed 
that blocking MIF-CD74 interaction selectively will decrease ERK1 and ERK2 activation, decrease cell 
proliferation, and increase apoptosis in tumour cells. The present study showed that knockdown of CD74 by 
CD74 siRNA significantly reduce CAMA-1 and MDA-MB-231 cell proliferation and increase the level of 
apoptotic cells.  
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7.1.4 Proteomics study of the effect of IFN-γ in CAMA-1 and MDA-MB-231 cells  
A proteomics study using 2-DE was performed to identify differences between untreated 
and IFN-γ-treated CAMA-1 and MDA-MB-231 cells. In comparison with IFN-γ-
stimulated and non-stimulated CAMA-1 and MDA-MB-231 cells, 19 protein spots 
resolved at a given pI and molecular weight were identified in CAMA-1 cells and 17 
spots were identified in MDA-MB-231 cells. The 2-DE results were analysed using 
ExPASy tool that yielded several potential useful results. The polypeptide spots that 
randomly selected and analysed were highlighted shown in (Table 6-2 and Table 6-3). 
Five spots out of the 19 polypeptide spots generated from the CAMA-1 cell sample were 
randomly selected and analysed. For example, the polypeptide spot number 1741 
correlated with interferon-induced transmembrane protein 10, which has a pI of ~ 6 and a 
MW 25 kDa.  The polypeptide spot number 2610, which it is believed to be related to 
programmed cell death protein 5 (PDCD5), was also evaluated. PDCD5 has a pI of ~ 6 
and a MW 16 kDa which is very similar to spot number 2610. PDCD5 is widely 
expressed in most types of normal human tissue and is unregulated in cells undergoing 
apoptosis (Chen et al., 2013). It has since been confirmed that IFN-γ inhibits growth of 
human carcinoma cells via caspase-1 dependent induction of apoptosis (Detjen et al., 
2001). It was assumed that IFN-γ played a critical role in the apoptosis inducing factors 
like PDCD5. The investigation of spot number 1387 which has a pI of ~ 3 and a MW 30 
kDa, showed a strong similarity to cell cycle checkpoint protein RAD1. Cycle checkpoint 
proteins play an important role in controlling cell division of damaged cells (Abraham, 
2001). Another interesting polypeptide spot number was 2086 which has a pI of ~ 9 and a 
MW 25 kDa. The search engine showed that this spot might be related TNF-α -induced 
protein 8-like protein 2 (TIPE2). TIPE2 is a novel immune negative molecule and an 
inhibitor of the oncogenic Ras in mice. However, its function in humans is still unclear 
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(Wang et al., 2013b). The polypeptide spot number 2361 which has a pI of ~ 7 and a MW 
20 kDa showed correlation with cyclin-dependent kinase 4. Cyclin-dependent kinases 
(CDKs) play a central role in the orderly transition from one phase of the eukaryotic 
mitotic cell division cycle to the next (Ullah et al., 2009; Roberts et al., 2012). CDKs 
regulate cell proliferation and coordinate the cell cycle checkpoint response to DNA 
damage.  Owing to this, it is assumed that the absence of spot number 2361 after IFN-γ 
treatment may act as a regulator of tumour cell division. CDK4/6 inhibitors have been 
proven to be attractive antineoplastic agents because of the importance of CDK4/6 
activity in regulating cell proliferation (Roberts et al., 2012). 
In the above manner, five spots out of the 17 the polypeptide spots obtained from MDA-
MB-231 cell lysates were randomly selected and analysed. The polypeptide spot number 
932, which has a pI of ~ 4 and a MW 110 kDa, was been investigated. This spot showed 
strong correlation with melanoma-associated antigen C. Melanoma-associated antigens 
(MAGEs) are classified into two subgroups, I and II. Subgroup I consists of antigens in 
which expression is generally restricted to tumour or germ cells, whereas subgroup II 
MAGEs are expressed in various normal adult human tissues (Xiao and Chen, 2004). 
Another polypeptide spot that was linked to ExPASy tool was number 905, which has a 
pI of ~ 5 and a MW 55 kDa. The database showed that spot number 905 corresponds to 
Myc proto-oncogene protein. The Myc proto-oncogene is a “master regulator” which 
controls many functions, including cellular metabolism and proliferation. The Myc 
oncogene has been shown to induce apoptosis, and has therefore been targeted to develop 
novel cancer therapies (Miller et al., 2012). It was noticed that the data obtained from 2-
DE indicates that the intensity of spot number 905 increased after IFN-γ treatment. In this 
context, IFN-γ has been shown to induce apoptosis of human carcinoma cells via a 
caspase-1 dependent mechanism, which is believed to control Myc proto-oncogene 
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(Detjen et al., 2001).  Therefore IFN-γ might increase the apoptosis of breast cancer cells 
via Myc proto-oncogene protein in the same manner. TP53-regulated inhibitor of 
apoptosis is linked to the polypeptide spot number 2299, which has a pI of ~ 5 and a MW 
10 kDa. The polypeptide spot number 1720, which has a pI of ~ 4 and a MW 20 kDa, 
showed correlation with growth arrest and DNA damage-inducible protein (GADD45β). 
GADD45β has been reported to inhibit apoptosis via attenuating c-Jun N-terminal kinase 
(JNK) activation. It has been reported that TNF-α treatment induces GADD45β protein 
expression through NF-κB-mediated transcription, and transforming growth factor-b 
induces its expression (Yu et al., 2013). The polypeptide spot number 1493 was then 
evaluated, which it is believed to be related to the HLA-DR alpha chain. The HLA-DR 
alpha chain has a pI of ~ 2 and MW 30 kDa, which is very similar to spot, number 1493. 
The expression of HLA-DR on cancer cells closely relates to a more favourable prognosis 
for cancer patients, but the immunological and non-immunological mechanisms are still 
obscure (Matsushita et al., 2006). 
The current study has found a number of differentially expressed proteins in the breast 
cancer model system in response to infectious agents. The data presented here could be 
used as baseline for further detailed investigation. In this regard, functional assays need to 
be employed to further validate the data presented. Further analysis by mass spectrometry 
is also required to identify sequences and differentially observed polypeptide spots.  
7.2 Limitations and significance of the main findings 
The use of breast cancer cells, normal breast luminal cells, normal breast tissues and 
solubilise cell extracts as well as the positive control cell lines, was a unique feature of 
this study. The study used a variety of techniques including RT-PCR, flow cyotemetry, 
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Western blotting, Co-IP, imaging of siRNA transfection, and 2-DE. There are, however, 
limitations to this study. 
This study utilized in vitro cell lines that cannot serve as a replacement for in vivo or ex 
vivo primary cells, in that the precise cellular conditions in vivo could be replicated. 
Therefore, investigating clinical samples from breast cancer patients and normal women 
would improve this study, providing more accurate outcomes for comparison with 
previous research. One of the main limitations of this study is that it did not evaluate the 
effect of IFN-γ and LPS in a dose- and time-dependent manner. However, in accordance 
with previously published methods, optimum conditions were implemented (Moldenhauer 
et al., 1999; Zheng et al., 2012).  Another limitation of this study is that the apoptosis 
assay did not include a direct measure of the total number of tumour cells after treatment 
with IFN-γ and LPS for comparison with the proliferation results.  
This study did not attempt to explain the mechanism of MIF action and the role of 
interacting proteins in influencing MIF signalling pathways. Microscopic techniques such 
as fluorescence resonance energy transfer (FRET) could be applied to study the physical 
association between CD74, MIF and CD44 molecules. FRET is a mechanism describing 
energy transfer between two light-sensitive molecules (chromophores). A donor 
chromophore, initially in its electronic excited state, may transfer energy to an acceptor 
chromophore through nonradiative dipole–dipole coupling. The efficiency of this energy 
transfer is inversely proportional to the sixth power of the distance between donor and 
acceptor, making FRET extremely sensitive to small changes in distance. Investigating 
the interacting binding sites of MIF and CD74 as well as CD74 and CD44 would facilitate 
the design of a clinical drug blocking the interaction.  
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This study investigated the effect of IFN-γ on breast cancer cell lines by 2-DE, but no 
further analysis was performed, such us spot analysis by mass spectrometry. However, 
ExPASy tool was utilised to analyse the protein spots that were identified in CAMA-1 
and MDA-MB-231 cells. Low recovery of hydrophobic proteins on 2-DE gels is another 
major limitation in proteome research.  However, much progress has been made in the 
analysis of integral membrane proteins by 2-DE (Santoni et al., 1999).  
7.3 Future directions 
Tumour immunology is a growing field of research that aims to discover innovative 
cancer immunotherapies to treat the disease and prevent its progression. There are still 
key questions that could be further investigated in future research. A major challenge in 
the future will be to understand CD74 interactions and modifications with different 
molecules such as CXCR1 and CXCR2 in breast cancer.  Since these molecules have 
been shown involve in signalling pathway with MIF and CD74; it may then become 
possible to target specific pathways and provide new therapeutic interventions. 
Future studies of the role of CD74, along with that of CD44, in mediating MIF’s 
signalling pathways would benefit from the application of RNA-Seq, a recently 
developed approach to transcriptome profiling that uses deep sequencing technologies. 
Using RNA-Seq to compare the transcriptome of normal and cancer breast tissues would 
permit the survey of the transcriptional dynamics implicated in health and disease. RNA-
Seq based experiments could profitably be combined with proteomic surveys carried out 
with liquid chromatography mass spectrometry (LC-MS).  Mass spectrometry operates in 
similar fashion to conventional flow cytometry, except that the detection of antigens of 
interest is based on elemental detection of lanthanide metals (via inductively coupled 
plasma mass spectrometry (ICP-MS)). The lanthanide metals are conjugated to probes 
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(usually an antibody) in place of the classical fluorescent labels of flow cytometry. By 
forgoing fluorescent measures, there is no need to compensate for fluorescent spill-over 
across channels. This greatly extends multiplexing potential, allowing simultaneous 
measurement of up to 35 antigens. Mass cytometry is the adaptation of ICP-MS to single-
cell analysis based on the concept that a purified single isotope could be used to tag 
antibodies, and that these conjugates could be quantified in an ICP-MS detection system. 
Mass cytometry is also readily combined with imaging to provide a spatial distribution of 
the antigens of interest over times, thereby providing further insight into the CD74-MIF-
CD44 network. 
7.4 Closing remarks 
In conclusion, this study indicates the feasibility of using immunological and proteomics 
techniques to find new connections between the ability of cancer cells to establish 
metastasis in distant organs and altered expression levels of specific proteins. The study 
was designed to focus on transmembrane proteins relative to the entire proteome, thereby 
increasing the likelihood of identifying proteins that could be targeted by antibodies and 
small molecule drugs as to inhibit the metastatic process. Several of the transmembrane 
proteins identified and characterized seem to be involved in the metastatic behaviour of 
human breast cancer. This indicates that further investigations hold promise for 
identifying novel mechanistically important targets for preventing metastasis and 
significantly advancing treatment of breast cancer. Because of novel technical 
improvements, future studies will also include identification and characterization of 
proteins with altered expression in subcellular compartments, bringing further insight to 
the tumour immunology field. 
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Appendix 1 Supplemental results  
 
 
Figure A1.1: The expression of CD74 in breast cancer cells (MCF-7).  
(A) Cell-surface expression of CD74 was acquired by flow cytometry using By2 (anti-CD74. (Empty 
histograms), displayed as mean fluorescence intensity, at the cell-surface of MCF-7 cells stained with 
indicated antibody. Negative controls were performed by using an isotype-matched control antibody (black 
filled histograms). (B) Total protein of CD74 detected by western blot and α-Tubulin was used as a loading 
control.  
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Figure A1.2: Cell-surface and intracellular expression of CD44 on IFN-γ or LPS 
treated CAMA-1 cells.  
CAMA-1 cells were cultured in the presence of the indicated concentrations of IFN-γ (100-1000 IU/ml) for 
72 hr or LPS (100-1000 ng/ml) for 24 hr were acquired by flow cytometry using 156-3C11  (anti-CD44). 
Empty histograms represent the expression of CD44 on untreated CAMA-1 and IFN-γ or LPS treated 
CAMA-1 cells whereas black filled histograms show negative controls. Cells were labelled with an FITC-
labelled secondary anti-mouse antibody. (A) Represent cells surface and intracellular expression of CD44 
on untreated CAMA-1cells and on IFN-γ treated cells. (B) Represents the expression of CD44 after LPS 
treatment with indicated concentration. The results show that CD44 expression does increases upon IFN-γ 
or LPS treatment and no significant change is detected in CD44 expression after exposing the cells to IFN-γ 
or LPS.  
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Figure A1.3: Cell-surface and intracellular expression of CD44 on IFN-γ or LPS 
treated MDA-MB-231 cells.  
MDA-MB-231 cells were cultured in the presence of the indicated concentrations of IFN-γ (100-1000 
IU/ml) for 72 hr or LPS (100-1000 ng/ml) for 24 hr were acquired by flow cytometry using 156-3C11  
(anti-CD44). Empty histograms represent the expression of CD44 on untreated MDA-MB-231 and IFN-γ or 
LPS treated MDA-MB-231 cells whereas black filled histograms show negative controls. Cells were 
labelled with an FITC-labelled secondary anti-mouse antibody. (A) Represent cells surface and intracellular 
expression of CD44 on untreated MDA-MB-231cells and on IFN-γ treated cells. (B) Represents the 
expression of CD44 after LPS treatment with indicated concentration. The results show that CD44 
expression does increases upon IFN-γ or LPS treatment and no significant change is detected in CD44 
expression after exposing the cells to IFN-γ or LPS.  
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Figure A1.4: CD44 and α-Tubulin expression according to their molecular weight in 
IFN-γ or LPS treated CAMA-1 cells. 
(A and B) Primary monoclonal antibodiesTU-02 (anti α-Tubulin as loading control) and 156-3C11  (anti-
CD44) were used. α-Tubulin is detected at 55 kDa molecular weight. The cervical cancer cells line HeLa 
was used as a positive control as it expresses high levels of CD44 without any stimulation of cytokines 
(lane 5; A and B). CAMA-1 cells, cultured in the presence of the indicated concentrations of IFN- γ for 72 
hr or LPS for 24 hr. (A) Lane 1 represents α-Tubulin, CD44s and CD44v on untreated CAMA-1 cells. (A) 
IFN-γ treated CAMA-1 cells with indicated concentrations are shown in lane 2, 3 and 4. (B) LPS treated 
CAMA-1 cells with indicated concentrations are shown in lane 2, 3 and 4. CD44 isoforms were detected at 
expected molecular weights; 80 and 90 kDa. No significant difference in CD44 isoform expression was 
detectable after treating CAMA-1 cells with IFN-γ or LPS. 
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Figure A1.5: CD44 and α-Tubulin expression according to their molecular weight in 
IFN-γ or LPS treated MDA-MB-231 cells.  
(A and B) Primary monoclonal antibodiesTU-02 (anti α-Tubulin as loading control) and 156-3C11  (anti-
CD44) were used. α-Tubulin is detected at a molecular weight of 55 kDa. The monocytes cell line Raji was 
used as a positive control as it expresses high levels of CD74 without any stimulation of cytokines (lane 5; 
A and B). MDA-MB-231 cells, cultured in the presence of the indicated concentrations of IFN- γ for 72 hr 
or LPS for 24 hr. (A) Lane 1 represents α-Tubulin and CD74 on untreated MDA-MB-231 cells. (A) IFN-γ 
treated MDA-MB-231 cells with indicated concentrations are shown in lane 2, 3 and 4. (B) LPS treated 
MDA-MB-231 cells with indicated concentrations are shown in lane 2, 3 and 4. CD44 isoforms were 
detected at expected molecular weights; 80 and 90 kDa. No significant difference in CD44 isoform 
expression was detectable after treating MDA-MB-231 cells with IFN-γ or LPS. 
 
 
Appendix 1 
 
 
248 
 
Figure A1.6: Calculated Pearson's product-moment correlation coefficients of MIF 
and CD74 for each image in CAMA-1, MDA-MB-231 and MDA-MB-435 cells. 
The coefficients were generated using Fiji software and specific plugins. For every batch of double 
immunostaining of MIF and CD74 cells, three samples were used for quantification. Yellow/ orange signals 
achieved by merging fluorochromes (Alexa Fluor® 488 and Alexa Fluor® 555) separately using using Fiji 
software. Florescence reveals the colocalisation and Pearson's correlation coefficients was used to study the 
degree of colocalisation. 
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Figure A1.7: Calculated Pearson's product-moment correlation coefficients of CD74 
and CD44 for each image in CAMA-1, MDA-MB-231 and MDA-MB-435 cells. 
The coefficients were generated using Fiji software and specific plugins. For every batch of double 
immunostaining of CD74 and CD44 cells, three samples were used for quantification. Yellow/ orange 
signals achieved by merging fluorochromes (Alexa Fluor® 488 and Alexa Fluor® 555) separately using 
using Fiji software. Florescence reveals the colocalisation and Pearson's correlation coefficients was used to 
study the degree of colocalisation. 
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Appendix 2 Buffer Recipes 
1X PBS (1000 ml) 
Reagent Amount Final Concentration 
NaCl 8.0gm 138 mM 
KCl 0.25gm 2.6 mM 
KH2PO4 0.25gm 1.5 mM 
Na2HPO4 0.25gm 6.3 mM 
Distilled Water 1000 ml - 
(PH 7.3; Store at 4°C). 
 
 4% Paraformaldehyde (100 ml) 
Reagent Amount 
PFA 4.0 g 
PBS 100 ml 
(PH 7.3; Store at 4°C). 
 
Blocking buffer (1000 ml) 
Reagent Amount Final concentration 
FCS 10 ml  1 % 
PBS 1000 ml - 
(PH 7.3; Store at 4°C). 
 
Coomasie Blue stain (1000 ml) 
Reagent Amount Final concentration 
Coomasie Blue R-250 1 g 0.1 % 
Methanol 450 ml 45 % 
Glacial acetic acid  100 ml 10 % 
Distilled Water  450 ml  
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Coomasie Blue destain (1000 ml) 
Reagent Amount  Final concentration 
Methanol 100 ml 10 % 
Glacial acetic acid 100 ml 10 % 
Distilled Water  800 ml - 
 
5X electrophoresis running buffer (1000 ml) 
Reagent Amount  Final concentration 
Tris 15.1 g 25 mM 
Glycine 72 g 250 mM 
10% SDS 5 g 0.1 % 
 
1X electrophoresis Buffer (1000 ml) 
Reagent Amount 
5X electrophoresis running buffer 200 ml 
Distilled Water  800 ml 
 
Ammonium Persulfate (10%) (1 ml) 
Reagent Amount  
Ammonium Persulfate  0.1 g 
Distilled Water  1 ml 
 
Transfer buffer (1000 ml) 
Reagent Amount Final concentration 
Tris 3.03 g 25 mM 
Glycine 14.4 g 192 mM 
Methanol 200 ml 20 % 
Distilled Water  800 ml  
(PH 8.3; Store at 4°C). 
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Wash buffer (PBS-T) (1000 ml) 
Reagent Amount Final concentration 
PBS 999 ml - 
Tween 20 1 ml 0.1 % 
 
Blocking buffer (100 ml) 
Reagent Amount Final concentration 
Non- fat dry milk 5 g 5 % 
PBS-T 100 ml - 
 
Sodium dodecyl sulfate SDS (10 %)(100 ml) 
Reagent Amount 
Sodium dodecyl sulfate  10 g 
Distilled Water  100 ml 
 
1.5 M Tris-HCl, pH 8.8 (100 ml) 
Reagent Amount 
Tris base  10 g 
Distilled Water  100 ml Adjust to pH 8.8 with HCl 
(PH 8.8; Store at 4°C). 
 
0.5 M Tris-HCl, pH 6.8 (100 ml) 
Reagent Amount 
Tris base 6.6 g 
Distilled Water  100 ml Adjust to pH 6.8 with HCl 
(PH 6.8; Store at 4°C). 
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Resolving and stacking gel  
Reagent Resolving gel (ml) Stacking gel (ml) 
Distilled Water 4.9 6.1 
1.5 M Tris-HCL 3.8 - 
0.5 M Tris-HCL - 2.5 
Bis acrylamide 6 1.33 
10% SDS 0.15 0.1 
APS 0.15 0.05 
TEMED 0.006 0.01 
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Appendix 3 Chemicals 
1. Accutase Sigma-Aldrich Dorset, UK 
2. Acrylamide 30% BIO-RAD, UK  
3. Agarose Invitrogen, UK 
4. Brilliant Blue G-Colloidal Concentrate Sigma-Aldrich, UK 
5. Bromophenol blue sodium salt Sigma-Aldrich, UK  
6. Calcium chloride Merck, Darmstadt  
7. CHAPS AppliChem, Darmstadt Chloroform Merck, Darmstadt  
8. Ethanol Fisher Scientific, UK 
9. Ethidiumbromide Roth, Karlsruhe  
10. Giemsa stain Sigma-Aldrich, UK 
11. Glutathione Amersham, Freiburg Glycerol Merck, Darmstadt  
12. Glycine Sigma-Aldrich, Steinheim  
13. Guanidine hydrochloride Sigma-Aldrich, Steinheim  
14. Imidazole Fluka, Steinheim  
15. Isopropylthio-β-D-galactoside Serva, Heidelberg  
16. Leupeptin Sigma-Aldrich, Steinheim  
17. Lipopolysaccharide Sigma-Aldrich, Steinheim  
18. Magnesium chloride Merck, Darmstadt  
19. Magnesium sulfate Sigma-Aldrich, Steinheim  
20. Methanol Fisher Scientific, UK 
21. N,N,N',N’-Tetramethylethylenediamin Roth, Karlsruhe  
22. Non-fat dry milk Bio-Rad, UK  
23. Paraformaldehyde Sigma, Germany 
24. Phenylmethylsulfonyl fluoride Sigma-Aldrich, Steinheim  
25. Ponceau S Roth, Karlsruhe  
26. Potassium chloride Fisher Scientific, UK 
27. Sodium acetate Roth, Karlsruhe  
28. Sodium azide Merck, Darmstadt  
29. Sodium carbonate Roth, Karlsruhe  
30. Sodium chloride Sigma-Aldrich, Steinheim  
31. Sodium citrate Merck, Darmstadt  
32. Sodium dodecyl sulfate Merck, Darmstadt  
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33. Sodium periodate Sigma-Aldrich, Steinheim  
34. Sodium thiosulfate Roth, Karlsruhe  
35. Sodium thiosulfate Roth, Karlsruhe  
36. Tris (hydroxymethyl) aminomethane Roth, Karlsruhe  
37. Triton X-100 Sigma-Aldrich, UK 
38. Trypan blue Gibco, USA  
39. Tween-20 Roth, Karlsruhe  
40. Urea Merck, Darmstadt 
41. β-Mercaptoethanol AppliChem, Darmstadt  
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Appendix 4 Training sessions attended during the period of PhD 
programme 
 
1. Advance project management 
2. Assertive communications boards  
3. Building an academic profile  
4. Communicating your research  
5. Communication skills for sciences postgraduates 
6. Completing your PhD 
7. Confocal microscopy training (Nikon and Bio-Rad Training)  
8. Correct referencing and avoiding plagiarism  
9. Diversity and quality training course 
10. Effective use of voice 
11. EndNote training  
12. Engaging your audience  
13. Flow cytometry training  
14. Focus group session 
15. General safety in the department and regulations in biology and risk assessment 
16. Getting published in science  
17. Graduate laboratory assistant  
18. How to be an effective researcher  
19. Intellectual property in bioscience research   
20. Poster presentation 
21. Presentations skills 
22. Surviving the viva 
23. The seven secretes of highly successful research students   
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Appendix 5 Conferences attended during the period of PhD programme 
 
Two abstracts have been submitted to European Society for Immunodeficiencies (ESID) 
conference, which was held in Prague, Czech Republic from the 29th October to the 1st 
November 2014.     
1. The tittle: "Analysis of the expression and interrelationship between the CD74 
and CD44 receptors expressed on human breast cancer derived cells” 
           The authors: Hussain Alssadh, Waleed Al Abdulmenaim and Nelson Fernández 
The abstract: CD74 is a transmembrane protein that functions as a chaperone of MHC 
class II and is also thought to be involved in signalling via MIF and CD44. CD44 is a 
transmembrane glycoprotein that acts as the receptor for hyaluronan and it is considered 
as a member of cell adhesion molecules. The relationship between these two proteins is 
not well understood; one hypothesis postulates that the expression of CD74 and CD44 is 
associated with inflammatory disorders including cancer. We have examined the 
expression of CD74 and CD44 by flow cytometry and western blot in three breast tumour 
cell lines, CAMA-1, MDA-MB-231 and MDA-MB-435. The cell-surface membrane 
expression of CD44 is higher than CD74 in all examined cell lines. On the other hand, the 
level of expression of CD74 in MDA-MB-435 cell lines was higher than in CAMA-1 and 
MDA-MB-231. To evaluate the physical association of these two proteins, co-localization 
experiments using bioimaging were carried out. It was observed that CD74 and CD44 are 
highly co-localized suggesting a possible mode of function in facilitating signalling. 
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2. The tittle: “Lack of Trophoblast-specific isoforms of CD74 may protect human 
pregnancy” 
           The authors: Waleed Al Abdulmenaim, Hussain Alssadh and Nelson Fernández 
The abstract: During pregnancy the maternal immune system protects the allogeneic 
foetus from rejection. At the same time the mother maintains immunity defences intact 
against potential pathogens. We wish to know whether immunological receptors 
associated with antigen presentation and hence strong inflammatory responses play a role 
at the feto-maternal tolerance. One such receptor is CD74, a membrane-bound protein 
involved in HLA Class mediated antigen presentation and as Macrophage Migration 
Inhibitory Factor (MIF) receptor. Consequently, we wish to investigate the expression of 
CD74 at mRNA and protein levels in trophoblast derived cells, JEG-3 and ACH-3P and 
human placenta. We also wish to obtain knowledge on the effect of IFN-γ and LPS-
mediated infection, in particular in the regulation of CD74 isoform expression. 
 
One abstract has been submitted to 7th Saudi Students Conference-UK, which was held in 
Edinburgh International Conference Centre, in Edinburgh, UK from the 1st to 2nd 
February 2014 
3. The tittle: “Role of MHC class II in association with CD74 on human breast 
cancer cell lines ” 
            The authors: Hussain Alssadh and Nelson Fernández 
The abstract: The expression of HLA-DR and CD74 has been identified in several types 
of cancer and is believed to play a role in immunotolerance. CD74 is a type II 
transmembrane protein that plays a role in the assembly of MHC class II molecule-
peptide complexes in antigen presentation. Their selective expression is assumed to 
activate certain mechanisms/signal transduction pathways that suppress or modulate the 
immune system and protect the developing of cancerous cells including metastasis. A 
recent study has shown that CD74 is over-expressed on various cancer cells, i.e., prostate 
cancer cells, B lymphomas and gastric carcinomas. So, it is believed that CD74 and HLA-
DR might be considered as tumour markers. 
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Publications 
A manuscript has been in progress for publications as described below: 
1. Title: Interactions between CD74 and CD44 receptors expressed by human breast 
cancer cells 
Authors: Al Ssadh Hussain, Alabdulmenaim Waleed and Nelson Fernández 
Journal: Journal of Immunology  
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Interactions between CD74 and CD44 receptors expressed by human 
breast cancer cells 
Al Ssadh Hussain, Alabdulmenaim Waleed, Alghamdi Rana and Nelson Fernández 
School of Biological Sciences, University of Essex, Wivenhoe Park, Colchester, Essex CO4 
3SQ, United Kingdom 
Corresponding author: nelson@essex.ac.uk; Tel: +44 1206 873330; Fax: +44 1206 872592 
 
Abstract 
Increasingly the interactions of pairs of membrane-bound receptors acting in synergy have 
been linked to tumor progression; in this study we show that, indeed, CD74 and CD44 act in 
synergy and thus could promote breast cancer progression. The transmembrane receptor, 
which is also known as Cluster of Differentiation (CD) 74 functions as a chaperone of MHC 
class II biosynthesis, it is also involved in signaling via (macrophage migration inhibitory 
factor) MIF and the adhesion receptor CD44. The latter is also a transmembrane receptor, 
which is a member of a large family of cell adhesion molecules that is responsible for 
mediating communication and adhesion between adjacent cells, and between cells and the 
extracellular matrix (ECM). We have employed flow cytometry and western blot to examine 
the breast tumor cell lines, CAMA-1, MDA-MB-231 and MDA-MB-435 for CD74 and 
CD44. We observed that CD44 was higher than CD74 in all examined cancer cells. On the 
other hand, the level of expression of CD74 in MDA-MB-435 cell lines was higher than in 
CAMA-1 and MDA-MB-231. We conclude that CD74 and CD44 showed significant 
quantitative variations and they associate in cytoplasmic compartments, suggesting a 
mechanistic and functional mode of action. Co-localization experiments using bioimaging 
indicate that CD74 and CD44 are physically associated suggesting a possible mode of 
function in facilitating signaling and hence tumor progression.  
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Introduction 
Breast cancer is the most frequently diagnosed cancer in women worldwide and the most 
common cause of malignancy-associated death [1-3]. Breast cancer is found in breast sites 
and it is more common in females than males [3].  Each year, 458,000 women die from breast 
cancer globally, making it the most common cause of female cancer death in both the 
developed and developing world [4]. In the UK, the age-standardised incidence of breast 
cancer in women has increased by 6% over the last decade, between 1999 to 2001 and 2008 
to 2010 [5].  Statistical surveys have estimated that around 550,000-570.000 people are 
diagnosed with breast cancer in the United Kingdom [6]. The number of women who are 
diagnosed with breast cancer is expected to increased three times by 2040 [7]. Recently, 
breast cancer research indicates that the annual cost of breast cancer healthcare increased 
over a third compared to the last 10 years [4].   
The expression of CD74 and CD44 has been identified in several types of cancer and is 
believed to play a role in immunotolerance [8]. Recently, Greenwood et al. [9] have 
determined that high expression of Stat1, Max1 and CD74 is associated with triple-negative 
breast cancer. It has also been demonstrated that adhesion of tumour cells on the reconstituted 
membrane matrix Matrigel increases after IFN-γ-induced over-expression of CD74 [9].  Jiang 
et al [10] have shown that WNT5A, a lipid-modified glycoprotein, inhibits metastasis and 
alters splicing of CD44 in breast cancer cells. Therefore, it is believed that selective 
expression of CD74 and CD44 activates certain mechanisms and signal transduction 
pathways that suppress or modulate the immune system and protect the development of 
cancerous cells and metastasis [11]. 
CD74, also known as invariant chain (Ii) or macrophage migration inhibitory factor (MIF) 
receptor, is classified as a type II transmembrane glycoprotein that is expressed on antigen-
presenting cells [11-13]. However, recent studies have demonstrated that CD74 is also 
expressed in numerous types of cancer cell, including prostate, bladder and breast cancer 
cells [14, 15]. Additionally, CD74 is thought to be involved in signalling via MIF, suggesting 
it has a crucial role in tumor progression [15, 16]. However, because the short cytoplasmic 
sequence of CD74 does not appear to signal directly, MIF-induced extracellular signal-
regulated kinase (ERK) signalling appears to be reliant upon CD44 [15, 17].  Thus CD74 is 
modified by the addition of chondroitin sulfate, permitting interaction with CD44 to form a 
receptor complex of MIF-CD74-CD44 [18, 19].   
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CD44 is an integral membrane glycoprotein expressed in many cell types that serves as the 
principal receptor for hyaluronan, a glycosaminoglycan constituent of extracellular matrix 
[20]. Through alternative splicing, cells produce a family of CD44 including (CD44s and 
CD44v) protein isoforms that are involved in multiple distinct cellular functions, including 
proliferation, adhesion, and migration. The expression of CD44 has been associated to 
particular cancer types such as prostate tumours, head and neck squamous tumours, nervous 
system tumours, respiratory track tumours, melanomas and breast cancer [21-24]. CD44 
expression in human breast cancer has been correlated with both favourable and unfavourable 
clinical outcomes [1, 25].  
The present study aimed to characterize the cell-surface and total protein expression of CD74 
and CD44 on human breast cancer cell lines (CAMA-1, MDA-MB-231 and MDA-MB-435). 
I also studied the interactive partners of CD74 and CD44 by target imaging and 
coimmunoprecipitation. We investigated the expression of CD74 and CD44 in immortalized 
normal breast luminal cells (226LDM) to validate the study. 
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Materials and Methods 
Cell lines and cell culture  
Three human mammary gland cell lines, CAMA-1, MDA-MB-231 and MDA-MB-435, all 
derived from malignant pleural effusion, were used. The CAMA-1 and MDA-MB-435 cell 
lines were maintained in RPMI 1640 medium (LONZA-Belgium), supplemented with 10% of 
(v/v) fetal calf serum (FCS; Imperials Laboratories). Although MDA-MB-435 has been 
debated to be melanoma cells due to its gene profile expression, it is yet widely used as breast 
cancer cells [26]. The MDA-MB-231 cell line was maintained in D-MEM (high glucose), 
supplemented with 10 % FCS. 226LDM immortalized normal breast luminal cells (kindly 
provided by Elena Klenova, School of Biological Sciences, University of Essex), were used 
as positive control cells. Raji cells (human negroid Burkitt’s lymphoma) and HeLa cells 
(human cervical cancer), expressing high levels of CD74 and CD44, respectively, served as 
additional positive controls. The 226LDM cell line was maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM)/F-12, supplemented with 10% FCS, 5 mg/ml gentamicine, 5 ug/m 
insulin, l ng/ml hydrocortine, 20 ng/ml epidermal growth factor and 20 ng/ml cholera toxin.  
Raji and HeLa cells were cultured in RPMI -1640 (LONZA-Belgium) containing 10% FCS 
and cultured in a humidified atmosphere of 5% CO2 and 37°C. HeLa cell line was generous 
gift from Professor Glyn Stanway, School of Biological Sciences, University of Essex .All 
media used for this study were purchased from PAA Laboratories GmbH (Pasching, Austria). 
Reagents 
The monoclonal primary antibodies mouse anti-human CD74 (clone: By2) and mouse anti-
human α-tubulin (clone: TU-02) were purchased from Santa Cruz Biotechnology, USA. 
Mouse antibody CD44 (clone: 156-3c11) was purchased from Cell Signaling Technology, 
USA. Rabbit anti-human β-actin (clone: poly 6221) was purchased from (BioLegend, UK). 
The secondary antibody used for flow cytometry was a goat anti-Mouse antibody conjugated 
with the fluorophore FITC (clone: poly4053) and was purchased from Bio-legend, UK. The 
secondary antibody used for Western blotting was either goat anti-mouse (IRDye 800CW) or 
goat anti-rabbit (IRDye 680 LT), purchased from LI-COR Biosciences. Finally, Alex 488 
(green) and Alex 555 (red) antibodies were purchased from Life Technologies, UK.
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Flow cytometry analysis 
Cell lines were lifted with accutase (Sigma) and 1x106 cells were used per sample. 
Monoclonal antibodies By2 (anti-CD74) and 156-3c11 (anti-CD44) were employed in 
indirect immunofluorescence staining. Cells were preincubated with saturating concentrations 
of primary antibody, followed by washing and labeling with FITC-conjugated goat anti-
mouse IgG (Bio-legend). For cell-surface staining, cells were fixed with 4% formaldehyde 
solution, and washed with 1X PBS. The cells were then blocked with blocking buffer 
(PBS/0.1 %BSA) followed by washing steps in PBS. Primary and secondary antibodies were 
diluted with 0.1% BSA in PBS. Samples were analysed on BD FACSAria and analyzed by 
FlowJo 8.8.6.  
Western blotting and immunedetection   
Cells were lysed with CelLytic reagent (Sigma) and total protein concentration was 
determined by Bradford assay. The Total cell lysate was separated on a 12% SDS-PAGE gel. 
A total of 40 µg protein was loaded per well, and, after electrophoresis, protein was 
transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon-FL, Merck Millipore, 
Merck KGaA, Darmstadt, Germany). Membranes were blocked with 5% skimmed milk in 
PBS-Tween-20 (Sigma) for 1 hr at room temperature and incubated in anti-CD74 (clone: 
By2) at a concentration of 1:200, and anti- CD44 (clone: 156-3C11) at a concentration of 
1:1000. As a control, an alpha subunit-specific tubulin mouse monoclonal antibody was used 
to probe the cell extracts at a concentration of 1:200, followed by washing in PBS-T for 30 
min. The membranes were then incubated with IRDye 800CW Donkey anti-Mouse IgG (Li-
Cor Bioscience, Licoln, NE, USA) at a concentration of 1:1000 for 1 hr followed by washing 
in PBS-T for 30 min. Signals were detected using the ODYSSEY Infrared Imaging System 
(Li-Cor Biosciences). Fermentas PageRulerTM Plus Prestained Protein Ladder (Thermo Fisher 
Scientific, Waltham, MA, USA) was used in order to estimate the molecular weight of the 
respective protein bands. 
Immunofluorescence staining  
CAMA-1, MDA-MB-231 and MDA-MB-435 cell lines were cultured in LabTek 8-well 
chambers (Thermo Fisher Scientific) at a density of 6 x 103 cells per well for two days and 
following that they were seeded. The cells were fixed with 4% paraformaldehyde for 20 min 
on ice. For immunofluorescence staining all procedures were carried out at ambient 
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temperature. Cells were permeabilized and then blocked with 2% (w/v) bovine serum 
albumin (BSA) prepared in 1x phosphate-buffered saline (PBS) for 1 h at room temperature. 
For single staining of each antigen, cells were incubated with anti-CD74 (clone: By2) at a 
concentration of 1:500, and anti- CD44 (clone: 156-3C11) at a concentration of 1:400, for 1 h 
followed by three washes with PBS. Secondary antibody, anti-mouse IgG conjugated with 
Alexa Fluor® 488 or Alexa Fluor® 555 (Invitrogen, Carlsbad, CA, USA), was used at a 
dilution of 0.25 µg/100ml for 1 h. For double staining, cells were blocked again with 2% 
BSA and the staining process was repeated for each desired pair. 4’, 6-diamidino-2-
phenylindole dihydrochloride (DAPI) counter stain (Vector Laboratories, Burlingame, CA, 
USA) was used at a 1:250 dilution. Cells were thoroughly washed with PBS, the chambers 
removed, and the slide was mounted with anti-fade mounting medium (Vector Shield) 
covered with a cover slip (Chance proper LTD, West Midlands, England) and sealed with 
Marabu fixogum rubber cement (Marabuwerke GmbH & Co. KG, Tamm, Germany).  
Confocal microscopy  
For image acquisition, a Nikon A1Si confocal microscope (Nikon Instruments Inc.) was used 
with a plan-apochromatic VC1.4 N.A. 60x magnifying the oil-immersion objective. NIS-
Elements Advanced Research Software (version 4.13.01, build 916; Nikon Instruments Inc.) 
was used for image acquisition. Images were acquired in three channels, using one-way 
sequential line scans. DAPI was excited at 398.7 nm with laser power 1.6 arbitrary units, and 
its emission was collected at 450 nm with a PMT gain of 86. Alexa Fluor 488 was excited at 
488 nm with laser power 5.8, its emission was collected at 525 nm with a PMT gain of 117. 
Alexa Fluor 555 was excited at 560.5 nm with laser power 3.7, and was collected at 595 nm 
with a PMT gain of 98.The scan speed was ¼ frames/s (galvano scanner). The pinhole size 
was 35.76 µm, approximating 1.2 times the Airy disk size of the 1.4-NA objective at 525 nm. 
Scanner zoom was centered on the optical axis and set to a lateral magnification of 60 
nm/pixel. Axial step size was 105 nm, with 80-100 image planes per z-stack.  
Image processing 
NIS-Elements software (version 3.21.03, build 705; Nikon Instruments Inc.) was used for 
image processing. CD74 (green) and CD44 (red) channels were segmented using regional 
maxima detection tools followed by manual threshold. The generated binary areas were 
visually inspected; the overlap of the green and red channels which were generated by the 
overlay tool, resulted in a new layer (yellow) that represents the intersection of CD74 and 
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CD44. Finally, automated volume measurement was carried out for CD74, CD44 and their 
intersection was measured by a volume measurements tool. 
Immunoprecipitation and coimmunoprecipitation 
Cells were lysed with the RIPA Lysis Buffer System (Santa Cruz Biotechnology, USA) and 
total protein concentration was determined by Bradford assay.1 mg/ml of each sample was 
incubated overnight with 4 µg of anti-CD74 (clone: By2), at 4°C.  Following that 40 µl of 
protein A/G PLUS- Agarose (Santa Cruz Biotechnology, USA) was added. To promote 
immunoglobulin binding, this solution was kept overnight on a rotator at 4°C. The samples 
were spun down for 30 s and the supernatant was discarded. Beads were then washed twice 
using PBS and the samples were boiled at 100°C after adding 50 µl of SDS-PAGE sample 
loading buffer containing dithiothreitol. Then 20 µl of each sample was loaded in each well 
of the gel that was left for 1 hr and 30 min at 120 V. After electrophoresis, protein was 
transferred to a PVDF membrane. Membranes were blocked with 5% skimmed milk in PBS-
Tween-20 (Sigma) for 1 h at room temperature and incubated in either anti-CD74 (clone: 
By2) at a concentration of 1:200, or anti-CD44 (clone: 156-3C11) at a concentration of 
1:1000, and flowed by washing in PBS-T for 30 min. The membranes were then incubated 
with secondary antibody (IRDye 800CW Donkey anti-Mouse IgG ;Li-Cor Bioscience, 
Licoln, NE, USA) at a concentration of 1:1000 for 1 h, followed by washing in PBS-T for 30 
min. Signals were detected using the ODYSSEY Infrared Imaging System (Li-Cor 
Biosciences).
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Results 
Identification and quantification of CD74 and CD44  
The cell surface expression of CD74 and CD44 was analyzed for CAMA-1, MDA-MB-231, 
and MDA-MB-435 and Raji cell lines. Non-permeabilized cells were stained with an 
appropriate concentration of By2 (anti-CD74) and 156-3C11 (anti-CD44) antibodies 
followed by 1 µl RAM-FITC secondary antibody. Cells only, without staining, and isotype 
cells, stained with only secondary antibody, were used as a negative control. CD74 and CD44 
were detected on the cell-surface membrane of CAMA-1, MDA-MB-231 and MDA-MB-435 
cells (Fig 1). 
Immunostaining of CD74 and CD44 
Laser scanning confocal microscopy using different wavelengths was used to visualize 
intracellular expression of CD74 and CD44 molecules.  The CAMA-1, MDA-MB-231 and 
MDA-MB-435 cell lines all showed expression of CD74 and D44 on the intracellular 
membrane (Fig 2).  
Immunoblot analysis of CD74 and CD44 proteins  
CD74 and CD44 protein expression in CAMA-1, MDA-MB-231, MDA-MB-435, Raji and 
HeLa cells was studied by Western blot analysis using By2 (anti-CD74), 156-3C11 (anti-
CD44) and Poly6221 (anti β-Actin). By2 (anti-CD74) is specific for CD74 isoforms 31-45 
kDa and 156-3C11 (anti-CD44) is a mouse mAb which detects endogenous levels of total 
CD44 protein that is specific for most isoforms 80-90 kDa.  
Results in figure 3 show that CD74, CD44 and anti β-actin have molecular weights of 33-41 
kDa, 80-90 kDa and 45 kDa respectively. β-actin was used as a loading control. Most of the 
cell lines expressed three different isoforms of CD74 (Fig. 3A). However CAMA-1 cells 
expressed two different isoforms of CD44 (Fig. 3A). To evaluate the differences in protein 
loading during the experiment, the percentage of expression was calculated after the intensity 
of each band was adjusted according to its respective β-actin band intensity using the Image 
Studio Lite software (LI-COR Biosciences) (Fig. 3B). 
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Validation study of tumour antigens  
In order to validate our study, we investigated the expression of CD74 and CD44 
receptors in immortalized normal breast luminal cells (226LDM). Cell-surface and 
intracellular expression of both CD74 and CD44 was assessed by flow cytometry (Fig 
4.A). Total protein of CD74 and CD44 was detected by Western blotting and α-Tubulin 
was used as a loading control (Fig 4.B). Confocal laser-scanning microscopy was utilized 
to study the intracellular staining of CD74 and CD44 in 226LDM cells (Fig 4.C). The 
results show that 226LDM cells do not seem to express CD74 however they do express 
CD44. Additionally, The expression of CD44 is very weak in the cell surface but it is 
higher intracellularly.  
Colocalization analysis of CD74 and CD44 
To investigate whether CD74 and CD44 are co-localized in CAMA-1, MDA-MB-231 
and MDA-MB-435 cells, all cell lines were immunostained with an appropriate primary 
antibody followed by a secondary antibody. CD74 was labeled with FITC Alexa Fluor 
488 (green) and CD44 was labeled with Alexa Flour 555 (red) (Fig 5 A.B.C). All breast 
cancer cells show expression of CD74 and CD44. Colocalization was assessed by 
merging green and red channels and the Pearson’s correlation coefficient was used to 
analyse the degree of colocalization. The scale lay between -1 and 1, where 1 stands for 
colocalization, -1 stands for negative colocalization and 0 stands for no colocalization Fig 
5D shows the comparison of colocalization in all cell lines versus the negative control. 
The colocalization of DAPI against FITC was used as a negative control. For more 
accuracy, 3D images were acquired in stack, with z-direction and segmented by NIS 
elements to calculate the exact degree of colocalized molecules of CD74 and CD44 
against the total volume in each of the images in (Fig 6.A.B.C). The results colocalization 
were obtained by correlation coefficient and total segmented volume showed that 
CAMA-1 cells seem to have the highest degree of colocalized CD74 and CD44 
molecules followed by MDA-MB-435 and then MDA-MB-231. 
Interaction of CD74 and CD44 
CD74-CD44 interaction in cell lysates as demonstrated by coimmunoprecipitation 
showed that there is an interaction between CD74 and CD44 in breast cancer cells 
(CAMA-1, MDA-MB-231 and MDA-MB-435) (Fig 7.B). It was further revealed that 
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CD74 interacts with both CD44s and CD44v isoforms, in CAMA-1 cells. MDA-MB-231 
and MDA-435 cells express only CD44s isoform, which also interact with CD74. To test 
whether CD44s and CD44v interact with all isoforms of CD74 we performed the Co-IP 
of CD44-CD74. The results obtained showed that CD44s and CD44v bind only to p41 of 
CD74 (Fig 7.C). 
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Discussion  
Characterization and identification of tumour antigens that are highly immunogenic in 
human tumours are considered important in tumour immunology [27]. Recent data 
suggest that CD74 and CD44 can play a significant role in the pathogenesis of various 
solid tumours [15, 16, 28]. For example, CD74 can mediate MIF binding, and MIF-
induced ERK1 and ERK2 kinase phosphorylation requires the co-expression of CD44 
[17]. Greenwood et al. [9] found  that Stat1, Max1 and CD74 are expressed at high levels 
in triple-negative breast tumours . It has also been shown that CD44 expression is 
associated with a high rate of cell division and proliferation status [22]. 
Our data have confirmed that cell-surface CD74 and CD44 molecules are detectable by 
flow cytometry on CAMA-1, MDA-MB-231 and MDA-MB-435 cells. We also 
confirmed intracellular expression of CD74 and CD44 by confocal microscopy in all 
breast cancer cell lines.  Our immunoblot results revealed that CAMA-1, MDA, MB-231 
and MDA-MB-435 cells express total protein of CD74 and CD44. In addition, our data, 
obtained from Western blotting and immuneprecipitation, reveal that the CAMA-1, 
MDA-MB-231 and MDA-MB-435 cell lines express three different isoforms of CD74 
(Fig. 4). These findings differ from that made by Verjans et al. [27] who found that 
MDA-MB-231 and MDA-MB-468 cells express only one isoform of CD74 [29].  
Similarly, Metodieva et al. [30]  found  that MDA-MB-435 express one isoform of 
CD74.  
It is generally accepted that CD74 facilitates export of MHC II/CD74 complexes from 
the endoplasmic reticulum, while blocking premature loading of peptides on to the MHC 
II molecules [31-34].  In humans, 80% of the CD74 protein pool is composed of the p33 
isoform, and p35 is considered the most enigmatic isoform [32]. Genève et al. [32] have  
suggested that  p33 and p35, together, facilitate antigen presentation, and this process  
does not require the co-expression of any other CD74 isoform  [11, 32]. However, it has 
been recently suggested that high levels of CD74 expression might prevent tumour 
antigen presentation by blocking the MHC class II peptide-binding cleft, thus  preventing 
binding of antigenic peptides  for presentation to T cells, rendering tumors less 
immunogenic [11, 35]. Moreover, several studies have shown that the level of CD74 
expression is proportionality associated with tumour grade [10, 35, 36]. Chao et al. [36] 
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have shown  that upregulation of CD74 expression influences tumor growth and 
dissemination.   
It was previously shown that MIF binds to the CD74 extracellular domain on 
macrophages and B cells to facilitate signaling [28, 37]. However, the interaction of MIF 
and CD74 requires CD44, due to lack of direct signal in the cell surface domain of CD74 
[38]. When CD74 forms a complex with CD44, CD74 is modified by the addition of 
chondroitin sulfate, which is essential for the MIF-induced signaling cascade [39-41].  
CD44, which is a multifunctional, class I transmembrane glycoprotein that generally acts 
as a specific receptor for hyaluronic acid, promotes migration in normal cells.  It is 
widely expressed in almost all cells [42], and in its standard or variant form CD44 
expression is found in most cancer cells  [43]. CD44 has been the subject of extensive 
research for more than three decades because of its role in breast cancer. It has been 
demonstrated that CD44’s role in breast cancer is twofold [25]. It was shown that CD44 
activates and inhibits oncogenic signalling by both promoting and inhibiting tumour 
progression in response to extracellular cues [25, 44]. CD44 has also been linked to 
cancer due to its ability to increase the proliferation and invasion of tumour cells [1].   
We have shown, by flow cytomtery, Western blotting and imaging, that CD44 is 
expressed in the CAMA-1, MDA-MB-231 and MDA-MB-435 cell lines. Equivalently, 
Sieuwerts et al. [43] observed  that MDA-MB-435, ZR 75 and MDA-MB-231 cells 
express high levels of CD44. Western blot results have shown that CAMA-1 cells 
express two different CD44 isoforms: CD44s and CD44v. Jung et al. [45] showed  that 
some breast cancer cell lines, such as MDA-MB-468 and SUM149, express several 
isoforms of CD44s and CD44v.  It is possible that CD44 expression in breast cancer is 
associated with highly aggressive breast tumour subtypes or highly invasive breast cancer 
cells [46]. 
To validate our study we have used immortalized normal breast luminal cells (226LDM) 
as a model.  We have investigated the expression of CD74 and CD44 by flow cytometry, 
Western blotting and bioimaging. Our findings confirmed that 226LDM cells do not 
express CD74 on the cell surface and intracellularly, while them do express CD44. This 
result was expected because it has been confirmed that the expression of CD74 can only 
be found antigen-presenting cells, including B cells, monocytes, macrophages, dendritic 
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cells, and Langerhans cells [47]. The presence of CD44 in normal breast cells is normal, 
since CD44 has a wide range of functions in normal tissues.  
In view of the fact that CD74 and CD44 are involved in signalling with MIF [19], several 
groups have studied the association of CD74 and CD44 in cancers . Meyer-Siegler et al. 
[16]  have shown that CD44 binds to the p35 isoform of CD74 in bladder cancer cells, 
although this isoform has been suggested to be involved in antigen presentation  [32].  
Meyer-Siegler et al. [16] did not specify, however,  whether bladder cancer cells express 
different CD74 isoforms. Yet, they found that CD44v interacts with CD74 and MIF, 
creating a complex in prostate cancer cells (DU-145). However, human benign prostate 
hyperplasia epithelial cells (BPH-1) and LNCaP prostate cancer cells do not express 
CD74 on the cell surface.  For this reason, both cells do not interact with CD44; however, 
LNCaP has been demonstrated to interact with MIF [15].  
Our study has confirmed that CD74 and CD44 are expressed on the cell surface and 
intracellularly in the breast cancer cell lines CAMA-1, MDA-MB231 and MDA-MB435. 
Confocal microscopy allowed for the determination that CD74 and CD44 are highly 
colocalized in cytoplasmic domain in all breast cancer cells. Pearson’s correlation 
coefficient was used to analyse the colocalization of CD74 and CD44 [48]. The 
segmentation of the images also showed the percentage of colocalized CD74 and CD44 
molecules. The result from Co-IP confirmed that CD74 interacts with CD44s and 
CD44v. However, CD44s and CD44v interact only with p41, the most abundant isoform 
of CD74. Shi et al. [17] have shown that mammalian COS-7 cells do not bind MIF unless 
engineered to express CD74 [37]. It has been confirmed that CD74 alone is sufficient to 
mediate MIF binding to cells [17] however, CD74 alone is insufficient to signal with 
MIF in the absence of CD44. It has also been demonstrated that although 
phosphorylation of serine takes place in the p35 variant of Ii, the short cytoplasmic 
sequence of CD74 does not appear to signal directly and depends on CD44 [19]. Shi et al. 
[17] showed  that COS-7 cells cannot instigate signalling when engineered to express 
CD74 and a truncated CD44 lacking its cytoplasmic signalling domain. Gore et al. [28] 
have also shown that CD74 binds to CD44 to initiate a signaling pathway involving with 
MIF in monocytes and macrophages. Furthermore, CD44-deficient cells do not have any 
activity that might involve in signaling pathway [28].   
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In summary, the present study has confirmed that all above used cell lines express CD74 
and CD44. In addition, CAMA-1, MDA-MB-231 and MDA-MB-435 cells have 
significant amounts of cell surface CD74, an event that was not observed immortalized 
normal breast luminal cells 226LDM. Colocalization analysis has demonstrated that 
CD74 and CD44 are colocalized at cytoplasmic membrane suggestion a crucial role in 
breast cancer cells. In specific, coimmunoprecipitation result has confirmed that CD44 
interact only with p41, the most abundant isoform of CD74. The emerging role of CD74 
and CD44 in breast tumorigenesis may have selective, therapeutic modalities for women 
with breast cancer. 
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FIGURE 1: Cell surface expression of CD74 and CD44 on CAMA-1, MDA-MB-231, MDA-MB-435, Raji 
and HeLa cells. All cells were cultured in the appropriate media and were acquired by flow cytometry using 
By2 (anti-CD74) and 156-3C11 (anti-CD44). (A and B) Empty histograms represent the aforementioned 
cell lines labeled with anti-CD74 and anti-CD44 antibody. Black-filled histograms show the isotype as 
negative controls. Cells were labelled with an FITC-labelled secondary anti-mouse antibody. Expression 
levels were analyzed by flow cytometry (Aria cell sorter) and FlowJo 8.8.6 software was used to analyze 
the data. Mean fluorescence intensity (MFI) values were measured based on geometric means. Mouse IgG 
was used as a negative control.  
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FIGURE 2: Confocal laser scanning microscopy images of intracellular staining of CD74 and CD44 in 
CAMA-1, MDA-MB-231 and MDA-MB-435 cells. The cells were cultured in LabTek 8-well chambers at a 
density of 6 x 103 cells per well overnight.  CD74 was labelled with Alexa Fluor 488 (green) and CD44 
with Alexa Fluor 555 (red). 4', 6-diamidino-2-phenylindole (DAPI) was used for nuclear staining (blue). 
Fluorochromes were acquired separately to evaluate the expression of CD74 and CD44 using the image-
analysis software platform Fiji. Scale bar 10 µm. 
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FIGURE 3: Western blotting was utilized to detect CD74, CD44 and β-actin expression in CAMA-1, MDA-
MB-231, MDA-MB-435 and Raji cell lines. (A) Primary monoclonal antibodies Poly6221 (anti β-actin as 
loading control), By2 (anti-CD74) and 156-3C11 (anti-CD44) were used. β-actin is detected at a molecular 
weight of 50 kDa; CD74 isoforms were detected at molecular weights 33 and 45 kDa, whereas CD44 
isoforms were detected at molecular weights 80 and 90 kDa. (B) CD74 and CD44 levels are normalized 
against β-actin. To account for the difference in protein loading during the experiment, the percentage of 
expression was calculated after the intensity of each band was adjusted according to its respective β-actin 
band intensity using the Image Studio Lite software (LI-COR Biosciences).  
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FIGURE 4:  The expression of CD74 and CD44 receptors in immortalized normal breast luminal cells 
(226LDM). (A) Cell-surface and intracellular expression of CD74 and CD44 was acquired by flow 
cytometry using By2 (anti-CD74) and 156-3C11 (anti-CD44). Empty histograms represent the 226LDM 
cells stained with indicated antibody. Black-filled histograms show the isotype as negative controls. (B) 
Total protein of CD74 and CD44 was detected by Western blotting and α-tubulin was used as a loading 
control. (C) Intracellular staining of CD74 and CD44 in 226LDM cells by confocal laser scanning 
microscopy. Scale bar 10 µm. 
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FIGURE 5: Colocalization of CD74 and CD44 at intracellular level on (A) CAMA-1, (B) MDA-MB-231 
and (C) MDA-MB-435 cells, determined by confocal microscopy analysis. Yellow/orange fluorescence 
reveals the potential colocalization of two antigens.  3 D images were acquired in stack, with z-direction 
step size 0.14 µm using NIS element. Single-plane of z-stack is shown in three directions as xy, yz and zx. 
(D) Graphical representation of colocalization analysis based on PCC on each cells.  
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FIGURE 6: The colocalisation of CD74 with CD44 was quantified on segmented 3D images. Maximum 
intensity projections of CAMA-1, MDA-MB-231 and MDA-MB-435 cells are represented in A, B and C. 
CD74 was labelled with Alexa Fluor 488 (green) and CD44 with Alexa Fluor 555 (red). Nuclei are 
visualized with blue 4', 6-diamidino-2-phenylindole (DAPI) staining.  Segmentation results from both 
channels merged with the DAPI. The percentages of the total volumes of CD74, CD44 and the 
colocalisation from each image are represented by pie charts. The result shows that CAMA-1 cells have the 
highest correlation between CD74 and CD44 followed by MDA-MB435 and MDA-MB231. 
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FIGURE 7: Coimmunoprecipitation to study the interaction of CD74 and CD44 in CAMA-1, MDA-MB-
231 and MDA-MB-435 cell lines. (A and B) Immunoblot of CD74 and CD44 from breast cancer cell lysate. 
The blots were probed with either mouse anti-CD74 or anti-CD44 antibodies. (C and D) IP was subjected to 
pull down either CD74 or CD44.The antibody (Ab) heavy and light chain bands are indicated so that Ab 
heavy and light chain fragments can be observed at approximately 55 and 25 kDa respectively. (E and F) 
Co-IP was applied to study the interaction of CD74/CD44 and CD44/CD74. The Co-IP of CD74 /CD44 
confirmed that all CD44 isoforms, including CD44s and CD44, interact with CD74. However, Co-IP of 
CD44/CD74 confirmed that only p41 of CD74 interacts with CD44.   
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